



(51) International Patent Classification:

A61K 31/444 (2006.01) A61P 11/00 (2006.01)
C07D 401/14 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2018/052503

(22) International Filing Date:

24 September 2018 (24.09.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201710875041.9 25 September 2017 (25.09.2017) CN
201810265417.9 28 March 2018 (28.03.2018) CN
201810710340.1 02 July 2018 (02.07.2018) CN
201811034891.7 05 September 2018 (05.09.2018) CN

(71) Applicant: SUZHOU YUNXUAN YIYAO KEJI
YOUXIAN GONGSI [CN/CN]; 218 Xinghu Street,
Biobay Building B1, Room 708, Suzhou Industrial Park,
Suzhou, Jiangsu 215123 (CN).

(72) Inventor; and

(71) Applicant (for US only): ZHANG, Xiaohu [US/CN];
Building 5-502, Yidun Garden, No.1, Nanshi Street, The In-
dustrial Park, Suzhou, Jiangsu 215028 (CN).

(72) Inventors: ZHENG, Jiyue; 218 Xinghu Street, Biobay
Building B1, Room 708, Suzhou Industrial Park, Suzhou,
Jiangsu 215123 (CN). MA, Haikuo; 218 Xinghu Street,
Biobay Building B1, Room 708, Suzhou Industrial Park,
Suzhou, Jiangsu 215123 (CN).

(74) Agent: TIAN, Feng; 2015 Gallows Tree Court, Vienna,
Virginia 22182 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME





FIG. 1

(57) Abstract: The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the CXCR4 pathway.



MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of Chinese Patent Applications 201710875041.9, filed on September 25, 2017; 201810265417.9, filed on March 28, 2018; 201810710340.1, filed on July 2, 2018; and 201811034891.7, filed on September 5, 2018, 2018; all of which are hereby incorporated by reference.

FIELD OF INVENTION

[0002] The present invention generally relates to heteroaryl compounds and, more particularly, relates to novel heteroaryl compounds that are useful in the therapies targeting C-X-C chemokine receptor type 4 (CXCR4) inhibitors, and use of the CXCR4 inhibitors for therapeutic intervention in infectious diseases, inflammatory diseases, tumors, and cancers.


BACKGROUND OF THE INVENTION

[0003] C-X-C chemokine receptor type 4 (CXCR4) is a transmembrane protein that belongs to the G-protein-coupled receptors and it is involved in physiological processes in the hematopoietic and immune systems. Studies show that CXCR4 is expressed in tissues including lymphatic tissues, thymus, brain, spleen, stomach and small intestine. CXCR4 /transmits signals from its natural chemokine ligand, stromal cell-derived factor (SDF)-1 α , to intracellular biological pathways via G-proteins. The interaction between CXCR4 and SDF-1 α has been targeted in various therapeutic treatments for a number of diseases, including, for example, human immunodeficiency virus (HIV) infection, cancers, tumors, and inflammation and autoimmune disease such as rheumatoid arthritis and allergic asthma. The CXCR4 antagonist, Plerixafor, was approved by the FDA in 2008 for the mobilization of hematopoietic stem cells. See Cho W.T.. et al., *J. Med. Chem.* 2011; 55: 977-94; Debnath B. et al., *Theranostics* 2013, 3 (1): 47-75.

SUMMARY OF THE INVENTION


[0004] The present disclosure provides heteroaryl compounds as CXCR4 inhibitors, and compositions and applications thereof. These disclosed heteroaryl compounds, and compositions and applications thereof, may effectively inhibit necrosis, thereby finding application in treatments of necrotic pathway-related diseases and disorders, including, for example, inflammation, tumors, metabolic diseases and neurodegenerative diseases such as cerebral ischemia and stroke.


[0005] An aspect of the present disclosure provides a compound of formula I:





or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof, wherein


Ar is 5-10 membered heteroaryl comprising one N and 1-3 additional heteroatoms independently selected from the group consisting of N, O, and S, and Ar is unsubstituted or substituted with 1-4 R_{31} ;





W is , each X is independently a bond, $CR_{32}R_{33}$, O, NR_{34} , S, $S(=O)$ or $S(=O)_2$; n is 0, 1, 2 or 3; o and p are different integers with values of 0 or 1; wherein when o is 0, p is 1, B_1 is CR_{11} , B_2 is N, and B_1 is bonded with Ar; wherein when o is 1, p is 0, B_1 is N, B_2 is CR_{11} , and the carbon bearing R'_5 and R'_6 is bonded with Ar;

or W is , wherein the carbon bonded with R₅ and R₆ is connected to the ring carbon bonded with Y;

Y is , wherein the carbon bonded with R₃ is bonded with the carbon bonded with R₂;

or Y is  ;


U is  or  ;




Q is a bond or CR₂₉R₃₀;

each of R₁, R₂, R₃, and R₄ is independently selected from the group consisting of H, deuterium, -CN, halide, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), -NHS(=O)₂(C₁₋₆ alkyl), -S(=O)₂(C₁₋₆ alkyl), C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, -OH, methanesulfonyl, and deuterium;

or R₄ together with the atoms it attached to forms a carbocyclic, aryl, heterocyclic, or heteroaryl ring;

each of R₅ and R₆ is independently selected from the group consisting of H, deuterium, -CN, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), and C₁₋₃ alkoxy;

or R₅ and R₆ together forms , and D₃ bonded with R₄ to form:



wherein each R'₄ is independently selected from the group consisting of H, deuterium, -CN, halide, -OH, amino, C₁₋₆ alkyl, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -S(=O)₂(C₁₋₆ alkyl), C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, wherein each of -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -S(=O)₂(C₁₋₆ alkyl), C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl is

unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, -OH, methanesulfonyl, and deuterium;

R₇ is selected from the group consisting of H, deuterium, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, amino, -OH, acyl, -CN, C₁₋₆ alkoxy, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -C(=O)O(C₁₋₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁₋₆ alkyl), -C(=O)N(C₁₋₆ alkyl)₂, -NHC(=O)O(C₁₋₆ alkyl), -S(=O)₂(C₁₋₆ alkyl), and C₃₋₆ cycloalkyl;

each of R₈ and R₉ is independently selected from the group consisting of H, deuterium, -CN, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, and C₁₋₃ alkoxy; or R₇ and R₈, and atoms attached thereto, form a ring;

or R₈ and R₉, together with atoms they attached to, form a ring;

each of R'₅, R'₆, R'₇, R'₈, R'₉, R'₁₀, R₁₁, R₃₂, and R₃₃ is independently selected from the group consisting of H, deuterium, -CN, halide, C₁₋₆ alkyl, -C(=O)O(C₁₋₆ alkyl), C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, and -OSi(C₁₋₆ alkyl)₃, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₆ alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, C₃₋₆ cycloalkyl, C₁₋₆ alkyl, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), -NHC(=O)NH(C₁₋₆ alkyl), -NHC(=O)N(C₁₋₆ alkyl)₂, -NHS(=O)₂(C₁₋₆ alkyl), and C₁₋₆ alkoxy;

each of R₁₉, R₂₀, R₂₁, R₂₂, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, and R₃₀ is independently selected from the group consisting of H, deuterium, -CN, -OH, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl),

–NHC(=O)O(C₁₋₆ alkyl), C₁₋₆ alkyl, and C₁₋₃ alkoxy; or R₂₁ and R₂₃, together with atoms they attached to, form a ring; or R₁₉ and R₂₇, together with atoms they attached to, form a ring; or R₂₁ and R₂₇, together with atoms they attached to, form a ring; or R₁₉ and R₂₆, together with atoms they attached to, form a ring; or R₂₁ and R₂₆, together with atoms they attached to, form a ring;

R₂₃ is selected from the group consisting of H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, –OH, amino, C₁₋₆ alkyl, –NH(C₁₋₆ alkyl), –N(C₁₋₆ alkyl)₂, –NHC(=O)(C₁₋₆ alkyl), –NHC(=O)O(C₁₋₆ alkyl), and C₁₋₃ alkoxy; or R₂₂ and R₂₃, together with atoms they attached to, form a 5-7 membered heterocycle;

R₂₄ is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ heterocycloalkyl comprising N or O, –C(=O)(C₁₋₆ alkyl), –C(=O)O(C₁₋₆ alkyl), and –C(=O)NH(C₁₋₆ alkyl), wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, –OH, –CN, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ heterocycloalkyl comprising N or O, –NH(C₁₋₆ alkyl), –N(C₁₋₆ alkyl)₂, –NHC(=O)(C₁₋₆ alkyl), –NHC(=O)O(C₁₋₆ alkyl), and C₁₋₃ alkoxy; or R and R₂₄, together with atoms they attached to, form a 5-7 membered heterocycle;

R₃₁ is selected from the group consisting of deuterium, halide, –CN, –OH, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkynyl, C₂₋₆ alkenyl, –S(C₁₋₆ alkyl), –NH(C₁₋₆ alkyl), –N(C₁₋₆ alkyl)₂, aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently


selected from the group consisting of deuterium, halide, $-\text{CN}$, $-\text{OH}$, amino, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-6} alkoxy;

R_{34} is selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, $-\text{C}(=\text{O})(\text{C}_{1-8}$ alkyl), $-\text{S}(=\text{O})_2(\text{C}_{1-8}$ alkyl), $-\text{C}(=\text{O})\text{O}(\text{C}_{1-6}$ alkyl), and $-\text{C}(=\text{O})\text{NH}(\text{C}_{1-6}$ alkyl), wherein each of C_{1-6} alkyl, C_{1-8} alkyl, and C_{3-6} cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-\text{OH}$, amino, C_{1-6} alkyl, $-\text{NH}(\text{C}_{1-6}$ alkyl), $-\text{NH}(\text{C}_{1-6}$ alkyl), $-\text{N}(\text{C}_{1-6}$ alkyl) $_2$, $-\text{NHC}(=\text{O})(\text{C}_{1-6}$ alkyl), $-\text{NHC}(=\text{O})\text{O}(\text{C}_{1-6}$ alkyl), and C_{1-3} alkoxy;

R is selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-8} heterocycloalkyl comprising N or O, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-8} heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-\text{OH}$, $-\text{CN}$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-3} alkoxy, $-\text{S}(=\text{O})_2(\text{C}_{1-6}$ alkyl), $-\text{C}(=\text{O})(\text{C}_{1-6}$ alkyl), and C_{3-6} heterocycloalkyl comprising N or O; or R and R_{24} , together with N atom they attached to, form a 5-7 membered heterocycle; or R and R_{21} , together with N atom they attached to, form a 5-7 membered heterocycle; and

R' is selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-8} heterocycloalkyl comprising N or O, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-8} heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-\text{OH}$, $-\text{CN}$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-3} alkoxy, $-\text{S}(=\text{O})_2(\text{C}_{1-6}$ alkyl), $-\text{C}(=\text{O})(\text{C}_{1-6}$ alkyl), and C_{3-6} heterocycloalkyl comprising N or O; or R' and R_{21} , together with atoms they attached to, form a 5-7 membered heterocycle.


[0006] In some embodiments of the present disclosure, the disclosed compound is according to Formula Ia



Ia

or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof,
wherein

Ar is unsubstituted or substituted with 1-4 groups of R_{31} , and Ar is selected from the group consisting of:



each X is independently a bond, $CR_{32}R_{33}$, O, or NR_{34} ;

each of R_{19} , R_{20} , R_{21} , R_{22} , R_{25} , R_{26} , R_{27} , R_{28} , R_{29} , and R_{30} is independently selected from the group consisting of H, deuterium, $-CN$, $-OH$, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3} alkoxy, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3} alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide,

deuterium, $-OH$, amino, C_{1-6} alkyl, and C_{1-3} alkoxy; or R_{19} and R_{27} , together with atoms they attached to, form a ring; or R_{21} and R_{27} , together with atoms they attached to, form a ring;

each of R_{23} and R_{24} is independently selected from the group consisting of H, C_{1-6} alkyl, and C_{3-6} cycloalkyl, wherein each of C_{1-6} alkyl and C_{3-6} cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, amino, C_{1-6} alkyl, and C_{1-3} alkoxy; or R_{22} and R_{23} , together with atoms they attached to, form a 5-7 membered heterocycle;


R_{31} is selected from the group consisting of deuterium, halide, $-CN$, $-OH$, amino, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} alkoxy, C_{2-6} alkynyl, C_{2-6} alkenyl, $-S(C_{1-6} \text{ alkyl})$, $-NH(C_{1-6} \text{ alkyl})$, $-N(C_{1-6} \text{ alkyl})_2$, aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of deuterium, halide, $-CN$, $-OH$, amino, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-6} alkoxy;

R is selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-8} heterocycloalkyl comprising N or O, $-C(=O)(C_{1-6} \text{ alkyl})$, $-C(=O)O(C_{1-6} \text{ alkyl})$, and $-C(=O)NH(C_{1-6} \text{ alkyl})$ wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-8} heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, $-CN$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-3} alkoxy, $-S(=O)_2(C_{1-6} \text{ alkyl})$, $-C(=O)(C_{1-6} \text{ alkyl})$, and C_{3-6} heterocycloalkyl comprising N or O; or R and R_{24} , together with N atom they attached to, form a 5-7 membered heterocycle; and

R' is selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-8} heterocycloalkyl comprising N or O, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-8}

heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-\text{OH}$, $-\text{CN}$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-3} alkoxy, $-\text{S}(=\text{O})_2(\text{C}_{1-6} \text{ alkyl})$, $-\text{C}(=\text{O})(\text{C}_{1-6} \text{ alkyl})$, and C_{3-6} heterocycloalkyl comprising N or O; or R' and R_{21} , together with N atom they attached to, form a 5-7 membered heterocycle.


[0007] In some embodiments of the present disclosure, the disclosed compound is according to Formula Ib:



Ib

or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof, wherein

Ar is unsubstituted or substituted with 1-4 groups of R_{31} , and Ar is selected from the group consisting of:



each X is independently a bond, CR₃₂R₃₃, O, or NR₃₄;

each of R₁₉, R₂₀, R₂₁, R₂₂, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, and R₃₀ is independently selected from the group consisting of H, deuterium, -CN, -OH, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, C₁₋₆ alkyl, and C₁₋₃ alkoxy; or R₁₉ and R₂₇, together with atoms they attached to, form a ring; or R₂₁ and R₂₇, together with atoms they attached to, form a ring;

each of R₂₃ and R₂₄ is independently selected from the group consisting of H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, C₁₋₆ alkyl, and C₁₋₃ alkoxy; or R₂₂ and R₂₃, together with atoms they attached to, form a 5-7 membered heterocycle;


R₃₁ is selected from the group consisting of deuterium, halide, -CN, -OH, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, C₂₋₆ alkynyl, C₂₋₆ alkenyl, -S(C₁₋₆ alkyl), -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered

heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of deuterium, halide, -CN, -OH, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₆ alkoxy;

R is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O; or R and R₂₄, together with N atom they attached to, form a 5-7 membered heterocycle; and

R' is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O; or R' and R₂₁, together with N atom they attached to, form a 5-7 membered heterocycle.

[0008] In some embodiments of the present disclosure, the disclosed compound is according to Formula Ic:



Ic

or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof,
wherein

each of Z1, Z2 and Z3 is independently selected from the group consisting of O and
CR₄₁R₄₂; and

each of R₄₁ and R₄₂ is independently selected from the group consisting of H, deuterium,
halide and C₁₋₃ alkyl.


[0009] In some embodiments of the present disclosure, for the disclosed compound:


each of R₁₉, R₂₀, R₂₁, R₂₂, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, and R₃₀ is independently selected from
the group consisting of H, deuterium, -CN, -OH, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃
alkoxy, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy is unsubstituted or
substituted with 1-3 groups independently selected from the group consisting of halide,
deuterium, -OH, C₁₋₆ alkyl, and C₁₋₃ alkoxy;

each of R₂₃ and R₂₄ is independently selected from the group consisting of H, C₁₋₆ alkyl,
and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or
substituted with 1-3 groups independently selected from the group consisting of halide,
deuterium, -OH, amino, C₁₋₆ alkyl, and C₁₋₃ alkoxy; or R₂₂ and R₂₃, together with atoms
they attached to, form a 5-7 membered heterocycle; and


each of R and R' is independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O.

[0010] In some embodiments of the present disclosure, the disclosed compound is selected from the group consisting of:





[0011] In some embodiments of the present disclosure, the disclosed compound is according to Formula II:



II

wherein

W_1 is D_1 , D_1-D_2 , or $D_1=D_2$, and D_1 is bonded with the pyridine ring;

each of R_1 , R_2 , and R_3 is independently selected from the group consisting of H,

deuterium, $-CN$, halide, $-OH$, amino, C_{1-6} alkyl, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl) $_2$,

$-S(=O)_2(C_{1-6}$ alkyl), C_{3-6} cycloalkyl, C_{1-8} alkoxy, C_{2-6} alkenyl, and C_{2-6} alkynyl, wherein

each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, -OH, methanesulfonyl, and deuterium;

R₇ is selected from the group consisting of H, deuterium, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl, and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, amino, -OH, acyl, -CN, C₁₋₆ alkoxy, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -C(=O)O(C₁₋₆ alkyl), -C(=O)NH₂, -C(=O)NH(C₁₋₆ alkyl), -C(=O)N(C₁₋₆ alkyl)₂, -NHC(=O)O(C₁₋₆ alkyl), -S(=O)₂(C₁₋₆ alkyl), and C₃₋₆ cycloalkyl;

R₂₃ is selected from the group consisting of H, C₁₋₆ alkyl and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, and C₁₋₃ alkoxy;

each of R₁₉, R₂₀, R₂₁, R₂₂, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, and R₃₀ is independently selected from the group consisting of H, deuterium, -CN, -OH, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), and C₁₋₃ alkoxy; or R₂₂ and R₂₃, together with atoms they attached to, form a ring; or R₁₉ and R₂₆, together with atoms they attached to, form a ring; or R₂₁ and R₂₆, together with atoms they attached to, form a ring;


each of R and R₂₄ is independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ heterocycloalkyl comprising N or O, -C(=O)(C₁₋₆ alkyl), -C(=O)O(C₁₋₆ alkyl), and -C(=O)NH(C₁₋₆ alkyl), wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₃₋₆

cycloalkyl, C₁₋₃ alkoxy, and C₃₋₆ heterocycloalkyl comprising N or O; or R and R₂₄, together with N atom they attached to, form a 5-7 membered heterocycle; and

R' is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O; or

R' and R₂₁, together with N atom they attached to, form a 5-7 membered heterocycle.

[0012] In some embodiments of the present disclosure, the disclosed compound is according to Formula IIa:




IIa

or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof,


wherein

Ar is unsubstituted or substituted with 1-4 groups of R₃₁, and Ar is selected from the group consisting of:



each of R_1 , R_2 , R_3 , and R_{43} is independently selected from the group consisting of H, deuterium, $-\text{CN}$, halide, $-\text{OH}$, amino, C_{1-6} alkyl, $-\text{NH}(\text{C}_{1-6} \text{ alkyl})$, $-\text{N}(\text{C}_{1-6} \text{ alkyl})_2$, $-\text{S}(=\text{O})_2(\text{C}_{1-6} \text{ alkyl})$, C_{3-6} cycloalkyl, C_{1-8} alkoxy, C_{2-6} alkenyl, and C_{2-6} alkynyl, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-8} alkoxy, C_{2-6} alkenyl, and C_{2-6} alkynyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, $-\text{OH}$, methanesulfonyl, and deuterium.

[0013] In some embodiments of the present disclosure, the disclosed compound is according to Formula IIb:




IIb

or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof,

wherein

each of D_1 , D_2 and D_3 is independently selected from the group consisting of N and CR'₄;

Ar is unsubstituted or substituted with 1-4 groups of R₃₁, and Ar is selected from the group consisting of:



each of R₁, R₂, R₃, and R'₄ is independently selected from the group consisting of H, deuterium, -CN, halide, -OH, amino, C₁₋₆ alkyl, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -S(=O)₂(C₁₋₆ alkyl), C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, -OH, methanesulfonyl, and deuterium.

[0014] In some embodiments of the present disclosure, for the disclosed compound:

R₂₃ is selected from the group consisting of H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups


independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, and C₁₋₃ alkoxy;

each of R₁₉, R₂₀, R₂₁, R₂₂, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, and R₃₀ is independently selected from the group consisting of H, deuterium, -CN, -OH, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), and C₁₋₃ alkoxy; or R₂₁ and R₂₃, together with atoms they attached to, form a ring;


each of R and R₂₄ is independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ heterocycloalkyl comprising N or O, -C(=O)(C₁₋₆ alkyl), -C(=O)O(C₁₋₆ alkyl), and -C(=O)NH(C₁₋₆ alkyl), wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, and C₃₋₆ heterocycloalkyl comprising N or O; or R and R₂₄, together with atoms they attached to, form a 5-7 membered heterocycle;

R' is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy; or R' and R₂₁, together with atoms they attached to, form a 5-7 membered heterocycle.


[0015] In some embodiments of the present disclosure, for the disclosed compound selected from the group consisting of:




D1




D2




D3




D4




D5




D6




D7




D8




D9




D10




D11




D12




D13




D14




D15




D16




D17




D18




D19




D20




D21




D22




D23




D24




D25






[0016] In some embodiments of the present disclosure, the disclosed compound is according to Formula III:



III

wherein

each of A_1 , A_2 , and A_3 is independently selected from the group consisting of N and CR_{44} , wherein at least one of A_1 , A_2 , and A_3 is N;



each of R₁, R₂, R₃, and R₄ is independently selected from the group consisting of H, deuterium, -CN, halide, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), -NHS(=O)₂(C₁₋₆ alkyl), C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₈ alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide and deuterium;

each of R₅ and R₆ is independently selected from the group consisting of H, deuterium, -CN, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), and C₁₋₃ alkoxy; or R₅ is O or CR₄₅R₄₆, and R₄ and R₅, together with atoms they attached to, form a ring;

R₇ is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl comprising an O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl comprising an O;

each of R₈ and R₉ is independently selected from the group consisting of H, deuterium, -CN, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, and C₁₋₃ alkoxy; or R₇ and R₈, and atoms attached thereto, form a ring;

or R₈ and R₉, together with atoms they attached to, form a ring;

R₄₄ is H, deuterium, halide, -CN, -OH, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -C(=O)NH(C₁₋₆ alkyl), -C(=O)N(C₁₋₆ alkyl)₂, -S(C₁₋₆ alkyl), C₂₋₆ alkenyl, C₂₋₆ alkynyl, 4-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the groups consisting of O, N and S, aryl, and 5-6

membered heteroaryl, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, heterocycle, aryl and heteroaryl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH and C₁₋₃ alkoxy;

R₂₃ is selected from the group consisting of H, C₁₋₆ alkyl and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, and C₁₋₃ alkoxy;

each of R₁₉, R₂₀, R₂₁, R₂₂, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, and R₃₀ is independently selected from the group consisting of H, deuterium, -CN, -OH, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), and C₁₋₃ alkoxy; or R₂₂ and R₂₃, together with atoms they attached to, form a ring; or R₁₉ and R₂₆, together with atoms they attached to, form a ring; or R₂₁ and R₂₆, together with atoms they attached to, form a ring;


each of R and R₂₄ is independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ heterocycloalkyl comprising N or O, -C(=O)(C₁₋₆ alkyl), -C(=O)O(C₁₋₆ alkyl), and -C(=O)NH(C₁₋₆ alkyl), wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, and C₃₋₆ heterocycloalkyl comprising N or O; or R and R₂₄, together with N atom they attached to, form a 5-7 membered heterocycle; or R and R₂₁, together with N atom they attached to, form a 5-7 membered heterocycle;

R' is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected


from the group consisting of halide, deuterium, $-\text{OH}$, $-\text{CN}$, C_{3-6} cycloalkyl, C_{1-3} alkoxy, $-\text{S}(=\text{O})_2(\text{C}_{1-6} \text{ alkyl})$, $-\text{C}(=\text{O})(\text{C}_{1-6} \text{ alkyl})$, and C_{3-6} heterocycloalkyl comprising N or O; or R' and R_{21} , together with N atom they attached to, form a 5-7 membered heterocycle; and

each of R_{45} and R_{46} is independently selected from the group consisting of H, deuterium, halide, C_{1-3} alkyl; or R_{45} and R_{46} , together with the atoms they attached to, form a ring.

[0017] In some embodiments of the present disclosure, the disclosed compound is according to Formula IIIa or IIIb:



IIIa



IIIb

wherein

each of E_1 , E_2 , and E_3 is independently selected from the group consisting of O and $\text{CR}_{45}\text{R}_{46}$; and

each of R_{45} and R_{46} is independently selected from the group consisting of H, deuterium, halide, C_{1-3} alkyl; or R_{45} and R_{46} , together with the atoms they attached to, form a ring.

[0018] In some embodiments of the present disclosure, the disclosed compound is according to formula IIIa and IIIb, and each of E_1 , E_2 , and E_3 is independently selected from the group


consisting of CH_2 , O and ; and at least one of E_1 , E_2 , and E_3 is .

[0019] In some embodiments of the present disclosure, the disclosed compound is according to formula IIIa and IIIb, and

A_3 is CR_{44} ;


each of A_1 and A_2 is independently selected from the group consisting of N and CR_{44} ,

wherein at least one of A_1 and A_2 is N;





W_2 is


[0020] In some embodiments of the present disclosure, $-\text{C}(\text{R}_5\text{R}_6)\text{W}_2$ is selected from the group consisting of:





[0021] In some embodiments of the present disclosure, for the disclosed compound is selected from the group consisting of:





















[0022] In some embodiments of the present disclosure, of formulas I, Ia, Ib, Ic, II, IIa, IIb, III, IIIa, and IIIb or other compounds disclosed herein, U is unsubstituted or substituted with is unsubstituted or substituted with 1-3 groups selected from the group consisting of deuterium, halide, -OH, C₁₋₃ alkyl, and C₁₋₃ alkoxy, and U is selected from the group consisting of:



[0023] Another aspect of the present disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formulas I, Ia, Ib, Ic, II, IIa, IIb,

III, IIIa, and IIIb or other compounds disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof, and a pharmaceutically acceptable carrier, diluent, adjuvant or excipient.

[0024] Another aspect of the present disclosure provides a combination composition comprising:

- (a) a compound of formulas I, Ia, Ib, Ic, II, IIa, IIb, III, IIIa, and IIIb or other compounds disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof; and
- (b) one or more additional compounds selected from the group consisting of antitumor agents, anti-cancer agents, antibacterial agents, antiviral agents, central nervous system agents, and anti-diabetes agents.

[0025] Another aspect of the present disclosure provides a compound of formulas I, Ia, Ib, Ic, II, IIa, IIb, III, IIIa, and IIIb or other compounds disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof, for treating diseases, mobilizing stem cells, and treating wounded or burned skin by antagonizing the CXCR4 pathway, wherein the diseases is selected from the group consisting of HIV infection, myocardial infarction, diseases associated with hematopoiesis, inflammation, allergic diseases, asthma, allergic pneumonia, interstitial lung disease, lupus erythematosus, ankylosing spondylitis, multiple sclerosis, systemic sclerosis, polymyositis, rheumatoid arthritis, myasthenia gravis, juvenile diabetes, glomerulonephritis, autoimmune thyroiditis, graft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, scleroderma, psoriasis, dermatitis, retinitis pigmentosa, proliferative vitreoretinopathy, Best's vitelliform macular degeneration, eczema, urticaria, vasculitis, eosinophilic fasciitis, wet and dry age-related macular degeneration (ARMD), diabetic retinopathy, retinopathy of prematurity (ROP), diabetic macular edema, uveitis, retinal vein occlusion, cystic macular edema, glaucoma, vein branch occlusion, breast cancer, lung cancer, bladder cancer, pancreatic cancer, liver cancer, head and neck squamous cell carcinoma, thyroid cancer, sarcoma, osteosarcoma, desmofibroma, melanoma, prostate cancer, colorectal cancer, ovarian cancer, cervical cancer, esophageal cancer, gastric cancer, myeloma, lymphoma, mantle cell lymphoma, cutaneous T cell lymphoma, chronic and non-progressive anemia,

spontaneous or primary thrombocytosis, idiopathic myelofibrosis, pulmonary fibrosis, renal fibrosis, liver fibrosis, cirrhosis, diabetic retinopathy, macroglobulinemia, leukemia, acute leukemia, chronic leukemia, lymphoblastic leukemia, myeloid leukemia, myelodysplastic syndrome, myeloproliferative disorders, encephaloma, astrocytoma, medulloblastoma, schwannoma, primary neuroectodermal tumor, and pituitary adenoma.

[0026] Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure.

Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.

BRIEF DESCRIPTION OF THE DRAWINGS

[0027] FIG. 1 depicts the 12G5 assay by compound A42.

[0028] FIG. 2 depicts the 12G5 assay by compound A43.

[0029] FIG. 3 depicts the 12G5 assay by compound A78.

[0030] FIG. 4 depicts the 12G5 assay by compound A83.

[0031] Before proceeding with the detailed description, it is to be appreciated that the following detailed description is merely exemplary in nature and is not intended to limit the invention or the application and uses thereof. Hence, although the present disclosure is, for convenience of explanation, depicted and described as shown in certain illustrative embodiments, it will be appreciated that it can be implemented in various other types of embodiments and equivalents, and in various other systems and environments. Furthermore, there is no intention to be bound by any theory presented in the preceding background or the following detailed description.

INCORPORATION BY REFERENCE

[0032] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

DETAILED DESCRIPTION OF THE INVENTION

[0033] While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.

DEFINITIONS

[0034] Compounds are generally described herein using standard nomenclature. For compounds having asymmetric centers, it should be understood that (unless otherwise specified) all of the optical isomers and mixtures thereof are encompassed. In addition, compounds with carbon-carbon double bonds may occur in Z- and E- forms, with all isomeric forms of the compounds being included in the present invention unless otherwise specified. Where a compound exists in various tautomeric forms, a recited compound is not limited to any one specific tautomer, but rather is intended to encompass all tautomeric forms.

[0035] As used herein, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a molecule” includes a plurality of such molecules, and the like.

[0036] The term “about” or “nearly” as used herein generally refers to within +/- 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the designated amount.

[0037] Compounds are generally described herein using standard nomenclature. For compounds having asymmetric centers, it should be understood that (unless otherwise specified) all of the optical isomers and mixtures thereof are encompassed. In addition, compounds with carbon-carbon double bonds may occur in Z- and E- forms, with all isomeric forms of the compounds

being included in the present invention unless otherwise specified. Where a compound exists in various tautomeric forms, a recited compound is not limited to any one specific tautomer, but rather is intended to encompass all tautomeric forms.

[0038] The term “alkyl” as used herein generally refers to a straight or branched chain saturated aliphatic hydrocarbon. Alkyl groups include groups having from 1 to 8 carbon atoms (C_1 - C_8 alkyl), from 1 to 6 carbon atoms (C_1 - C_6 alkyl) and from 1 to 4 carbon atoms (C_1 - C_4 alkyl), including, for example, methyl, ethyl, propyl, isopropyl, n-butyl, *sec*-butyl, *tert*-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl and 3-methylpentyl. In some instances, a substituent of an alkyl group is specifically indicated. For example, “cyanoalkyl” refers to an alkyl group substituted with at least one cyano substituent.

[0039] The term “alkenyl” as used herein generally refers to straight or branched chain alkene groups, which comprise at least one unsaturated carbon-carbon double bond. Alkenyl groups include C_2 - C_8 alkenyl, C_2 - C_6 alkenyl and C_2 - C_4 alkenyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively, including, for example, ethenyl, allyl or isopropenyl. The term “alkynyl” as used herein generally refers to straight or branched chain alkyne groups, which have one or more unsaturated carbon-carbon bonds, at least one of which is a triple bond. Alkynyl groups include C_2 - C_8 alkynyl, C_2 - C_6 alkynyl and C_2 - C_4 alkynyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively.

[0040] The term “cycloalkyl” as used herein generally refers to a group that comprises one or more saturated rings in which all ring members are carbon, including, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl. Cycloalkyl groups do not comprise an aromatic ring or a heterocyclic ring. For example, certain cycloalkyl groups are C_3 - C_7 cycloalkyl, in which the cycloalkyl group contains a single ring having from 3 to 7 ring members, all of which are carbon. The term “cycloalkenyl” as used herein generally refers to a group that comprises one or more unsaturated rings in which all ring members are carbon.

[0041] The term “alkoxy” as used herein generally refers to an alkyl group as described above attached via an oxygen bridge. Alkoxy groups include C_1 - C_6 alkoxy and C_1 - C_4 alkoxy groups,

which have from 1 to 6 or from 1 to 4 carbon atoms, respectively. Methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, *sec*-butoxy, *tert*-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy are representative alkoxy groups.

[0042] The term “alkylamino” as used herein generally refers to a secondary or tertiary amine that has the general structure -NH-R1 or -N(R1)(R2), wherein R1 and R2 are selected independently from alkyl, cycloalkyl and (cycloalkyl)alkyl groups. Such groups include, but are not limited to, for example, mono- and di-(C₁-C₆ alkyl)amino groups, in which each C₁-C₆ alkyl may be the same or different. It will be apparent that the definition of “alkyl” as used in the term “alkylamino” differs from the definition of “alkyl” used for all other alkyl-containing groups, in the inclusion of cycloalkyl and (cycloalkyl)alkyl groups.

[0043] The term “alkylthio” as used herein generally refers to an alkyl-substituted thio group, wherein the term alkyl is as defined above.

[0044] The term “halogen” or “halide” as used herein generally refers to fluorine, chlorine, bromine, and iodine. The term “haloalkyl” as used herein generally refers to an alkyl group that is substituted with one or more independently chosen halogens (e.g., “C₁-C₆ haloalkyl” groups have from 1 to 6 carbon atoms and at least one halogen). Examples of haloalkyl groups include, but are not limited to, mono-, di- or tri-fluoromethyl; mono-, di- or tri-chloromethyl; mono-, di-, tri-, tetra- or penta-fluoroethyl; mono-, di-, tri-, tetra- or penta-chloroethyl; and 1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl.

[0045] The term “heteroaryl” as used herein generally refers to an aromatic group in which at least one aromatic ring comprises at least one heteroatom selected from N, O and S. Heteroaryls include, for example, 5-12 membered heteroaryls. Examples include, but are not limited to, imidazole, furan, furazan, isothiazole, isoxazole, oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, tetrazole, thiazole and thiophene.

[0046] The term “heterocycloalkyl” as used herein generally refers to a ring structure containing 3-12 ring atoms, in which in which at least one ring atom is carbon and at least one ring atom is

heteroatom selected from N, O, and S. Examples include, but are not limited to, aziridine, oxiran, thiirane, azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, and tetrahydrothiophene.

[0047] The term “heterocyclic” or “heterocycle” as used herein generally refers to a ring structure containing 3-12 ring atoms, in which at least one ring atom is carbon and at least one ring atom is heteroatom selected from N, O, and S. A heterocyclic group may be aromatic or non-aromatic. Piperidine and oxetane are non-limiting examples of non-aromatic heterocycles. Thiazole and pyridine are non-limiting examples of aromatic heterocycles.

[0048] The terms “substituent” and “substituted,” as used herein, generally denote that a molecular moiety is covalently bonded to an atom within a molecule of interest. For example, a ring substituent may be a moiety such as a halogen, alkyl group, haloalkyl group or other group that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a ring member. Substituents of aromatic groups are generally covalently bonded to a ring carbon atom. A straight chain substituent may be a moiety such as a halogen, alkyl group, haloalkyl group or other group that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a member of a straight chain.

[0049] The term “pharmaceutically acceptable” as used herein generally refers to a form of the compound that is safe for administration to a subject. For example, a free base, a salt form, a solvate, a hydrate, a prodrug or derivative form of a compound of formula I, which has been approved for mammalian use, via oral ingestion or any other route of administration, by a governing authority or regulatory agency, such as the Food and Drug Administration (FDA) of the United States, is pharmaceutically acceptable.

[0050] Included in the compounds of formulas I, Ia, Ib, Ic, II, IIa, IIb, III, IIIa, and IIIb are the pharmaceutically acceptable salt forms of the free-base compounds. The term “pharmaceutically-acceptable salts” as used herein generally refers to salts, commonly used to form alkali metal salts and to form addition salts of free acids or free bases, which have been approved by a regulatory agency. Salts are formed from ionic associations, charge-charge

interactions, covalent bonding, complexation, coordination, etc. The nature of the salt is not critical, provided that it is pharmaceutically acceptable.

[0051] In some embodiments, the compound(s) of formulas I, Ia, Ib, Ic, II, IIa, IIb, III, IIIa, and IIIb is used to treat a subject by administering the compound(s) as a pharmaceutical composition. To this end, the compound(s), in one embodiment, is combined with one or more pharmaceutically acceptable excipients, including carriers, diluents or adjuvants, to form a suitable composition, which is described in more detail herein.

[0052] The term “excipient” as used herein generally refers to any pharmaceutically acceptable additive, carrier, adjuvant, or other suitable ingredient, other than the active pharmaceutical ingredient (API), which is typically included for formulation and/or administration purposes.

[0053] The term “diluent” as used herein generally refers to an agent used as filler in order to achieve the desired composition volume or weight. The diluent may be present in the pharmaceutical composition within granules in the form of a single compound or in the form of a mixture of compounds. Non-limiting examples of diluent include lactose, starch, pregelatinized starch, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose acetate, dextrose, mannitol, sodium phosphate, potassium phosphate, calcium phosphate, fructose, maltose, sorbitol, or sucrose.

[0054] The term “adjuvant,” as used herein generally refers to any substance or mixture of substances that increases the efficacy or potency of a compound disclosed herein on a target where the adjuvant is used together with the compound disclosed herein. However, when the adjuvant is used alone, no pharmacological effect is observed on the same target.

[0055] The terms “treat”, “treating,” “treatment,” and “therapy” as used herein generally refer to therapy, including without limitation, curative therapy, prophylactic therapy, and preventative therapy. Prophylactic treatment generally constitutes either preventing the onset of disorders altogether or delaying the onset of a pre-clinically evident stage of disorders in individuals.

[0056] The phrase "effective amount" as used herein generally refers to quantifying the amount of each agent, which will achieve the goal of improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies. The effective amount, in one embodiment, is administered in a single dosage form or in multiple dosage forms.

[0057] Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms or by other conventional methods known to those of skill in the art.

[0058] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an effective amount of the active ingredient to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0059] The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular hedgehog inhibitor employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

[0060] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0061] In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous,

intracerebroventricular and subcutaneous doses of the compounds of this invention for a patient will range from about 0.0001 to about 100 mg per kilogram of body weight per day. The mode of administration can have a large effect on dosage. Higher doses may be used for localized routes of delivery.

[0062] If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Those of skill in the art will readily appreciate that dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to side effects. Dosages for a given compound disclosed herein are readily determinable by those of skill in the art by a variety of means.

PHARMACEUTICAL COMPOSITIONS/FORMULATIONS

[0063] One embodiment provides a pharmaceutical composition comprising a compound of formula I, or a stereoisomer, tautomer, hydrate, solvate or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

[0064] In some embodiments, the compounds described herein are formulated into pharmaceutical compositions. Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. A summary of pharmaceutical compositions described herein can be found, for example, in Remington: *The Science and Practice of Pharmacy*, Nineteenth Ed., Easton, Pa.: Mack Publishing Company (1995); Hoover, John E., *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, Pennsylvania (1975); Liberman, H.A. and Lachman, L., Eds., *Pharmaceutical Dosage Forms*, Marcel Decker, New York, N.Y. (1980); and *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Seventh Ed., Lippincott Williams & Wilkins (1999), herein incorporated by reference for such disclosure.

[0065] A pharmaceutical composition, as used herein, refers to a mixture of a compound of formula I with other chemical components (i.e. pharmaceutically acceptable inactive ingredients), such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combination thereof. The pharmaceutical composition facilitates administration of the compound to an organism. In practicing the methods of treatment or use provided herein, therapeutically effective amounts of compounds described herein are administered in a pharmaceutical composition to a mammal having a disease, disorder, or condition to be treated. In some embodiments, the mammal is a human. A therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. The compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.

[0066] The pharmaceutical formulations described herein are administered to a subject by appropriate administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes. The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.

[0067] All formulations for oral administration are in dosages suitable for such administration. Examples of such dosage units are tablets or capsules. In some embodiments, these contain an amount of active ingredient from about 1 to 2000 mg, advantageously from about 1 to 500 mg, and typically from about 5 to 150 mg. A suitable daily dose for a human or other mammal vary

widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods and practices.

[0068] Conventional formulation techniques include, e.g., one or a combination of methods: (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion. Other methods include, e.g., spray drying, pan coating, melt granulation, granulation, fluidized bed spray drying or coating (e.g., wurster coating), tangential coating, top spraying, tableting, extruding and the like.

SYNTHETIC METHODS

[0069] Methods of the present invention may include the use of at least one compound of Formulas I, Ia, Ib, Ic, II, IIa, IIb, III, IIIa, and IIIb, which inhibits necrosis in the regulation of repair and/or functional performance of a wide range of cells, tissues and organs, and have therapeutic and cosmetic applications ranging from regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth muscle, regulation of lung, liver and other organs arising from the primitive gut, regulation of hematopoietic function, regulation of skin and hair growth, etc. Accordingly, the methods and compositions of the present invention include the use of the subject inhibitors for all such uses as inhibitors of necrosis may be implicated. Moreover, the subject methods can be performed on cells which are provided in culture (*in vitro*), or on cells in a whole animal (*in vivo*).

[0070] The examples and preparations provided below illustrated and exemplify the compounds described herein and methods of preparing such compounds. In general, the compounds described herein may be prepared by processes known in the general chemical arts.

[0071] The compounds of the present invention can be prepared using various synthetic routes, including those described below, starting from commercially available materials. Starting materials of the invention, are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the examples. In synthesizing starting materials, functional groups in some cases are

protected with suitable protecting groups when necessary. Functional groups may be removed according to known procedures in the art.

[0072] The protection of functional groups by protecting groups, the protecting groups themselves, and their removal reactions (commonly referred to as “deprotection”) are described, for example, in standard reference works, such as J.F.W. McOmie, *Protective Groups in Organic Chemistry*, Plenum Press, London and New York (1973), in T.W. Greene, *Protective Groups in Organic Synthesis*, Wiley, New York (1981), in *The Peptides*, Volume 3, E. Gross and J. Meienhofer editors, Academic Press, London and New York (1981).

[0073] All synthetic procedures described herein can be carried out under known reaction conditions, advantageously under those described herein, either in the absence or in the presence (usually) of solvents or diluents.

[0074] The invention further encompasses “intermediate” compounds, including structures produced from the synthetic procedures described, whether isolated or not, prior to obtaining the finally desired compound. Structures resulting from carrying out steps from a transient starting material, structures resulting from divergence from the described method(s) at any stage, and structures forming starting materials under the reaction conditions are all “intermediates” included in the invention. Further, structures produced by using starting materials in the form of a reactive derivative or salt, or produced by a compound obtainable by means of the process according to the invention and structures resulting from processing the compounds of the invention in situ are also within the scope of the invention.

[0075] New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention. In select embodiments, such starting materials are used and reaction conditions so selected as to obtain the desired compound(s).

[0076] Starting materials of the invention, are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the examples. In synthesizing starting materials, functional groups

in some cases are protected with suitable protecting groups when necessary. Protecting groups, their introduction and removal are described above.

[0077] All reagents and solvents were obtained commercially unless stated otherwise. All commercial reagents and solvent were used without purification unless stated otherwise. When required, some reagents and solvents were purified by standard techniques. For example, tetrahydrofuran may be purified by distillation from sodium. All thin-layer chromatography (TLC, GF254) analyses and column purification (100-200 mesh) were performed on silica gel (Qingdao Haiyang Chemical Co. Ltd. or Yantai Chemical Co. Ltd.), using petroleum ether (b.p. 60-90 °C)/ethyl acetate (v/v) as eluent; and spots revealed by UV visualization at 254 nm and I₂ vapor or phosphomolybdic acid. All organic layers after extraction were dried over anhydrous Na₂SO₄ unless stated otherwise. All nuclear magnetic resonance spectra were recorded using a Bruker-400 spectrometer at 400 MHz using TMS as an internal standard. LC-MS was run using an Agilent 1100 system with LC-MSD Trap recorder, diode array detector (DAD) with detecting wavelength at 214 nm and 254 nm, and ESI source. The HPCL column is an Agela Durashell C18 3.5 μm 4.6×50 mm column. Gradients were run using 0.1 NH₄HCO₃ aqueous solution and acetonitrile with gradient 5/95 to 95/5 in the run time indicated (for example, 5 min), flow rate at 1.8 mL/min.

[0078] The size and scale of the synthetic methods will vary depending on the desired amount of end product. It is understood that while specific reactants and amounts are provided in the Examples, one of skill in the art knows other alternative and equally feasible sets of reactants that will also yield the same compounds. Thus, where general oxidizers, reducers, solvents of various nature (aprotic, apolar, polar, etc.) are utilized, equivalents will be known in the art and are herein contemplated for use in the present methods.

[0079] Many of the steps below indicate various work-ups following termination of the reaction. A work-up involves generally quenching of a reaction to terminate any remaining catalytic activity and starting reagents. This is generally followed by addition of an organic solvent and separation of the aqueous layer from the organic layer. The product is typically obtained from

the organic layer and unused reactants and other spurious side products and unwanted chemicals are generally trapped in the aqueous layer and discarded. The work-up in standard organic synthetic procedures found throughout the literature is generally followed by drying the product by exposure to a drying agent, such as anhydrous Na₂SO₄, to remove any excess water or aqueous byproducts remaining partially dissolved in the organic layer and concentration of the remaining organic layer. Concentration of product dissolved in solvent may be achieved by any known means, such as evaporation under pressure, evaporation under increased temperature and pressure, and the like. Such concentrating may be achieved by use of standard laboratory equipment such as rotary-evaporator distillation, and the like. This is optionally followed by one or more purification steps which may include, but is not limited to, flash column chromatography, filtration through various media and/or other preparative methods known in the art and/or crystallization/recrystallization. (See, for instance, Addison Ault, "Techniques and Experiments for Organic Chemistry," 6th Ed., University Science Books, Sausalito, Calif., 1998, Ann B. McGuire, Ed., pp. 45-59).


GENERAL SYNTHETIC ROUTES

[0080] The methods and examples provided below illustrated and exemplified the compounds described herein and methods of preparing such compounds. In general, the compounds described herein may be prepared by processes known in the general chemical arts. The following methods are embodiments for some general synthetic routes leading to compounds of Formulas I, Ia, Ib, Ic, II, IIa, IIb, III, IIIa, and IIIb. Detailed reaction conditions for each Method can be found in the examples shown *vide infra*.

[0081] The compounds of the present invention can be prepared using various synthetic routes, including those described by methods A-N, BA-BS and AA-AT below, starting from commercially available materials. Starting materials of the invention, are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the methods and examples. In


synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Functional groups may be removed according to known procedures in the art.

[0082] Method A:




[0083] The (6-chloropyrimidin-4-yl)methanol could be converted to 4-chloro-6-chloromethylpyrimidine treated with SOCl_2 (step a).

[0084] Method B:




[0085] Substituted 4-chloro-3-oxobutanoate could be reacted with amidine and carbonate to give the pyrimidine intermediate (step a). Conversion of the hydroxypyrimidine to the chloropyrimidine may be achieved with POCl_3 (step b).

[0086] Method C, D:




[0087] Substituted 4-chloro-3-oxobutanoate could also be reacted with amidine and DBU to give the pyrimidine intermediate (step a). Conversion of the hydroxypyrimidine to the chloropyrimidine may be achieved with POCl_3 (step b). 4-aminopyrimidine core may be synthesized via methyl amine substitution (step c) followed by condensation of hydroxypyrimidine with 1-methylpiperazine (step d).

[0088] Method E




[0089] Pyrimidine-4-carbaldehyde core could be synthesized via cyclization to the pyrimidine core (step a) followed by condensation of hydroxypyrimidine with corresponded amine (step b), following hydrolysis (step c).

[0090] Method F, G, H




[0091] The key intermediate 4-(dimethoxymethyl)-6-(4-methylpiperazin-1-yl)-2-(methylthio)pyrimidine may be formed via cyclization followed condensation 6-(dimethoxymethyl)-2-(methylthio)pyrimidin-4-ol with 1-methylpiperazine (step b). Then 2-substituted Pyrimidine-4-carbaldehyde core could be synthesized via oxidation of methyl sulfide to methylsulfonyl (step c), substitution with corresponding alcohol (step f) or amine (step d) followed by hydrolysis (step e, g) or can be formed by Suzuki coupling (step h) followed hydrolysis (step i).

[0092] Method I




[0093] The targeted compounds may be formed via cyclization (step a) followed condensation hydroxypyrimidine with 1-methylpiperazine (step b), following substitution with corresponding amine (step c).

[0094] Method J




[0095] 4-(4-methylpiperazin-1-yl)pyrimidine core can be achieved by condensation the amino acid with 2,2-dimethyl-1,3-dioxane-4,6-dione followed decarboxylation (step a); following cyclization (step b) followed condensation hydroxypyrimidine with 1-methylpiperazine (step c) and at last de-Boc protective group (step c).

[0096] Method K




[0097] The pyridine-2-one core could be formed vis treatment pyridine lithium reagent with N-Boc lactam ($n = 0, 1, 2$).

[0098] Method L




[0099] The heteroaromatic core could be substituted with bromine treated with NBS and free radical initiator.

[00100] Method M




[00101] The 2-methyl-5-nynaopyrimidine core may be achieved by cyclization (step a) followed condensation hydroxypyrimidine with corresponding amine (step b), following chlorination (step c) and substitution with corresponding amine (step d).

[00102] Method N




[00103] 5-bromo-2-(bromomethyl)imidazo[1,2-a]pyridine may be synthesized by 6-bromopyridin-2-amine cyclization with ethyl 3-bromo-2-oxopropanoate (step a), and then followed by reduction with NaBH₄ (step b) and bromination with PBr₃ (step c).

[00104] Method BA, BB




[00105] The targeted core can be synthesized via the reductive amination(step a, b) with the ketone, or followed the reductive amination(step c) again with the aldehyde, then de-protective group treated with TFA (step d).

[00106] Method BC




[00107] The targeted core may be achieved by chlorination (step a) with TCCA and substitution with corresponding amine (step b).

[00108] Method BD




[00109] The 6,7-dihydroquinolin-8(5H)-one was treated with NaH and then added 1,2-dibromoethane to give 5',6'-dihydro-8'H-spiro[cyclopropane-1,7'-quinolin]-8'-one (step a).

[00110] Method BE




[00111] The spiro[2.5]octan-6-one was reacted with prop-2-yn-1-amine in the presence of NaAuCl₄ to give 7',8'-dihydro-5'H-spiro[cyclopropane-1,6'-quinoline] (step a).

[00112] Method BF, BG




[00113] The intermediate 1-(3-aminopyridin-2-yl)ethan-1-one may be formed by substitution with (4-methoxyphenyl)methanamine (step a) followed by Grignard reaction using CH₃MgCl (step b), then de-PMB group with TFA (step c). The targeted compounds can be obtained by acylation (step c) or mesylation (step d).

[00114] Method BH, BI




[00115] The 2-(pyrrolidin-2-yl)pyridine(S/R) can be formed by Grignard reaction with picolinonitrile and hydrolysis (step a), following the reductive amination with (4-methoxyphenyl)ethan-1-amine (R/S) (step b, d), then de-protective group treated with TFA (step c, e).

[00116] Method BJ




[00117] The racemic 2-(3-methylpyrrolidin-2-yl)pyridine may be achieved by imidization catalysis by TsOH (step a) followed Michael addition reaction treatment with ethyl (E)-but-2-enoate (step b), following formation lactam with con. HCl (step c), then reduction using LiAlH₄ (step d).

[00118] Method BK




[00119] The Picolinaldehyde may be reacted with aminoacetonitrile to generate the Schiff base. Pyrrole ring could be made via a [3 + 2] cyclization. The cyano group could be knock out by a series of reductive reaction.

[00120] Method BL




[00121] The substituted 8-nitroquinoline can be formed by cyclization treatment glycerin with 2-nitroaniline (step a), then substituted 8-nitroquinoline was reduced to the 8-aminoquinoline core with Pd/C(step b).

[00122] Method BM




[00123] The 8-aminoquinoline core could be methylated using methyl iodide.

[00124] Method BN




[00125] The quinoline containing core can be formed by cyclization treatment glycerin with 2-fluoroaniline (step a) and substitution with corresponding amine (step b).

[00126] Method BO




[00127] The PMB protective group could be removed under the acid condition.

[00128] Method BP




[00129] 8-chloro-1,7-naphthyridine can be formed via cyclization (step a), then chlorination through Sandmeyer reaction (step b).

[00130] Method BQ




[00131] 8-bromo-1,6-naphthyridine can be formed via cyclization (step a), then bromination with bromine.

[00132] Method BR




[00133] 4-chloro-1,5-naphthyridine could be obtained via oxidation with mCPBA (step a) followed chlorination treatment with POCl₃ (step b).

[00134] Method BS




[00135] 2-(pyridin-2-yl)propan-2-amine could be formylated (step a) followed by alkylation and hydrolyzation (step b) to give the desired target.

[00136] Method AA




[00137] The finally targeted compounds can be obtained by substitution the chlorine of 4-chloro-6-(chloromethyl)pyrimidine with corresponding amines respectively (step a, b).

[00138] Method AB




[00139] The finally targeted compounds can be obtained by substitution the chlorine of 4-chloropyrimidine core with N -Boc-piperazine (step a) followed de-Boc group treatment with acid (step b), following Michael addition reaction treatment with acrylonitrile (step c).

[00140] Method AC




[00141] The finally targeted compounds may be formed by reduced amination using $\text{NaBH}(\text{OAc})_3$ or NaBH_3CN (step a).

[00142] Method AD




[00143] The finally targeted compounds may be formed by de-Boc group under acid condition (step a) followed reduced amination using $\text{NaBH}(\text{OAc})_3$ or NaBH_3CN (step b).

[00144] Method AE




[00145] The finally targeted compounds can be obtained by substitution the bromine of 4-(bromomethyl)-6-chloropyrimidine with corresponding amines firstly (step a), then substitution the chlorine of 6-chloropyrimidine with corresponding amines (step b).

[00146] Method AF




[00147] The heteroaromatic derivatives could be synthesized via the reductive amination (step a) followed by substitution with corresponding amine (step b).

[00148] Method AG



[00149] The chlorine of the pyrimidine core was removed under Pd/C condition to give N-methyl-N-(pyrimidin-4-ylmethyl)-5,6,7,8-tetrahydroquinolin-8-amine.


[00150] Method AH



[00151] The (2-methylpyrimidin-5-yl)methanol containing targeted compounds could be synthesized from 2-methylpyrimidine-4,6-diol. The Vilsmeier-Haack reaction with DMF and POCl₃ (step a) followed by reduction aldehyde to alcohol with NaBH₄ (step a); protection of the alcohol group with TBSCl (step b), and then Heck reaction with trifluoroborate (step c).


Oxidation of the double bond to aldehyde with ozone (step c); the reductive amination (step d) followed by displacement of the pyrimidine chlorine with corresponding amines (step e).

[00152] Method AI




[00153] The TBS protective group could be removed under the acid condition.

[00154] Method AJ




[00155] The methyl ester of quinoline core could be reduced to alcohol by NaBH_4 or LiAlH_4 .

[00156] Method AK




[00157] The finally targeted compounds can be obtained by substitution the bromine of 5-bromo-2-(bromomethyl)imidazo[1,2-*a*]pyridine with corresponding amines firstly (step a) followed by substitution the bromine of 5-bromoimidazo[1,2-*a*]pyridine core with 1-methylpiperazine (step b), following introduction of hydroxymethyl group at 3-position of imidazo[1,2-*a*]pyridine core under formaldehyde condition (step 3).

[00158] Method AL




[00159] The finally targeted compound can be synthesized by fluorination of the commercially 6,7-dihydroquinolin-8(5H)-one using selectfluoro (step a), then the reduced amination of ketone with methyl amine (step b), following by alkylation with 4-chloro-6-(chloromethyl)-2-methylpyrimidine (step c), and finally substitution with 1-methylpiperazine(step d).

[00160] Method AM



[00161] The finally targeted compounds may be formed by reduced amination with corresponding aldehydes using NaBH(OAc)₃ or NaBH₃CN (step a).

[00162] Method AN




[00163] The finally targeted compounds may be formed by substitution with aryl halogen under base, high temperature condition (step a).

[00164] Method AO




[00165] The finally targeted compounds may be formed by Buchwald coupling reaction with aryl halogen $\text{Pd}_2(\text{dba})_3$, BINAP, Cs_2CO_3 condition (step a).

[00166] Method AP




[00167] The finally targeted compound may be formed by de-Boc group under the acid condition (step a) followed condensation using HATU (step b).

[00168] Method AQ




[00169] The halogen of quinoline core could be converted to cyano group under the condition of $\text{Pd}(\text{PPh}_3)_4$, dppf, and zinc cyanide or $\text{Pd}_2(\text{dba})_3$, dppf, and zinc cyanide.


[00170] Method AR



[00171] The halogen of quinoline core could be converted to methylsulfonyl group under the condition of sodium methanesulfonate, L-Proline and cuprous iodide.

[00172] Method AS


[00173] The finally targeted compounds could be synthesized from 8-fluoroquinoline. The nitration with HNO_3 (step a) followed by displacement of the aryl fluorine with corresponding amines (step b). The nitro group can be reduced to the amino group with SnCl_2 (step c) and then mesylation with MsCl (step d).

[00174] Method AT

[00175] The finally targeted compounds could be synthesized under the MsCl and TEA condition.

[00176] Examples


[00177] General reaction progress was monitored by analytical thin layer chromatography performed on silica gel HSGF254 pre-coated plates. Organic solutions were dried over anhydrous Na_2SO_4 , and the solvents were removed under reduced pressure. ^1H NMR were obtained on 400 MHz (Varian) spectrometers. Chemical shifts were given in ppm using tetramethylsilane as internal standard. Mass spectra were obtained using an Agilent 1100 LC/MSD Trap SL version Mass Spectrometer. Final compounds were purified with silica gel 100-200 mesh for column chromatography.

[00178] Method A**[00179] Preparation of 4-chloro-6-(chloromethyl)pyrimidine**

[00180] Step a. 4-chloro-6-(chloromethyl)pyrimidine: To a solution of (6-Chloropyrimidin-4-yl)methanol (280 mg, 1.9 mmol, see reference WO2016128529) in dichloromethane (10 mL) was added SOCl_2 (280 mg, 2.3 mmol). The reaction was stirred at room temperature overnight. The mixture was quenched with saturated NaHCO_3 aqueous solution (50 mL) and extracted with dichloromethane (20 mL x 3). The combined organic layer was washed with brine, dried over Na_2SO_4 and concentrated to give the desired product (180 mg, 58%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.95 (s, 1H), 7.62 (s, 1H), 4.62 (s, 2H).

[00181] Method B

[00182] Preparation of 4-chloro-6-(chloromethyl)-2-(methylthio)pyrimidine




[00183] Step a. 6-(chloromethyl)-2-(methylthio)pyrimidin-4-ol: To a solution of ethyl 4-chloro-3-oxobutanoate (13 g, 79 mmol) and methyl carbamimidothioatesulphate (20 g, 72 mmol) in water (200 mL) was added sodium carbonate (11.5 g, 108 mmol). The reaction was stirred at room temperature overnight. The mixture was quenched with 6M HCl aqueous solution to pH acid and filtered. The filter cake was dried to give the desired product (11.1 g, 73%) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 12.91 (s, 1H), 6.42 (s, 1H), 4.36 (s, 2H), 2.59 (s, 3H).

[00184] Step b. 4-chloro-6-(chloromethyl)-2-(methylthio)pyrimidine: The solution of 6-(chloromethyl)-2-(methylthio)pyrimidin-4-ol (2.8 g, 14.7 mmol) in POCl_3 (10 mL) was heated to 100 °C, and stirred for 1 h. The reaction mixture was concentrated and added saturated NaHCO_3 aqueous solution (100 mL) and extracted with ethyl acetate (100 mL). The organic layers was concentrated and the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 100/3) to give the desired product (2.4 g, 80%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.23 (s, 1H), 4.53 (s, 2H), 2.58 (s, 3H).

[00185] Method C

[00186] Preparation of 4-chloro-6-(chloromethyl)-2-methylpyrimidine




[00187] Step a. 6-(chloromethyl)-2-methylpyrimidin-4-ol: To a solution of ethyl 4-chloro-3-oxobutanoate (16.5 g, 100 mmol) and acetamidine hydrochloride (10 g, 106 mmol) in ethanol (150 mL) was slowly added DBU (30.4 g, 200 mmol) at 4 °C. The reaction was stirred at room temperature overnight. The reaction mixture was concentrated and the residue was dissolved in

dichloromethane (120 mL), then washed with brine (30 mL x 3). The organic layer was dried over Na₂SO₄ and concentrated to give the desired product (7.93 g, 50%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 13.01 (s, 1H), 6.53 (s, 1H), 4.37 (s, 2H), 2.50 (s, 3H).

[00188] Step b. 4-chloro-6-(chloromethyl)-2-methylpyrimidine: The solution of 6-(chloromethyl)-2-methylpyrimidin-4-ol (7.93 g, 50 mmol) in POCl₃ (20 mL) was heated to 110 °C, and stirred for 30 min. Then reaction mixture was concentrated and dissolved in ethyl acetate (20 mL), then added this solution into ice water (100 mL), extracted with ethyl acetate (30 mL x 3). The combined organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 5/1) to give the desired product (4.0 g, 23%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.41 (s, 1H), 4.55 (s, 2H), 2.71 (s, 3H).

[00189] Method D


[00190] Preparation of *N*-methyl-1-(2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methanamine



[00191] Step c. 2-methyl-6-((methylamino)methyl)pyrimidin-4-ol: The solution of 6-(chloromethyl)-2-methylpyrimidin-4-ol (1.7 g, 11 mmol), methylamine solution (30 wt percent in absolute ethanol, 3 g), KI (183 mg, 1.1 mmol) and DIPEA (7.1 g, 55 mmol) in CH₃CN (50 mL) was added into a sealed tube, and heated to 60 °C. The reaction was stirred at this temperature overnight. The reaction mixture was concentrated and the residue was purified by silica gel column chromatography (dichloromethane /methanol = 10/1) to give the desired product (600 mg, 35%) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 6.36 (s, 1H), 3.80 (s, 2H), 2.66 (s, 1H), 2.55 (s, 3H), 2.43 (s, 2H).

[00192] Step d. *N*-methyl-1-(2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methanamine: To a solution of 2-methyl-6-((methylamino)methyl)pyrimidin-4-ol (300 mg, 1.96 mmol), TEA (1.9 g, 19.6 mmol) and *N*-methylpiperazine (980 mg, 9.8 mmol) in CH₃CN (20 mL) was added PyBOP (1.1 g, 2.15 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (dichloromethane /methanol = 20/1) to give the desired product (300 mg, 65%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 6.38 (s, 1H), 3.67-3.63 (m, 6H), 2.47-2.45 (m, 10H), 2.32 (s, 3H).

[00193] Method E

[00194] Preparation of 2-methyl-6-(4-methylpiperazin-1-yl)pyrimidine-4-carbaldehyde


[00195] Step a. 6-(dimethoxymethyl)-2-methylpyrimidin-4-ol: To a solution of methyl 4,4-dimethoxy-3-oxobutanoate (300 mg, 1.7 mmol) and acetamidine hydrochloride (320 mg, 3.4 mmol) in water (10 mL) was added K_2CO_3 (940 mg, 6.8 mmol). The reaction was stirred at room temperature overnight. The mixture was quenched with AcOH to pH acid and extracted with dichloromethane (100 mL x 3). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 50/1) to give the desired product (110 mg, 35%) as a white solid.

[00196] Step b. 4-(dimethoxymethyl)-2-methyl-6-(4-methylpiperazin-1-yl)pyrimidine: To a solution of 6-(dimethoxymethyl)-2-methylpyrimidin-4-ol (110 mg, 0.6 mmol), TEA (600 mg, 6 mmol) and *N*-methylpiperazine (90 mg, 0.9 mmol) in CH_3CN (10 mL) was added PyBOP (340 mg, 0.7 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was evaporated to remove most of CH_3CN , added saturated $NaHCO_3$ aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 100/3) to give the desired product (140 mg, 88%) as a yellow oil.

[00197] Step c. 2-methyl-6-(4-methylpiperazin-1-yl)pyrimidine-4-carbaldehyde: The mixture of 4-(dimethoxymethyl)-2-methyl-6-(4-methylpiperazin-1-yl)pyrimidine (140 mg, 0.5 mmol) and sulfuric acid (20 wt percent in water, 5 mL) was stirred at reflux overnight. Then the saturated $NaHCO_3$ aqueous solution was added to adjust pH to basic and extracted with dichloromethane (100 mL x 3). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated to give the crude desired product (110 mg, 97%) as a yellow oil.

[00198] Method F

[00199] Preparation of 2-(dimethylamino)-6-(4-methylpiperazin-1-yl)pyrimidine-4-carbaldehyde



[00200] Step a. 6-(dimethoxymethyl)-2-(methylthio)pyrimidin-4-ol: To a solution of methyl 4,4-dimethoxy-3-oxobutanoate (3 g, 17 mmol) and methyl carbamimidothioatesulphate (9.5 g, 34 mmol) in water (100 mL) was added K_2CO_3 (17.6 g, 76.5 mmol). The reaction was stirred at room temperature overnight. The mixture was quenched with AcOH to adjust pH to acid and extracted with dichloromethane (100 mL x 3). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 100/1) to give the desired product (3.4 g, 92%) as a white solid. ^1H NMR (400 MHz, $CDCl_3$) δ 12.80 (s, 1H), 6.46 (s, 1H), 5.07 (s, 1H), 3.40 (s, 6H), 2.60 (s, 3H).

[00201] Step b. 4-(dimethoxymethyl)-6-(4-methylpiperazin-1-yl)-2-(methylthio)pyrimidine: To a solution of 6-(dimethoxymethyl)-2-(methylthio)pyrimidin-4-ol (3.4 g, 16 mmol), TEA (16 g, 160 mmol) and *N*-methylpiperazine (2.4 g, 40 mmol) in CH_3CN (100 mL) was added PyBOP (9g, 17.6 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was evaporated to remove most of CH_3CN , added saturated $NaHCO_3$ aqueous solution (200 mL) and extracted with dichloromethane (200 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol= 100/3) to give the desired product (2.8 g, 59%) as a yellow oil. ^1H NMR (400 MHz, $CDCl_3$) δ 6.45 (s, 1H), 5.07 (s, 1H), 3.70 (s, 4H), 3.40 (s, 6H), 2.51 (s, 3H), 2.47 (t, J = 5.0 Hz, 4H), 2.34 (s, 3H).

[00202] Step c. 4-(dimethoxymethyl)-6-(4-methylpiperazin-1-yl)-2-(methylsulfonyl)pyrimidine: To a solution of 4-(dimethoxymethyl)-6-(4-methylpiperazin-1-yl)-2-(methylthio)pyrimidine (2.8 g, 9.4 mmol) in THF (90 mL) and water (4.5 mL) was added Oxone (7 g, 11 mmol). The reaction was stirred at room temperature for 4h. Then the reaction was added saturated $NaHCO_3$ aqueous solution (200 mL) and extracted with ethyl acetate (200 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated to give the desired product (2.4 g, 78%) as a yellow oil.


[00203] Step d. 4-(dimethoxymethyl)-*N,N*-dimethyl-6-(4-methylpiperazin-1-yl)pyrimidin-2-amine: To a solution of 4-(dimethoxymethyl)-6-(4-methylpiperazin-1-yl)-2-

(methylsulfonyl)pyrimidine (340 mg, 1 mmol) in THF (5 mL) in a sealed tube was added dimethylamine (5 mL). The reaction mixture was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, added saturated NaHCO_3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/1 to 100/3/1) to give the desired product (260 mg, 88%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 6.06 (s, 1H), 4.98 (s, 1H), 3.62 (s, 4H), 3.39 (s, 6H), 3.11 (s, 6H), 2.42 (s, 4H), 2.30 (s, 3H).

[00204] Step e. 2-(dimethylamino)-6-(4-methylpiperazin-1-yl)pyrimidine-4-carbaldehyde: The mixture of 4-(dimethoxymethyl)-N,N-dimethyl-6-(4-methylpiperazin-1-yl)pyrimidin-2-amine (260 mg, 1.3 mmol) and sulfuric acid (20 wt percent in water, 5 mL) was stirred at reflux overnight. Then the saturated NaHCO_3 aqueous solution was added to adjust pH to basic and extracted with dichloromethane (100 mL x 3). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated to give the crude desired product (210 mg, 65%) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 9.76 (s, 1H), 6.39 (s, 1H), 3.68 (s, 4H), 3.18 (s, 6H), 2.45 (s, 4H), 2.33 (s, 3H).

[00205] Method G

[00206] Preparation of 2-ethoxy-6-(4-methylpiperazin-1-yl)pyrimidine-4-carbaldehyde




[00207] Step f. 4-(dimethoxymethyl)-2-ethoxy-6-(4-methylpiperazin-1-yl)pyrimidine: To a solution of 4-(dimethoxymethyl)-6-(4-methylpiperazin-1-yl)-2-(methylsulfonyl)pyrimidine (200 mg, 0.61 mmol) in ethanol (5 mL) was added sodium ethanolate (206 mg, 3 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, added saturated NaHCO_3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/1 to 100/3/1) to give the desired product (160 mg, 89%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 6.42 (s, 1H), 5.04 (s, 1H), 4.35 (q, $J = 7.2$ Hz, 2H), 3.68 (s, 4H), 3.40 (s, 6H), 2.45 (t, $J = 5.0$ Hz, 4H), 2.32 (s, 3H), 1.38 (t, $J = 7.0$ Hz, 3H).

[00208] Step g. 2-ethoxy-6-(4-methylpiperazin-1-yl)pyrimidine-4-carbaldehyde: The mixture of 4-(dimethoxymethyl)-2-ethoxy-6-(4-methylpiperazin-1-yl)pyrimidine (160 mg, 0.5

mmol) and sulfuric acid (20 wt percent in water, 5 mL) was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, and the saturated NaHCO_3 aqueous solution was added to adjust pH to basic and extracted with dichloromethane (100 mL x 3). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated to give the crude desired product (100 mg, 80%) as a yellow solid.

[00209] Method H

[00210] Preparation of 6-(4-methylpiperazin-1-yl)-2-phenylpyrimidine-4-carbaldehyde



[00211] Step h. 4-(dimethoxymethyl)-6-(4-methylpiperazin-1-yl)-2-phenylpyrimidine:


The mixture of 4-(dimethoxymethyl)-6-(4-methylpiperazin-1-yl)-2-(methylthio)pyrimidine (298 mg, 1 mmol), phenylboronic acid (244 mg, 2 mmol), copper(I) thiophene-2-carboxylate (497 mg, 2.6 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (115 mg, 0.1 mmol) in THF (20 mL) was stirred at reflux overnight under N_2 atmosphere. Then the reaction solution was concentrated and the residue was purified by silica gel column chromatography (dichloromethane/methanol = 100/1.5) to give the desired product (240 mg, 73%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 8.41 (d, J = 3.6 Hz, 2H), 7.44-7.43 (m, 3H), 6.70 (s, 1H), 5.24 (s, 1H), 3.82-3.80 (m, 4H), 3.47 (s, 6H), 2.53-2.52 (m, 4H), 2.37 (s, 3H).

[00212] Step i. 6-(4-methylpiperazin-1-yl)-2-phenylpyrimidine-4-carbaldehyde: The

mixture of 4-(dimethoxymethyl)-6-(4-methylpiperazin-1-yl)-2-phenylpyrimidine (240 mg, 0.73 mmol) and sulfuric acid (20 wt percent in water, 10 mL) was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, and washed with diethyl ether (10 mL). The water phase was added 6M NaOH aqueous solution to adjust pH to 10 and extracted with dichloromethane (30 mL x 3). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 100/2) to give the desired product (170 mg, 82%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 10.02 (s, 1H), 8.50-8.45 (m, 2H), 7.50-7.49 (m, 3H), 6.99 (s, 1H), 3.95-3.80 (m, 4H), 2.63-2.47 (m, 4H), 2.37 (s, 3H).

[00213] Method I

[00214] Preparation of 1-(5-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)-N-methylmethanamine



[00215] Step a. ethyl 2,4-difluoro-3-oxobutanoate: To a solution of NaH (60 wt percent moistened with oil, 936 mg, 23.4 mmol) in diethyl ether (50 mL) was added dropwise ethyl 2-fluoroacetate (5 g, 47.2 mmol) at room temperature. The reaction was stirred at 40°C for 4h. The reaction mixture was cooled to 0°C and poured into 2M sulfuric acid aqueous solution (15 mL). The mixture was extracted with diethyl ether (50 mL x 3). The combined organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 10/1 to 2/1) to give the desired product (2 g, 25%) as a yellow oil.

[00216] Step b. 5-fluoro-6-(fluoromethyl)-2-methylpyrimidin-4-ol: To a solution of methyl 4,4-dimethoxy- 3-oxobutanoate (1.9 g, 11.4 mmol) and acetamidine hydrochloride (2.2 g, 22.8 mmol) in ethanol (40 mL) was added EtONa (2.3 g, 34.2 mmol). The reaction was stirred at reflux overnight. The mixture was cooled to room temperature. 6M HCl aqueous solution (2 mL) was added and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 3/1 to 1/1) to give the desired product (800 mg, 43%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 13.07 (br s, 1H), 5.35 (d, *J* = 46.8 Hz, 2H), 2.53 (s, 3H).


[00217] Step c. 5-fluoro-4-(fluoromethyl)-2-methyl-6-(4-methylpiperazin-1-yl)pyrimidine: To a solution of 5-fluoro-6-(fluoromethyl)-2-methylpyrimidin-4-ol (800 mg, 5 mmol), TEA (1.5 g, 15 mmol) and *N*-methylpiperazine (750 mg, 7.5 mmol) in CH₃CN (10 mL) was added PyBOP (2.9 g, 5.5 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was evaporated to remove most of CH₃CN, added dichloromethane (100 mL) to dilute, washed with saturated NaCl aqueous solution (50 mL x 3). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (pure ethyl acetate) to give the desired product (1.0 g, 90%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 5.36 (d, *J* = 47.2 Hz, 2H), 3.87-3.73 (m, 4H), 2.57-2.50 (m, 4H), 2.49 (s, 3H), 2.33 (s, 3H).

[00218] Step d. 1-(5-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)-*N*-methylmethanamine: The mixture of 5-fluoro-4-(fluoromethyl)-2-methyl-6-(4-methylpiperazin-

1-yl)pyrimidine (1.0 g, 4.1 mmol) and 2M methyl amine (in methanol, 6 mL) in water (15 mL) and i-propanol (15 mL) in a sealed tube was stirred at reflux overnight. The reaction solution was evaporated to remove most of i-propanol, and extracted with dichloromethane (30 mL x 3). The combined organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 400/10/1 to 200/10/1) to give the desired product (800 mg, 76%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 3.80-3.74 (m, 4H), 3.73 (s, 2H), 2.48 -2.46 (m, 4H), 2.44 (s, 6H), 2.31 (s, 3H).

[00219] Method J

[00220] Preparation of (S)-4-(4-methylpiperazin-1-yl)-2-(methylthio)-6-(pyrrolidin-2-yl)pyrimidine



[00221] Step a. (S)-tert-butyl 2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-1-carboxylate: To a mixture of Boc-L-Proline-OH (5 g, 23 mmol), 2,2-dimethyl-1,3-dioxane-4,6-dione (3.4 g, 23 mmol) and DMAP (5.7 g, 46 mmol) in dichloromethane (70 mL) was added DCC (4.8 g, 23 mmol) at 0 °C. The mixture was stirred at room temperature for 48 h before the reaction mixture was filtered. The filtrate was added 1M HCl aqueous solution (100 mL) and the water phase was extracted with dichloromethane (200 mL). The combined organic layer was dried over Na₂SO₄, filtered and evaporated to give a yellow oil, about 7.5 g. This residue was diluted with EtOH (100 mL) and stirred at reflux for 2h. The resulting solution was concentrated and purified by silica gel column chromatography (petroleum ether/ethyl acetate = 4/1) to give the desired product (4.0 g, 60%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 4.41-4.23 (m, 1H), 4.23-4.13 (m, 2H), 3.59-3.39 (m, 4H), 2.25-2.05 (m, 2H), 1.91-1.83 (m, 2H), 1.46-1.40 (m, 9H), 1.31-1.23 (m, 3H).


[00222] Step b. (S)-tert-butyl 2-(6-hydroxy-2-(methylthio)pyrimidin-4-yl)pyrrolidine-1-carboxylate: To a solution of (S)-tert-butyl 2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-1-carboxylate (500 mg, 1.8 mmol) and methyl carbamimidodithioatesulphate (1.0 g, 3.6 mmol) in water (25 mL) was added K₂CO₃ (1.1 g, 8.1 mmol). The reaction was stirred at room temperature overnight. The reaction mixture was quenched with 1M HCl aqueous solution to adjust pH to acid and extracted with dichloromethane (50 mL x 3). The combined organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column

chromatography (dichloromethane/methanol = 20/1) to give the desired product (200 mg, 37%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 6.09-6.05 (m, 1H), 4.75-4.50 (m, 1H), 3.59-3.39 (m, 2H), 2.55 (s, 3H), 2.28-2.14 (m, 1H), 2.00-1.80 (m, 3H), 1.51-1.32 (m, 9H).

[00223] Step c. (*S*)-4-(4-methylpiperazin-1-yl)-2-(methylthio)-6-(pyrrolidin-2-yl)pyrimidine: To a solution of (*S*)-*tert*-butyl 2-(6-hydroxy-2-(methylthio)pyrimidin-4-yl)pyrrolidine-1-carboxylate (200 mg, 0.64 mmol), TEA (650 mg, 6.4 mmol) and *N*-methylpiperazine (100 mg, 0.96 mmol) in CH_3CN (5 mL) was added PyBOP (510 mg, 0.96 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was evaporated to remove most of CH_3CN , added dichloromethane (100 mL) to dilute, washed with saturated NaHCO_3 aqueous solution (100 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 100/1) to give the crude intermediate (150 mg) as a yellow oil. Then it was diluted with ethyl acetate (3 mL), added 3M HCl/ ethyl acetate (4 mL). The mixture was stirred at room temperature overnight. Then the reaction solution was evaporated, added saturated NaHCO_3 aqueous solution (50 mL), and extracted with dichloromethane (50 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated to give the desired product (100 mg, 53%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 6.29 (s, 1H), 3.98 (t, $J = 7.4$ Hz, 1H), 3.74-3.58 (m, 4H), 3.19-3.09 (m, 1H), 3.02-2.92 (m, 1H), 2.49 (s, 3H), 2.45 (t, $J = 5.2$ Hz, 4H), 2.33 (s, 3H), 2.23-2.10 (m, 1H), 1.82-1.76 (m, 2H), 1.76-1.63 (m, 1H).

[00224] Method K

[00225] Preparation of *tert*-butyl 5-oxo-5-(pyridin-2-yl)pentylcarbamate




[00226] Step a. *tert*-butyl 5-oxo-5-(pyridin-2-yl)pentylcarbamate: To a THF solution (30 mL) containing commercially available 2-bromopyridine (1.4 g, 9 mmol) and *N,N,N',N'*-tetramethyl ethylene diamine (960 mg, 6.5 mmol), a hexane solution (3 mL, 7.5 mmol) of 2.5M *n*-butyl lithium was added dropwise at -78°C , and the resulting solution was stirred at the same temperature for 2h. To the reaction solution, *tert*-butyl 2-oxopiperidine-1-carboxylate (1 g, 5 mmol) was added at -78°C , and the resulting solution was stirred at the same temperature for 2h. To the reaction solution, water (10 mL) was added, and the solution was extracted with ethyl acetate (100 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 5/1) to give the desired product (670 mg, 48%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.68 (d, $J = 4.8$

Hz, 1H), 8.03 (d, $J = 8.0$ Hz, 1H), 7.79-7.77 (m, 1H), 7.51-7.44 (m, 1H), 4.69 (s, 1H), 3.27-3.21 (m, 2H), 3.21-3.15 (m, 2H), 1.80-1.74 (m, 2H), 1.63-1.55 (m, 2H), 1.44 (s, 9H).

[00227] Method L


[00228] Preparation of 2-(bromomethyl)-4-chloropyrimidine



[00229] Step a. 2-(bromomethyl)-4-chloropyrimidine: To a solution 4-chloro-2-methylpyrimidine (370 mg, 2.9 mmol), NBS (566 mg, 3.2 mmol) and AIBN (50 mg, 0.3 mmol) in CCl_4 (10 mL) was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, added saturated NaHCO_3 aqueous solution (50 mL) and extracted with dichloromethane (50 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 50/1) to give the desired product (130 mg, 22%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.62 (d, $J = 5.6$ Hz, 1H), 7.27 (d, $J = 5.6$ Hz, 1H), 4.54 (s, 2H).

[00230] Method M

[00231] Preparation of *tert*-butyl 4-(5-cyano-2-methyl-6-((methyl(1,2,3,4-tetrahydronaphthalen-1-yl)amino)methyl)pyrimidin-4-yl)piperazine-1-carboxylate



[00232] Step a. 4-hydroxy-2,6-dimethylpyrimidine-5-carbonitrile: To a solution of methyl (Z)-ethyl 2-cyano-3-ethoxybut-2-enoate (5.0 g, 27 mmol) and acetamidine hydrochloride (3.9 g, 41 mmol) in ethanol (80 mL) was added K_2CO_3 (11.3 g, 82 mmol). The reaction was stirred at room temperature overnight. The mixture was concentrated, added 3M HCl aqueous solution to adjust pH to 5 and extracted with n-butanol (50 mL x 6). The combined organic layer was evaporated to give the desired product (3.5 g, 87%) as a yellow solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.30 (s, 1H), 2.39 (s, 3H), 2.35 (s, 3H).

[00233] Step b. *tert*-butyl 4-(5-cyano-2,6-dimethylpyrimidin-4-yl)piperazine-1-carboxylate: To a solution of 4-hydroxy-2,6-dimethylpyrimidine-5-carbonitrile (2.5 g, 16.8


mmol), TEA (5.1 g, 50.4 mmol) and *tert*-butyl piperazine-1-carboxylate (4.7 g, 25.2 mmol) in CH₃CN (60 mL) was added PyBOP (9.6 g, 18.5 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 5/1 to 3/1) to give the desired product (4.3 g, 81%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 3.94 (s, 4H), 3.55 (s, 4H), 2.57 (s, 3H), 2.50 (s, 3H), 1.47 (s, 9H)

[00234] Step c. *tert*-butyl 4-(6-(chloromethyl)-5-cyano-2-methylpyrimidin-4-yl)piperazine-1-carboxylate: A mixture of *tert*-butyl 4-(5-cyano-2,6-dimethylpyrimidin-4-yl)piperazine-1-carboxylate (10 g, 60.4 mmol) in DCM (100 mL) was added TCCA (2.9 g, 12.6 mmol) at 0°C, and the resulting solution was stirred at the same temperature for 1h, then stirred at room temperature for 6h. The reaction was quenched with the saturated Na₂S₂O₃ aqueous solution. The reaction mixture was filtered and the filtrate was extracted with dichloromethane (50 mL x 3). The combined organic layer was washed with brine and dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 10/1 to 5/1) to give the desired product (2.4 g, 54%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 3.94 (s, 4H), 3.55 (s, 4H), 2.57 (s, 3H), 2.50 (s, 3H), 1.47 (s, 9H)

[00235] Step d. *tert*-butyl 4-(5-cyano-2-methyl-6-((methyl(1,2,3,4-tetrahydronaphthalen-1-yl)amino)methyl)pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of *N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (421 mg, 2.6 mmol, see reference WO2006026703), *tert*-butyl 4-(6-(chloromethyl)-5-cyano-2-methylpyrimidin-4-yl)piperazine-1-carboxylate (1.0 g, 2.8 mmol), KI (45 mg, 0.3 mmol) and DIPEA (671 mg, 5.2 mmol) in CH₃CN (10 mL) was stirred at room temperature overnight. The reaction solution was evaporated and the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 1/1) to give the desired product (800 mg, 64%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.44 (d, *J* = 3.6 Hz, 1H), 7.35 (d, *J* = 7.2 Hz, 1H), 7.04 (dd, *J* = 7.2, 4.8 Hz, 1H), 4.15-4.08 (m, 1H), 4.08-3.97 (m, 2H), 3.97-3.88 (m, 4H), 3.02-2.93 (m, 4H), 2.86-2.76 (m, 1H), 2.73-2.63 (m, 1H), 2.53 (s, 3H), 2.28 (s, 3H), 2.22-2.12 (m, 1H), 2.10-1.92 (m, 2H), 1.76 (s, 10H).

[00236] Method N

[00237] Preparation of 5-bromo-2-(bromomethyl)imidazo[1,2-*a*]pyridine




[00238] Step a. ethyl 5-bromoimidazo[1,2-*a*]pyridine-2-carboxylate: The solution of methyl 6-bromopyridin-2-amine (1.7 g, 10 mmol) and ethyl 3-bromo-2-oxopropanoate (2.3 g, 12 mmol) in ethanol (80 mL) was stirred at reflux overnight. The reaction mixture was cooled to room temperature and filtered. The filter cake was dried by oil pump to give the crude desired product (2.8 g) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.49 (s, 1H), 7.76 (d, *J* = 8.4 Hz, 1H), 7.53-7.50 (m, 1H), 7.47-7.43 (m, 1H), 4.36 (q, *J* = 7.2 Hz, 2H), 1.34 (q, *J* = 7.2 Hz, 3H).

[00239] Step b. (5-bromoimidazo[1,2-*a*]pyridin-2-yl)methanol: To the solution of ethyl 5-bromoimidazo[1,2-*a*]pyridine-2-carboxylate (1.5 g, 5.6 mmol) in ethanol (20 mL) was added NaBH₄ (1.0 g, 28 mmol), and stirred at reflux overnight. The reaction solution was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 40/1) to give the desired product (500 mg, 39 %) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.84 (s, 1H), 7.59 (d, *J* = 8.8 Hz, 1H), 7.31 (d, *J* = 6.8 Hz, 1H), 7.27-7.23 (m, 1H), 5.27 (br s, 1H), 4.64 (s, 2H).

[00240] Step c. 5-bromo-2-(bromomethyl)imidazo[1,2-*a*]pyridine: The solution of (5-bromoimidazo[1,2-*a*]pyridin-2-yl)methanol (400 mg, 1.76 mmol) in dichloromethane (50 mL) was added PBr₃ (475 mg, 1.73 mmol) at 0°C, and stirred at the same temperature for 4h. The saturated NaHCO₃ aqueous solution (10 mL) was added to adjust pH to 8. The water phase was extracted with dichloromethane (100 mL). The combined organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 40/1) to give the desired product (260 mg, 50 %) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.85 (s, 1H), 7.59 (s, 1H), 7.14 (s, 1H), 7.07 (s, 1H), 4.67 (s, 2H).

[00241] Method BA

[00242] Preparation of *N*-methyl-1-(3-methylpyridin-2-yl)ethanamine




[00243] Step a. *N*-methyl-1-(3-methylpyridin-2-yl)ethanamine: To a solution of 1-(3-methylpyridin-2-yl)ethanone (500 mg, 3.7 mmol) in THF (10 mL) was added methylamine solution (30 wt percent in absolute ethanol, 14.8 mL) and Ti(OEt)₄ (1.7 g, 7.4 mmol). The reaction mixture was stirred for 10min at room temperature, before NaBH₄ (563 mg, 14.8 mmol) was added, this reaction mixture was stirred for 2h at room temperature. The saturated NaHCO₃ aqueous solution (100 mL) was added and extracted with dichloromethane (100 mL). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica

gel column chromatography (dichloromethane/methanol/ ammonium hydroxide = 100/1/1) to give the desired product (300 mg, 54%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.44 (d, J = 4.8 Hz, 1H), 7.41 (d, J = 7.2 Hz, 1H), 7.09-7.02 (m, 1H), 3.95 (q, J = 6.4 Hz, 1H), 2.34 (s, 3H), 2.25 (s, 3H), 1.31 (d, J = 6.4 Hz, 3H).

[00244] Method BB

[00245] Preparation of (*S*)-*N*-methyl-1-(pyridin-2-yl)ethanamine



[00246] Step b. (*S*)-1-(4-methoxyphenyl)-*N*-((*S*)-1-(pyridin-2-yl)ethyl)ethanamine and (*S*)-1-(4-methoxyphenyl)-*N*-((*R*)-1-(pyridin-2-yl)ethyl)ethanamine: The solution of 1-(pyridin-2-yl)ethanone (605 mg, 5 mmol) in dichloromethane (30 mL) was added $\text{NaBH}(\text{OAc})_3$ (2.12 mg, 10 mmol) and (*S*)-1-(4-methoxyphenyl)ethanamine (755 mg, 5 mmol) at 0 °C. The resulting suspension was stirred at room temperature overnight. The reaction mixture was added saturated NaHCO_3 aqueous solution (20 mL) and extracted with dichloromethane (50 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/acetone/ammonium hydroxide = 200/5/2) to give the desired product (*S*)-1-(4-methoxyphenyl)-*N*-((*S*)-1-(pyridin-2-yl)ethyl)ethanamine (1.0 g, 78%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.60 (d, J = 3.2 Hz, 1H), 7.66-7.54 (m, 1H), 7.20-7.12 (m, 3H), 7.06 (d, J = 7.6 Hz, 1H), 6.86 (d, J = 8.0 Hz, 2H), 3.81 (s, 3H), 3.61-3.55 (m, 1H), 3.46-3.35 (m, 1H), 1.31-1.25 (m, 6H). And (*S*)-1-(4-methoxyphenyl)-*N*-((*R*)-1-(pyridin-2-yl)ethyl)ethanamine (70 mg, 6%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.54 (s, 1H), 7.61-7.50 (m, 1H), 7.26-7.11 (m, 4H), 6.81 (d, J = 7.2 Hz, 2H), 3.90-3.80 (m, 1H), 3.80-3.70 (m, 4H), 1.42-1.30 (m, 6H).


[00247] Step c. (*S*)-1-(4-methoxyphenyl)-*N*-methyl-*N*-((*S*)-1-(pyridin-2-yl)ethyl)ethanamine: The solution of (*S*)-1-(4-methoxyphenyl)-*N*-((*S*)-1-(pyridin-2-yl)ethyl)ethanamine (500 mg, 2 mmol) and formaldehyde (37 wt percent in water, 1 mL) in dichloromethane (20 mL) was added $\text{NaBH}(\text{OAc})_3$ (636 mg, 3 mmol). The resulting suspension was stirred at room temperature overnight. The reaction mixture was added saturated NaHCO_3 aqueous solution (50 mL) and extracted with dichloromethane (100 mL). The organic layer was

dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 100/1) to give the desired product (400 mg, 70%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.56 (d, J = 3.6 Hz, 1H), 7.74-7.58 (m, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.33-7.27 (m, 2H), 7.20-7.10 (m, 1H), 6.88 (d, J = 8.0 Hz, 2H), 3.99-3.93 (m, 1H), 3.87-3.72 (m, 4H), 2.02 (s, 3H), 1.39-1.25 (m, 6H).

[00248] Step d. (*S*)-*N*-methyl-1-(pyridin-2-yl)ethanamine: To a solution of (*S*)-1-(4-methoxyphenyl)-*N*-methyl-*N*-((*S*)-1-(pyridin-2-yl)ethyl)ethanamine (400 mg, 1.48 mmol) in dichloromethane (10 mL) was added TFA (5 mL). The mixture was stirred at room temperature overnight. The reaction mixture was concentrated and 1M HCl aqueous (15 mL) was added. The water phase was wash with ethyl acetate (10 mL x 3). Then 1M NaOH aqueous solution was added to adjust pH = 9, and extracted with dichloromethane (10 mL x 4). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated to give the desired product (90 mg, 45%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 8.56 (d, J = 4.0 Hz, 1H), 7.65 (t, J = 7.2 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.16 (t, J = 6.0 Hz, 1H), 3.81-3.70 (m, 1H), 2.31 (s, 3H), 1.38 (d, J = 6.4 Hz, 3H).

[00249] Method BC

[00250] Preparation of *N*-ethyl-5,6,7,8-tetrahydroquinolin-8-amine




[00251] Step a. 8-chloro-5,6,7,8-tetrahydroquinoline: A mixture of 5,6,7,8-tetrahydroquinoline (10 g, 60 mmol) in DCM (200 mL) was added TCCA (21 g, 90 mmol) and stirred at reflux overnight. The reaction mixture was filtered and the filtrate was solution was added saturated NaHCO_3 aqueous solution (50 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 10/1 to 5/1) to give the desired product (8.6 g, 86%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.53 (d, J = 4.6 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.19 (dd, J = 7.6, 4.8 Hz, 1H), 5.43 (d, J = 3.4 Hz, 1H), 2.97-2.88 (m, 1H), 2.81-2.76 (m, 1H), 2.40-2.38 (m, 1H), 2.29-2.16 (m, 2H), 1.91-1.89 (m, 1H).

[00252] Step b. *N*-ethyl-5,6,7,8-tetrahydroquinolin-8-amine: The solution of 8-chloro-5,6,7,8-tetrahydroquinoline (500 mg, 3 mmol) in ethylamine/ethanol (10 mL) in a sealed tube was stirred at reflux overnight. Then the reaction solution was concentrated and added saturated NaHCO_3 aqueous solution (5 mL) and extracted with dichloromethane (10 mL x 3). The organic layer was dried over Na_2SO_4 , filtered and evaporated to give the crude desired product (960 mg) as a brown oil. ^1H NMR (400 MHz, CDCl_3) δ 8.42-8.35 (m, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.10-

7.02 (m, 1H), 3.89-3.72 (m, 1H), 2.86-2.71 (m, 4H), 2.20-2.12 (m, 1H), 2.03-1.98 (m, 1H), 1.79-1.74 (m, 2H), 1.20 (t, $J = 7.0$ Hz, 3H).

[00253] Method BD


[00254] Preparation of 5'*H*-spiro[cyclopropane-1,7'-quinolin]-8'(6'*H*)-one



[00255] Step a. 5'*H*-spiro[cyclopropane-1,7'-quinolin]-8'(6'*H*)-one: To a solution of NaH (60 wt percent moistened with oil, 420 mg, 10.5 mmol) in DMF (50 mL) was added dropwise 6,7-dihydroquinolin-8(5*H*)-one (441 mg, 3.0 mmol) and 1,2-dibromoethane (1.95g, 10.5 mmol) in DMF (5 mL) in sequence at 0°C under N₂ atmosphere. The reaction was stirred at 0°C for 1h. The reaction mixture was diluted with dichloromethane (40 mL) and washed with saturated brine solution (40 mL). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 10/3) to give the desired product (110 mg, 21%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.71 (s, 1H), 7.66 (s, 1H), 7.37 (s, 1H), 3.04 (d, $J = 4.4$ Hz, 2H), 2.03 (d, $J = 4.8$ Hz, 2H), 1.52 (s, 2H), 0.89 (s, 2H).

[00256] Method BE


[00257] Preparation of 7',8'-dihydro-5'*H*-spiro[cyclopropane-1,6'-quinoline]



[00258] Step a. 7',8'-dihydro-5'*H*-spiro[cyclopropane-1,6'-quinoline]: To a solution of spiro[2.5]octan-6-one (667 mg, 6 mmol) in ethanol (25 mL) was added prop-2-yn-1-amine (1.3 g, 24 mmol) and NaAuCl₄ (60 mg, 0.15 mmol) in sequence. The reaction was stirred at 85°C for 1 day. The reaction mixture was concentrated, diluted with ethyl acetate (30 mL) and washed with saturated NaHCO₃ aqueous solution (15 mL) and saturated brine solution (15 mL). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 12/1) to give the desired product (118 mg, 12%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.37(s, 1H), 7.30(d, $J = 7.2$ Hz, 1H), 7.07-6.98 (m, 1H), 3.00(t, $J = 6.4$ Hz, 2H), 2.64(s, 2H), 1.69(t, $J = 6.0$ Hz, 2H), 0.43(d, $J = 10.0$ Hz, 4H).

[00259] Method BF

[00260] Preparation of *N*-(2-acetylpyridin-3-yl)acetamide




[00261] Step a. 3-(4-methoxybenzylamino)picolinonitrile: The solution of 3-fluoropicolinonitrile (10 g, 82 mmol), (4-methoxyphenyl)methanamine (16.8 g, 123 mmol) and Cs_2CO_3 (40 g, 123 mmol) in DMF (50 mL) was stirred at 70°C overnight. The reaction mixture was concentrated, diluted with ethyl acetate (50 mL) and washed with saturated brine solution (20 mL x 3). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 20/1) to give the desired product (11 g, 56%) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.98 (s, 1H), 7.28-7.18 (m, 3H), 7.00 (d, J = 8.8 Hz, 1H), 6.90 (d, J = 8.0 Hz, 2H), 5.05 (s, 1H), 4.36 (d, J = 5.6 Hz, 2H), 3.81 (s, 3H).

[00262] Step b. 1-(3-(4-methoxybenzylamino)pyridin-2-yl)ethanone: To a solution of 3-(4-methoxybenzylamino)picolinonitrile (11 g, 46 mmol) in THF (200 mL) was added dropwise 3M $\text{CH}_3\text{MgCl}/\text{Et}_2\text{O}$ solution (77 mL, 230 mmol) at 0°C and stirred for 30min. The reaction mixture was quenched with saturated brine (50 mL), and extracted with ethyl acetate (100 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 5/1) to give the desired product (4 g, 34%) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 9.02 (s, 1H), 8.03-7.90 (m, 1H), 7.28-7.15 (m, 2H), 7.08-6.98 (m, 1H), 6.93-6.83 (m, 2H), 4.50-4.30 (m, 2H), 3.79 (s, 3H), 2.72 (s, 3H).

[00263] Step c. *N*-(2-acetylpyridin-3-yl)acetamide: The solution of 1-(3-(4-methoxybenzylamino)pyridin-2-yl)ethanone (1.5 g, 5.8 mmol) in TFA (5 mL) was stirred at room temperature overnight. The reaction mixture was concentrated and added saturated NaHCO_3 aqueous solution to adjust pH to 8, and extracted with dichloromethane (20 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was dissolved in acetate acid (10 mL), and added Ac_2O (20 mL), stirred at room temperature overnight. The reaction mixture was concentrated and added saturated NaHCO_3 to adjust pH to 8, and extracted with dichloromethane (20 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated to give the desired product (1 g, 97%) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 11.54 (s, 1H), 9.10 (d, J = 8.8 Hz, 1H), 8.37 (d, J = 4.4 Hz, 1H), 7.48 (dd, J = 8.8 Hz, 4.4 Hz, 1H), 2.80 (s, 3H), 2.26 (s, 3H).

[00264] Method BG


[00265] Preparation of *N*-(2-acetylpyridin-3-yl)methanesulfonamide



[00266] Step d. *N*-(2-acetylpyridin-3-yl)methanesulfonamide: The solution of 1-(3-(4-methoxybenzylamino)pyridin-2-yl)ethanone (1.3 g, 5.1 mmol) in TFA (7 mL) was stirred at room temperature overnight. The reaction mixture was concentrated and added saturated NaHCO_3 to adjust pH to 8, and extracted with dichloromethane (20 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was dissolved in dichloromethane (15 mL), and added TEA (1.5 g, 15.3 mmol) and MsCl (1.3 g, 11.2 mmol), stirred at room temperature for 1h. The reaction mixture was concentrated and the residue was dissolved in THF (10 mL). 1M NaOH aqueous solution (5 mL) was added and stirred at room temperature overnight. 1M HCl aqueous solution was added to adjust pH to 8, and extracted with dichloromethane (20 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated to give the desired product (800 mg, 73%) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 11.13 (s, 1H), 8.45-8.32 (m, 1H), 8.15-8.03 (m, 1H), 7.51-7.45 (m, 1H), 3.09 (s, 3H), 2.79 (s, 3H).

[00267] Method BH

[00268] Preparation of (*S*)-2-(pyrrolidin-2-yl)pyridine



[00269] Step a. 4-oxo-4-(pyridin-2-yl)butanal: To a solution of Mg powder (1.06 g, 44 mmol) and I_2 (20 mg, 0.08 mmol) in THF (15 mL) was added dropwise the solution of 2-(2-bromoethyl)-1,3-dioxolane (7.16 g, 40 mmol) in THF (15 mL). The reaction mixture was stirred at room temperature for 1.5h. Then this mixture was cooled to 0°C and added dropwise to a THF (10 mL) containing picolinonitrile (2.08 g, 20 mmol) at 0°C . The reaction mixture was stirred at this temperature for 1.5h. Water (10 mL) was added to quenched the reaction, and the mixture was filtered. The filtrate was diluted with ethyl acetate (50 mL), and washed with saturated brine solution (30 mL x 2). The organic layer was dried over Na_2SO_4 , filtered and evaporated to get the residue as a colorless oil (1.3 g). This residue was dissolved in acetone (15 mL), and added 3M HCl aqueous solution (10 mL), then stirred at room temperature overnight. The saturated NaHCO_3 solution was added to adjust pH to 9. The acetone was concentrated and the residue water phase was extracted with dichloromethane (10 mL x 3). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column


chromatography (petroleum ether/ethyl acetate = 10/1) to give the desired product (800 mg, 82%) as a slight green oil. ^1H NMR (400 MHz, CDCl_3) δ 9.89 (s, 1H), 8.68 (d, J = 4.0 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.48 (t, J = 5.6 Hz, 1H), 3.57 (t, J = 8.0 Hz, 2H), 2.91 (t, J = 8.0 Hz, 2H).

[00270] Step b. 2-((*S*)-1-((*R*)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine: The solution of 4-oxo-4-(pyridin-2-yl)butanal (490 mg, 3 mmol) in dichloromethane (20 mL) was added $\text{NaBH}(\text{OAc})_3$ (1.9 g, 9 mmol) and AcOH (20 mg, 0.33 mmol) at -70°C . The resulting suspension was stirred at the same temperature for 30 min. The reaction was warmed to 0°C and added (*R*)-1-(4-methoxyphenyl)ethanamine (500 mg, 3.3 mmol). The resulting suspension was stirred at room temperature overnight. The reaction mixture was evaporated and the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 1/10) to give the desired product (410 mg, 48%) as a red solid. ^1H NMR (400 MHz, CDCl_3) δ 8.43 (s, 1H), 7.55 (s, 1H), 7.49 (d, J = 4.0 Hz, 1H), 7.16 (d, J = 8.0 Hz, 2H), 7.05 (s, 1H), 6.79 (d, J = 8.0 Hz, 2H), 3.98 (s, 1H), 3.80-3.71 (m, 4H), 3.11 (s, 1H), 2.63 (s, 1H), 2.24 (s, 1H), 1.99-1.85 (m, 1H), 1.76 (s, 2H), 1.35 (d, J = 4.8 Hz, 3H).

[00271] Step c. (*S*)-2-(pyrrolidin-2-yl)pyridine: The solution of 2-((*S*)-1-((*R*)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine (400 mg, 1.48 mmol) in TFA (5 mL) was stirred at 50°C for 12h. The reaction mixture was concentrated and 1M HCl aqueous (15 mL) was added. This solution was wash with dichloromethane (5 mL x 3). Then saturated NaHCO_3 solution was added to adjust pH to 9, and extracted with dichloromethane (10 mL x 5). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated to give the desired product (110 mg, 50%) as a colorless oil.

[00272] Method BI

[00273] Preparation of (*R*)-2-(pyrrolidin-2-yl)pyridine




[00274] Step d. 2-((*R*)-1-((*S*)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine: The solution of 4-oxo-4-(pyridin-2-yl)butanal (326 mg, 2 mmol) in dichloromethane (15 mL) was added $\text{NaBH}(\text{OAc})_3$ (1.27 g, 6 mmol) and HOAc (20 mg, 0.33 mmol) at -70°C . The resulting suspension was stirred at the same temperature for 30 min. The reaction was warmed to 0°C and added (*S*)-1-(4-methoxyphenyl)ethanamine (332 mg, 2.2 mmol). The resulting suspension was stirred at room temperature overnight. The reaction mixture was evaporated and the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 1/10) to give the

desired product (400 mg, 71 %) as a red solid. ^1H NMR (400 MHz, CDCl_3) δ 8.42 (s, 1H), 7.58-7.45 (m, 1H), 7.35 (d, $J = 7.2$ Hz, 1H), 7.15 (d, $J = 7.6$ Hz, 2H), 7.02 (s, 1H), 6.68 (d, $J = 8.0$ Hz, 2H), 3.91 (s, 1H), 3.74-3.71 (m, 4H), 3.09 (s, 1H), 3.62 (d, $J = 7.2$ Hz, 1H), 2.26-2.15 (m, 1H), 1.99-1.89 (m, 1H), 1.76 (s, 2H), 1.34 (d, $J = 4.8$ Hz, 3H).

[00275] Step e. (*R*)-2-(pyrrolidin-2-yl)pyridine: The solution of 2-((*R*)-1-((*S*)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine (400 mg, 1.48 mmol) in TFA (5 mL) was stirred at 50°C for 12h. The reaction mixture was concentrated and 1M HCl aqueous (15 mL) was added. This solution was wash with dichloromethane (5 mL x 3). Then saturated NaHCO_3 solution was added to adjust pH to 9, and extracted with dichloromethane (10 mL x 5). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated to give the desired product (100 mg, 45%) as a colorless oil.

[00276] Method BJ

[00277] Preparation of 2-(3-methylpyrrolidin-2-yl)pyridine



[00278] Step a. *N*-(diphenylmethylene)-1-(pyridin-2-yl)methanamine: To the solution of pyridin-2-ylmethanamine (3.97g, 37 mmol) and benzophenone (6.69 g, 37 mmol) in toluene (50 mL) was added p-TsOH (10 mg, 0.058 mmol). The mixture was stirred at reflux overnight. The reaction solution was cooled to room temperature and washed with saturated NaHCO_3 solution (30 mL x 2). The organic layer was dried over Na_2SO_4 , filtered and evaporated to give the crude desired product (10 g) as a yellow oil.

[00279] Step b. ethyl 4-(diphenylmethyleneamino)-3-methyl-4-(pyridin-2-yl)butanoate: The solution of crude *N*-(diphenylmethylene)-1-(pyridin-2-yl)methanamine (1.5 g), NaOH solution (50 wt percent in water, 110 mg, 2.75 mmol) and BnEt_3NCl (60 mg, 0.3 mmol) in acetonitrile (50 mL) was stirred at room temperature for 30 min. Then (*E*)-ethyl but-2-enoate (630 mg, 5.5 mmol) was added. The mixture was stirred at room temperature overnight. The reaction solution was extracted with dichloromethane (10 mL x 3). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column


chromatography (petroleum ether/ethyl acetate = 1/10) to give the crude desired product (1.3 g,) as a yellow oil.

[00280] Step c. 4-methyl-5-(pyridin-2-yl)pyrrolidin-2-one: The solution of crude ethyl 4-(diphenylmethyleneamino)-3-methyl-4-(pyridin-2-yl)butanoate (1.3 g) in acetonitrile (15 mL) was added dropwise concentrated HCl aqueous (3 mL). The mixture was stirred at room temperature for 2h. The reaction solution was washed with dichloromethane (10 mL x 2). The water phase was diluted with acetonitrile (15 mL) and added dropwise ammonia water (5 mL). The mixture was stirred at room temperature for 5h. Then the reaction solution was extracted with dichloromethane (10 mL x 3). The combined organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol= 100/1) to give the desired product (360 mg, 62%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.58 (s, 1H), 7.73-7.70 (m, 1H), 7.34-7.32 (m, 1H), 7.25-7.22 (m, 1H), 6.57 (s, 1H), 4.40-4.39 (m, 1H), 2.66-2.60 (m, 1H), 2.51-2.46 (m, 1H), 2.14-2.08 (m, 1H), 1.27-1.26 (m, 3H).

[00281] Step d. 2-(3-methylpyrrolidin-2-yl)pyridine: The solution of 4-methyl-5-(pyridin-2-yl)pyrrolidin-2-one (200 mg, 1.1 mmol) in THF (5 mL) was added LiAlH₄ (174 mg, 4.5 mmol) in portions. The mixture was stirred at reflux overnight. Water (1 mL), NaOH solution (10 wt percent in water, 1 mL) and Water (1 mL) were added in sequence. The mixture was filtered and the filtrate was evaporated to give the desired product (89 mg, 50%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.54 (s, 1H), 7.65-7.62 (m, 1H), 7.28 (m, 1H), 7.18-7.15 (m, 1H), 3.67-3.60 (m, 1H), 3.30-3.21 (m, 1H), 3.10-3.02 (m, 1H), 1.67 (s, 1H), 1.60-1.53 (m, 1H), 1.37-1.33 (m, 1H), 1.07 (d, *J* = 6.0 Hz, 3H).

[00282] Method BK

[00283] Preparation of *cis*-ethyl 2-(pyridin-2-yl)pyrrolidine-3-carboxylate



[00284] Step a. (*E*)-2-(pyridin-2-ylmethyleneamino)acetonitrile: The solution of 2-aminoacetonitrile hydrochloride (5.09 g, 55 mmol) and TEA (9.09 g, 90 mmol) in ethanol (250 mL) was added stirred at room temperature for 30 min. Then picolinaldehyde (5.36 g, 50 mmol) was added. The mixture was stirred at room temperature overnight. The reaction solution was concentrated and dissolved in Et₂O (200 mL). The mixture was filtered and the filtrate was evaporated to give the crude desired product (4.8 g) as a yellow oil.


[00285] Step b. *cis*-ethyl 5-cyano-2-(pyridin-2-yl)pyrrolidine-3-carboxylate: To the solution of crude (*E*)-2-(pyridin-2-ylmethyleneamino)acetonitrile (4.8 g, 33 mmol) in toluene

(120 mL) was added AgOAc (550 mg, 3.3 mmol) and Cs₂CO₃ (2.15 g, 66 mmol) at 0°C, and stirred for 5 min. Then ethyl acrylate (3.31 g, 66 mmol) was added. The mixture was stirred at room temperature overnight. The reaction solution was evaporated and the residue was purified by silica gel column chromatography (dichloromethane/methanol= 50/1) to give the crude desired product (2.0 g, 25%) as a yellow oil.

[00286] Step c. *cis*-ethyl 2-(pyridin-2-yl)pyrrolidine-3-carboxylate: To the solution of crude *cis*-ethyl 5-cyano-2-(pyridin-2-yl)pyrrolidine-3-carboxylate (245 mg, 1 mmol) in THF (5 mL) was added 1M BH₃/THF solution (2 mL, 2 mmol), and stirred for 20 min. Then cooled to 0°C, NaBH₄ (76 mg, 2 mmol) was added. The mixture was stirred at the same temperature for 3h before room temperature overnight. Water (1 mL) was added to quench the reaction, and extracted with ethyl acetate (20 mL x 2). The combined organic layer was evaporated and the residue was dissolved in ethanol (20 mL). Pd/C (10 wt percent, 0.2 g) was added to this solution, and stirred at room temperature overnight. The mixture was filtered and the filtrate was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol= 10/1) to give the desired product (88 mg, 40%) as a yellow oil.

[00287] Method BL

[00288] Preparation of 6-methylquinolin-8-amine




[00289] Step a. 6-methyl-8-nitroquinoline: The pure glycerol (5.0 g, 54 mmol) was heated to 150°C for 30 min. Then it was cooled to 110°C, and added 4-methyl-2-nitroaniline (3.0 g, 20 mmol) and NaI (60 mg, 0.40 mmol). The mixture was heated to 150°C again, and added concentrated sulfuric acid (4.51 g, 46 mmol). The resulting suspension was stirred at this temperature for 1h. The reaction mixture was cooled to room temperature and added water (20 mL). This water phase was extracted with dichloromethane (20 mL x 4). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 5/1) to give the desired product (960 mg, 26%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 9.02-8.99 (m, 1H), 8.18-8.16 (m, 1H), 7.91-7.88 (m, 1H), 7.81-7.78 (m, 1H), 7.51 (s, 1H), 2.61 (s, 3H).

[00290] Step b. 6-methylquinolin-8-amine: To the solution of 6-methyl-8-nitroquinoline (350 mg, 1.86 mmol) in methanol (30 mL) was added Pd/C (10 wt percent, 0.2 g), and stirred at room temperature under N₂ atmosphere overnight. The mixture was filtered and the filtrate was evaporated to give the crude desired product (250 mg, 85%) as a yellow oil. ¹H NMR (400 MHz,

CDCl_3) δ 8.69 (s, 1H), 7.98 (s, 1H), 7.33 (s, 1H), 6.94 (s, 1H), 6.79 (s, 1H), 4.90 (s, 2H), 2.43 (s, 3H).

[00291] Method BM


[00292] Preparation of *N*,6-dimethylquinolin-8-amine hydroiodide



[00293] Step a. *N*,6-dimethylquinolin-8-amine hydroiodide: To the solution of 6-methylquinolin-8-amine (250 mg, 1.58 mmol) in ethanol (10 mL) in a sealed tube was added CH_3I (337 mg, 2.37 mmol), and stirred at reflux overnight. The reaction mixture was cooled to room temperature and filtered. The filter cake was washed with diethyl ether (10 mL) and the filter cake obtained was dried by oil pump to give the crude desired product hydroiodide (200 mg, 42%) as a red solid. ^1H NMR (400 MHz, CDCl_3) δ 8.79 (s, 1H), 8.58 (s, 1H), 7.75 (s, 1H), 7.08 (s, 1H), 6.82 (s, 1H), 3.08 (s, 3H), 2.57 (s, 3H).

[00294] Method BN

[00295] Preparation of 5,6-difluoro-*N*-methylquinolin-8-amine




[00296] Step a. 5,6,8-trifluoroquinoline: To the solution of concentrated sulfuric acid (18 mL) diluted with water (6 mL), was added 2,4,5-trifluoroaniline (3.68 g, 25 mmol), glycerol (4.60 g, 50 mmol) and sodium 3-nitrobenzenesulfonate (6.75 g, 30 mmol) in sequence. The resulting suspension was stirred at 140°C overnight. The reaction mixture was cooled to room temperature and added saturated NaHCO_3 aqueous solution to adjust pH to 7, extracted with dichloromethane (200 mL x 2). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 3/1) to give the desired product (3.5 g, 76%) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.99 (s, 1H), 8.46-8.44 (m, 1H), 7.61-7.56 (m, 1H), 7.38-7.31 (m, 1H).

[00297] step b. 5,6-difluoro-*N*-methylquinolin-8-amine: To the solution of 5,6,8-trifluoroquinoline (436 mg, 2.38 mmol) and K_2CO_3 (657 mg, 4.76 mmol) in DMSO (3 mL) in a sealed tube, was added MeNH_2 solution (30 wt percent in ethanol, 3 mL). The resulting suspension was stirred at 120°C for 2 days. The reaction mixture was cooled to room temperature and filtered. The filtrate was diluted with ethyl acetate (50 mL) was added, extracted with water (15 mL). The organic layer was evaporated. The residue was purified by

silica gel column chromatography (petroleum ether/ethyl acetate = 10/1) to give the desired product (200 mg, 43%) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.88 (d, J = 4.4 Hz, 1H), 8.31 (d, J = 8.4 Hz, 1H), 7.47-7.44 (m, 1H), 6.40-6.35 (m, 1H), 6.08 (s, 1H), 3.00 (s, 3H).

[00298] Method BO


[00299] Preparation of 7-fluoroquinolin-8-amine



[00300] Step a. 7-fluoroquinolin-8-amine: The mixture of 7-fluoro-*N*-(4-methoxybenzyl)quinolin-8-amine (480 mg, 1.7 mmol) and HBr solution (48 wt percent in water, 15 mL) was stirred at 80°C overnight. The reaction mixture was cooled to room temperature and added saturated NaHCO_3 aqueous solution to adjust pH to 8, extracted with dichloromethane (30 mL x 2). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 10/1) to give the desired product (232 mg, 84%) as a yellow oil. MS (ESI/APCI) m/z 163.0 $[\text{M} + \text{H}]^+$.

[00301] Method BP

[00302] Preparation of 8-chloro-1,7-naphthyridine




[00303] Step a. 1,7-naphthyridin-8-amine: To the solution of concentrated sulfuric acid (15 mL) diluted with water (15 mL), was added pyridine-2,3-diamine (1.09 g, 10 mmol), glycerol (4.1g, 33.6 mmol) and sodium 3-nitrobenzenesulfonate (4.5 g, 20.1 mmol) in sequence. The resulting suspension was stirred at 125°C overnight. The reaction mixture was cooled to room temperature and added saturated NaOH aqueous solution to adjust pH to 8, extracted with dichloromethane (100 mL x 2). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol= 50/1) to give the desired product (295 mg, 20%) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 8.77 (s, 1H), 8.00-7.96 (m, 2H), 7.54 (d, J = 4.0 Hz, 1H), 6.93 (d, J = 5.6 Hz, 1H), 5.92 (s, 2H).

[00304] step b. 8-chloro-1,7-naphthyridine: To the solution of 1,7-naphthyridin-8-amine (290 mg, 2.0 mmol) in concentrated HCl aqueous solution (5 mL), was added NaNO_2 (1.38 g, 20 mmol) and CuCl (238 mg, 33.6mmol) in sequence. The resulting suspension was stirred at room temperature for 3h. The reaction mixture was added saturated NaHCO_3 aqueous solution to adjust pH to 8, extracted with ethyl acetate (100 mL x 3). The combined organic layer was

evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 30/1) to give the desired product (85 mg, 26%) as a pale solid. ^1H NMR (400 MHz, CDCl_3) δ 9.15 (d, J = 2.4 Hz, 1H), 8.40 (d, J = 5.2 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.70 (dd, J = 8.0, 4.0 Hz, 1H), 7.63 (d, J = 5.2 Hz, 1H).

[00305] Method BQ

[00306] Preparation of 8-bromo-1,6-naphthyridine




[00307] Step a. 1,6-naphthyridine: To the solution of concentrated sulfuric acid (30 mL) diluted with water (20 mL), was added pyridin-4-amine (3.76 g, 40.0 mmol), glycerol (12.52 g, 136 mmol) and sodium 3-nitrobenzenesulfonate (19.8 g, 88.0 mmol) in sequence. The resulting suspension was stirred at 130°C overnight. The reaction mixture was cooled to room temperature and added saturated NaOH aqueous solution to adjust pH to 10, extracted with dichloromethane (200 mL x 2). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 1/1) to give the desired product (900 mg, 69%) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 9.30 (s, 1H), 9.12 (s, 1H), 8.78 (d, J = 5.2 Hz, 1H), 8.32 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 5.2 Hz, 1H), 7.62-7.48 (m, 1H).

[00308] step b. 8-bromo-1,6-naphthyridine: To the solution of 1,6-naphthyridine (830 mg, 6.38 mmol) in HOAc (5 mL), was added dropwise dibromine (612 mg, 3.83 mmol). The resulting suspension was stirred at 80°C overnight. The reaction mixture was cooled to room temperature and added saturated NaHCO_3 aqueous solution to adjust pH to 8, extracted with dichloromethane (100 mL x 3). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 1/1) to give the desired product (700 mg, 68%) as a pale solid. ^1H NMR (400 MHz, CDCl_3) δ 9.24 (d, J = 2.8 Hz, 1H), 9.21 (s, 1H), 9.02 (s, 1H), 8.34 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 8.0, 4.0 Hz, 1H).

[00309] Method BR

[00310] Preparation of 4-chloro-1,5-naphthyridine




[00311] Step a. 1,5-naphthyridine 1-oxide: To the solution of 1,5-naphthyridine (3.0 g, 23.1 mmol), was added mCPBA (3.6 g, 20.9 mmol). The resulting suspension was stirred at

room temperature overnight. The reaction mixture was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol= 50/1) to give the desired product (3.0 g, 89%) as an off-white solid. ^1H NMR (400 MHz, CDCl_3) δ 9.05 (d, J = 4.0 Hz, 1H), 9.04 (s, 1H), 8.56 (d, J = 6.0 Hz, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.70-7.67 (m, 1H), 7.54 (dd, J = 8.4, 6.0 Hz, 1H).

[00312] step b. 4-chloro-1,5-naphthyridine: The solution of 1,5-naphthyridine 1-oxide (3.0 g, 20.5 mmol) in POCl_3 (30 mL), was stirred at 100°C for 6h. The reaction mixture was concentrated and diluted with dichloromethane (100 mL). This solution was added saturated NaHCO_3 aqueous solution to adjust pH to 8. Filtered and the filtrate was partitioned. The water phase was extracted with ethyl acetate (100 mL). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 5/1) to give the desired product (930 mg, 27%) as a pale solid. ^1H NMR (400 MHz, CDCl_3) δ 9.11 (dd, J = 4.4, 2.0 Hz, 1H), 8.87 (d, J = 4.8 Hz, 1H), 8.46 (dd, J = 8.4, 2.0 Hz, 1H), 7.78 (d, J = 4.8 Hz, 1H), 7.74 (dd, J = 8.4, 4.0 Hz, 1H). MS (ESI/APCI) m/z 164.9 $[\text{M}+\text{H}]^+$.

[00313] Method BS

[00314] Preparation of *N*-methyl-2-(pyridin-2-yl)propan-2-amine



[00315] Step a. *N*-(2-(pyridin-2-yl)propan-2-yl)formamide: To the solution of 2-(pyridin-2-yl)propan-2-amine (350 mg, 2.6 mmol) in toluene (10 mL), was added formic acid (237 mg, 5.2 mmol). The resulting suspension was stirred at reflux for 6h. The reaction mixture was cooled to room temperature and added saturated NaHCO_3 aqueous solution (50 mL), the water phase was extracted with dichloromethane (50 mL). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/1 to 100/3/1) to give the desired product (300 mg, 70%) as a slight yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.56-8.49 (m, 1H), 8.40-8.25 (m, 1H), 7.90 (s, 1H), 7.78-7.65 (m, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.24-7.17 (m, 1H), 1.75 (d, J = 28.0 Hz, 6H).


[00316] Step b. *N*-methyl-2-(pyridin-2-yl)propan-2-amine: To the solution of *N*-(2-(pyridin-2-yl)propan-2-yl)formamide (300 mg, 1.8 mmol) in THF (10 mL), was added NaH (60 wt percent moistened with oil, 222 mg, 5.4 mmol). The resulting suspension was stirred at room temperature for 15 min. Then CH_3I (390 mg, 2.7 mmol) was added, the reaction mixture was stirred at reflux for 2h. The reaction mixture was cooled to room temperature and added the

solution of NaOH (252 mg, 6.12 mmol) in methanol (5 mL) and water (1 mL). The reaction mixture was stirred at reflux overnight. The reaction mixture was cooled to room temperature and extracted with dichloromethane (100 mL x 3). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography

(dichloromethane/methanol/ammonium hydroxide = 100/1/1) to give the desired product (250 mg, 90%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, *J* = 4.4 Hz, 1H), 7.77-7.63 (m, 1H), 7.39 (d, *J* = 8.0 Hz, 1H), 7.13 (dd, *J* = 7.2, 4.8 Hz, 1H), 2.13 (s, 3H), 1.47 (s, 6H).

[00317] Example 1

[00318] Preparation of *N*-methyl-*N*-((6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine (A1)




[00319] Method AA-Step a. *N*-((6-chloropyrimidin-4-yl)methyl)-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine: A mixture of *N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (160 mg, 1 mmol, see reference WO2006026703), 4-chloro-6-(chloromethyl)pyrimidine (170 mg, 1.05 mmol), KI (16 mg, 0.1 mmol) and DIPEA (320 mg, 2.5 mmol) in CH₃CN (10 mL) was stirred at room temperature overnight. The reaction solution was evaporated to remove most of CH₃CN, diluted with water (50 mL) and extracted with dichloromethane (50 mL x 3). The combined organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol= 100/1 to 50/1) to give the desired product (200 mg, 69%) as a brown oil. ¹H NMR (400 MHz, CDCl₃) δ 8.83 (s, 1H), 8.50 (d, *J* = 8.0 Hz, 1H), 7.89 (s, 1H), 7.37 (d, *J* = 8.0 Hz, 1H), 7.08 (dd, *J* = 8.0, 4.0 Hz, 1H), 4.03-3.99 (m, 1H), 3.80 (s, 2H), 2.82-2.77 (m, 1H), 2.75-2.70 (m, 1H), 2.41 (s, 3H), 2.17-2.14 (m, 1H), 2.06-2.04 (m, 1H), 1.92-1.89 (m, 1H), 1.72-1.71 (m, 1H).

[00320] Method AA-Step b. *N*-methyl-*N*-((6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine: A mixture of *N*-((6-chloropyrimidin-4-yl)methyl)-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (100 mg, 0.35 mmol), TEA (350 mg, 3.5 mmol) and *N*-methylpiperazine (40 mg, 0.38 mmol) in ethanol (4 mL) was stirred at reflux overnight. The reaction mixture was concentrated and added saturated NaHCO₃ aqueous solution (50 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 50/1) to give the desired product (98 mg, 80 %)

as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 8.45 (s, 2H), 7.33 (d, $J = 6.8$ Hz, 1H), 7.20 (s, 1H), 7.03 (s, 4.8 Hz, 1H), 3.99 (s, 1H), 3.68 (s, 4H), 3.62 (s, 2H), 2.77 (s, 1H), 2.68-2.64 (m, 1H), 2.44 (s, 4H), 2.35 (s, 3H), 2.30 (s, 3H), 1.97 (s, 1H), 1.91-1.88 (m, 1H), 1.85 (s, 1H), 1.67 (s, 1H). HRMS (ESI): calcd for $\text{C}_{20}\text{H}_{29}\text{N}_6$ $[\text{M}+\text{H}]^+$ 353.2448, found 353.2451.

[00321] Example 2

[00322] Preparation of *N*-methyl-*N*-((6-(piperazin-1-yl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine (A7) and 3-(4-(6-((methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)pyrimidin-4-yl)piperazin-1-yl)propanenitrile (A8)



[00323] Method AB-Step a. tert-butyl-4-(6-((methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of *N*-((6-chloropyrimidin-4-yl)methyl)-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (200 mg, 0.7 mmol), TEA (700 mg, 7 mmol) and tert-butyl piperazine-1-carboxylate (140 mg, 0.77 mmol) in ethanol (10 mL) was stirred at reflux overnight. The reaction mixture was added saturated NaHCO_3 aqueous solution (50 mL) and extracted with dichloromethane (50 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 50/1 to 25/1) to give the desired product (290 mg, 94 %) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 8.50 (s, 2H), 7.37 (d, $J = 7.6$ Hz, 1H), 7.29 (s, 1H), 7.08 (dd, $J = 7.6, 4.8$ Hz, 1H), 4.02 (t, $J = 7.6$ Hz, 1H), 3.71 (s, 4H), 3.67 (s, 2H), 3.50 (s, 4H), 2.88-2.76 (m, 1H), 2.76-2.66 (m, 1H), 2.39 (s, 3H), 2.17-2.08 (m, 1H), 2.01 (s, 1H), 1.94-1.89 (m, 1H), 1.74-1.68 (m, 1H), 1.49 (s, 9H). MS (ESI/APCI) m/z 438.8 $[\text{M} + \text{H}]^+$.


[00324] Method AB-Step b. *N*-methyl-*N*-((6-(piperazin-1-yl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine: To a solution of tert-butyl-4-(6-((methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)pyrimidin-4-yl)piperazine-1-carboxylate (270 mg, 0.6 mmol) in dichloromethane (5 mL) was added dropwise 3M HCl/ ethyl acetate (5 mL). The mixture was stirred at room temperature for 12 h. Saturated aqueous NaHCO_3 solution was added to adjust pH = 9, and the mixture was then extracted with dichloromethane (20 mL x 3). The combined organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 50/1 to 25/1) to give the desired product (180 mg, 90%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 8.49-8.48

(m, 2H), 7.37 (d, $J = 7.6$ Hz, 1H), 7.21 (s, 1H), 7.06 (dd, $J = 7.6, 4.8$ Hz, 1H), 4.08-3.98 (m, 1H), 3.68-3.64 (m, 6H), 2.93 (t, $J = 4.8$ Hz, 4H), 2.86-2.76 (m, 1H), 2.72 (s, 1H), 2.40 (s, 3H), 2.11 (s, 1H), 2.01-1.97 (m, 1H), 2.00-1.88 (m, 1H), 1.76-1.67 (m, 2H). MS (ESI/APCI) m/z 338.9 $[M + H]^+$

[00325] Method AB-Step c. 3-(4-(6-((methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)pyrimidin-4-yl)piperazin-1-yl)propanenitrile: To a solution of *N*-methyl-*N*-((6-(piperazin-1-yl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine (50 mg, 0.13 mmol) in methanol (2 mL) was added TEA (15 mg, 0.13 mmol) and acrylonitrile (20 mg, 0.26 mmol). The mixture was stirred at room temperature overnight. The reaction mixture was added saturated NaHCO_3 aqueous solution (50 mL) and extracted with dichloromethane (50 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 50/1 to 25/1) to give the desired product (40 mg, 78 %) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 8.53-8.47 (m, 2H), 7.38 (d, $J = 7.6$ Hz, 1H), 7.25 (s, 1H), 7.08 (dd, $J = 7.6, 4.8$ Hz, 1H), 4.09-3.97 (m, 1H), 3.73 (s, 4H), 3.65 (s, 2H), 2.86-2.78 (m, 1H), 2.75-2.71 (m, 3H), 2.58-2.53 (m, 6H), 2.40 (s, 3H), 2.16-2.08 (s, 1H), 2.05-1.97 (m, 1H), 1.93-1.88 (m, 1H), 1.75-1.69 (m, 1H).

[00326] Example 3

[00327] Preparation of *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine (A9)




[00328] Method AC-Step a. *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine: A mixture of *N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (37 mg, 0.23 mmol, see reference WO2006026703), 2-methyl-6-(4-methylpiperazin-1-yl)pyrimidine-4-carbaldehyde (46 mg, 0.21 mmol) and AcOH (13 mg, 0.21 mmol) in 1,2-dichloroethane (5 mL) was stirred for 10 min. $\text{NaBH}(\text{OAc})_3$ (66 mg, 0.3 mmol) was then added to the reaction solution. The resulting suspension was stirred at room temperature overnight. The reaction mixture was added saturated NaHCO_3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/1 to 50/1/1) to give the desired product (30 mg, 39 %) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 8.49 (d, $J = 4.6$ Hz, 1H), 7.35 (d, $J = 8.0$ Hz, 1H), 7.07-7.03 (m, 2H), 4.04 (t, $J = 7.4$ Hz, 1H), 3.71 (t, $J = 5.2$ Hz, 4H),

3.60 (s, 2H), 2.86-2.75 (m, 1H), 2.73-2.65 (m, 1H), 2.46-2.43 (m, 7H), 2.39 (s, 3H), 2.33 (s, 3H), 2.15-2.07 (m, 1H), 2.04-1.96 (m, 1H), 1.95-1.87 (m, 1H), 1.74-1.71 (m, 1H).

[00329] Example 4

[00330] Preparation of (*S*)-*N*-((6-((*R*)-2,4-dimethylpiperazin-1-yl)-2-methylpyrimidin-4-yl)methyl)-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (A63)




[00331] Method AD-Step a. (*S*)-*N*-methyl-*N*-((2-methyl-6-((*R*)-2-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine: To a solution of (*R*)-*tert*-butyl 3-methyl-4-(2-methyl-6-((methyl(*S*)-5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)pyrimidin-4-yl)piperazine-1-carboxylate (50 mg, 0.11 mmol) in ethyl acetate (2 mL) was added 3M HCl/ethyl acetate (3 mL) and stirred at room temperature overnight. The reaction mixture was added saturated NaHCO₃ aqueous solution (50 mL) and extracted with dichloromethane (30 mL x 3). The combined organic layer was dried over Na₂SO₄, filtered and evaporated to give the desired product (26 mg, 65%) as a colorless oil.

[00332] Method AD-Step b. (*S*)-*N*-((6-((*R*)-2,4-dimethylpiperazin-1-yl)-2-methylpyrimidin-4-yl)methyl)-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine: A mixture of (*S*)-*N*-methyl-*N*-((2-methyl-6-((*R*)-2-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine (26 mg, 0.07 mmol) and formaldehyde (37 wt percent in water, 30 mg, 0.36 mmol) in 1,2-dichloroethane (4 mL) was added NaBH(OAc)₃ (30 mg, 0.14 mmol). The resulting suspension was stirred at room temperature overnight. The reaction mixture was added saturated NaHCO₃ aqueous solution (50 mL) and extracted with dichloromethane (30 mL x 3). The combined organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/1) to give the desired product (10 mg, 38%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.48 (s, 1H), 7.35 (d, *J* = 7.6 Hz, 1H), 7.09-6.92 (m, 2H), 4.62 (s, 1H), 4.35-4.28 (m, 1H), 4.09-3.98 (m, 1H), 3.74-3.49 (m, 2H), 3.23-3.08 (m, 1H), 2.91-2.83 (m, 1H), 2.82-2.75 (m, 1H), 2.74-2.65 (m, 2H), 2.46 (s, 3H), 2.42-2.36 (m, 3H), 2.28 (s, 3H), 2.22-2.17 (m, 1H), 2.14-2.07 (m, 1H), 2.05-1.91 (m, 3H), 1.74-1.63 (m, 1H), 1.29-1.23 (m, 3H).

[00333] Example 5

[00334] Preparation of *N*-methyl-*N*-((4-(4-methylpiperazin-1-yl)pyrimidin-2-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine (A50)




[00335] Method AE-Step a. *N*-((4-chloropyrimidin-2-yl)methyl)-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine: The mixture of 2-(bromomethyl)-4-chloropyrimidine (94 mg, 0.58 mmol), *N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (130 mg, 0.6 mmol, see reference WO2006026703), KI (10 mg, 0.06 mmol) and DIPEA (740 mg, 5.8 mmol) in MeCN (10 mL) was stirred at room temperature for 4h. The reaction solution was evaporated to remove most of MeCN, added saturated NaHCO₃ aqueous solution (50 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/1) to give the desired product (140 mg, 84%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 4.8 Hz, 1H), 8.46 (d, *J* = 2.8 Hz, 1H), 7.38 (d, *J* = 7.6 Hz, 1H), 7.22 (d, *J* = 4.8 Hz, 1H), 7.09-7.06 (m, 1H), 4.28-4.26 (m, 1H), 4.22 (s, 1H), 4.15-4.12 (m, 1H), 2.84-2.78 (m, 1H), 2.72-2.68 (m, 1H), 2.50 (s, 3H), 2.25-2.24 (m, 1H), 2.04-1.96 (m, 2H), 1.73-1.70 (m, 1H).

[00336] Method AE-Step b. *N*-methyl-*N*-((4-(4-methylpiperazin-1-yl)pyrimidin-2-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine: The mixture of *N*-((4-chloropyrimidin-2-yl)methyl)-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (50 mg, 0.17 mmol), DIPEA (244 mg, 1.7 mmol) and 1-methylpiperazine (87 mg, 0.85 mmol) in NMP (2 mL) was stirred at 200 °C under microwave for 2 h. The reaction was diluted with ethyl acetate (50 mL) and washed with brine (50 mL). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/1) to give the desired product (34 mg, 57%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.46 (s, 1H), 8.18 (d, *J* = 6.0 Hz, 1H), 7.34 (d, *J* = 8.0 Hz, 1H), 7.05-7.02 (m, 1H), 6.32 (d, *J* = 6.4 Hz, 1H), 4.15-4.12 (m, 1H), 3.81 (s, 2H), 3.65 (s, 4H), 2.87-2.77 (m, 1H), 2.72-2.69 (m, 1H), 2.65-2.44 (m, 7H), 2.32 (s, 3H), 2.11-1.98 (m, 3H), 1.73-1.64 (m, 1H). HRMS (ESI): calcd for C₂₀H₂₉N₆ [M+H]⁺ 353.2448, found 353.2448.

[00337] Example 6

[00338] Preparation of *N*-methyl-*N*-((6-(4-methylpiperazin-1-yl)pyridin-2-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine (B6)




[00339] Method AF-Step a. *N*-((6-bromopyridin-2-yl)methyl)-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine: The mixture of 6-bromopicolinaldehyde (162 mg, 0.68 mmol), *N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (100 mg, 0.62 mmol, see reference WO2006026703), AcOH (48 mg, 0.62 mmol) in 1,2-dichloroethane (10 mL) was stirred for 15 min. NaBH(OAc)₃ (252 mg, 0.93 mmol) was then added to the reaction solution. The resulting suspension was stirred at room temperature overnight. The reaction solution was added saturated NaHCO₃ aqueous solution (50 mL) and extracted with dichloromethane (100 mL). The combined organic layers was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 100/1) to give the desired product (180 mg, 87%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.50 (s, 1H), 7.73 (d, *J* = 7.6 Hz, 1H), 7.50 (t, *J* = 7.6 Hz, 1H), 7.35 (d, *J* = 7.2 Hz, 1H), 7.29 (d, *J* = 7.6 Hz, 1H), 7.05 (t, *J* = 5.8 Hz, 1H), 4.03 (t, *J* = 7.0 Hz, 1H), 3.73 (s, 2H), 2.81-2.77 (m, 1H), 2.72-2.68 (m, 1H), 2.39 (s, 3H), 2.12 (s, 1H), 2.01 (s, 1H), 1.95-1.87 (m, 1H), 1.71 (s, 1H).

[00340] Method AF-Step b. *N*-methyl-*N*-((6-(4-methylpiperazin-1-yl)pyridin-2-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine: The mixture of *N*-((6-bromopyridin-2-yl)methyl)-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (50 mg, 0.15 mmol), DIPEA (193 mg, 1.5 mmol) and 1-methylpiperazine (73 mg, 0.75 mmol) in NMP (2 mL) was stirred at 120 °C overnight. The reaction was diluted with ethyl acetate (50 mL) and washed with brine (30 mL x 5). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 100/1) to give the desired product (12 mg, 23%). ¹H NMR (400 MHz, CDCl₃) δ 8.51 (d, *J* = 4.4 Hz, 1H), 7.43 (t, *J* = 7.8 Hz, 1H), 7.34 (d, *J* = 7.6 Hz, 1H), 7.05 (d, *J* = 4.8 Hz, 1H), 7.00 (d, *J* = 7.2 Hz, 1H), 6.46 (d, *J* = 8.4 Hz, 1H), 4.03 (s, 1H), 3.64 (q, *J* = 15.0 Hz, 2H), 3.53 (s, 4H), 2.82-2.78 (m, 1H), 2.71-2.66 (m, 1H), 2.50 (t, *J* = 4.4 Hz, 5H), 2.37 (s, 3H), 2.33 (s, 3H), 2.07 (s, 1H), 2.02-2.98 (m, 1H), 1.95-1.92 (m, 1H), 1.65 (s, 1H). HRMS (ESI): calcd for C₂₁H₃₀N₅ [M+H]⁺ 352.2496, found 352.2514.

[00341] Example 7


[00342] Preparation of *N*-methyl-*N*-(pyrimidin-4-ylmethyl)-5,6,7,8-tetrahydroquinolin-8-amine (B2)



[00343] Method AG-Step a. *N*-methyl-*N*-(pyrimidin-4-ylmethyl)-5,6,7,8-tetrahydroquinolin-8-amine: A mixture of *N*-((6-chloropyrimidin-4-yl)methyl)-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (70 mg, 0.24 mmol) and Pd/C (5 %, 15 mg) in 5 mL of methanol was stirred at 50 °C under H₂ (1 atm) overnight. The reaction solution was filtered and the filtrate was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol= 100/1) to give the desired product (50 mg, 82%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 9.06 (s, 1H), 8.65 (d, *J* = 4.8 Hz, 1H), 8.50 (s, 1H), 7.80 (d, *J* = 4.4 Hz, 1H), 7.37 (d, *J* = 7.2 Hz, 1H), 7.08-7.05 (m, 1H), 4.04-4.01 (m, 1H), 3.82-3.72 (m, 2H), 2.82-2.78 (m, 1H), 2.73-2.69 (m, 1H), 2.39 (s, 3H), 2.13 (s, 1H), 2.03 (s, 1H), 1.97-1.88 (m, 1H), 1.72 (s, 1H). MS (ESI/APCI) *m/z* 254.9 [M + H]⁺.

[00344] Example 8

[00345] Preparation of (*S*)-(2-methyl-4-((methyl(1-(pyridin-2-yl)ethyl)amino)methyl)-6-(4-methylpiperazin-1-yl)pyrimidin-5-yl)methanol (A85)



[00346] Method AH-Step a. (4,6-dichloro-2-methylpyrimidin-5-yl)methanol: To POCl₃ (60.6 g, 396.5 mmol) was added dropwise DMF (9.8 g, 134.8 mmol) at 0 °C. The resulting suspension was stirred at the same temperature for 1h. Then 2-methylpyrimidine-4,6-diol (10 g, 79.3 mmol) was added in portions and stirred at room temperature for 1h, after that, stirred at 105 °C overnight. The reaction solution was concentrated and diluted with cold ethyl acetate (100mL). This solution was added dropwise into ice-water, filtered and the filtrate was extracted with ethyl acetate (200 mL). The combined organic layer was dried over Na₂SO₄, filtered and evaporated to give a yellow oil (10 g). This oil was dissolved in THF (50 mL) and water (10 mL), and NaBH₄ (4 g, 104.7 mmol) was added in portions at 0 °C. The resulting suspension was stirred at the same temperature for 30min. Water (50 mL) was added, and extracted with ethyl

acetate (50 mL). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 10/1) to give the desired product (2 g, 20%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 4.91 (s, 2H), 2.69 (s, 3H).

[00347] Method AH-Step b. 5-((*tert*-butyldimethylsilyloxy)methyl)-4,6-dichloro-2-methylpyrimidine: To the solution of (4,6-dichloro-2-methylpyrimidin-5-yl)methanol (2 g, 10.3 mmol) and imidazole (770 mg, 11.3 mmol) in dichloromethane (20mL) was added TBSCl (1.7 g, 11.3 mmol) in portions. The resulting suspension was stirred at room temperature overnight. Water (20 mL) was added, and extracted with dichloromethane (20 mL). The combined organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 100/1) to give the desired product (2.6 g, 84 %) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 4.85 (s, 2H), 2.68 (s, 3H), 0.91 (s, 9 H), 0.14 (s, 6H).

[00348] Method AH-Step c. 5-((*tert*-butyldimethylsilyloxy)methyl)-6-chloro-2-methylpyrimidine-4- carbaldehyde: To the solution of 5-((*tert*-butyldimethylsilyloxy)methyl)-4,6-dichloro-2- methylpyrimidine (1.5 g, 4.8 mmol), potassium vinyltrifluoroborate (655 mg, 4.88 mmol), Cs₂CO₃ (2.4 g, 7.32 mmol) and Pd(PPh₃)₄ (566 mg, 0.49 mmol) in 1,4-dioxane (20 mL) and water (4 mL) was stirred at reflux overnight under N₂ atmosphere. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 100/1) to give a crude oil (900 mg). This resulting oil was added methanol (30 mL) and dichloromethane (7 mL) to dissolve. Then O₃ was introduced into this reaction solution at -65°C and stirred at this temperature for 4h before dimethyl sulfide was added to quench the reaction. The solvent was concentrated and added water (20 mL), extracted with dichloromethane (50 mL). The combined organic layer was dried over Na₂SO₄, filtered and evaporated to give the crude desired product (610 mg) as a white solid.


[00349] Method AH-Step d. (*S*)-(4-chloro-2-methyl-6-((methyl(1-(pyridin-2-yl)ethyl)amino)methyl)pyrimidin-5-yl)methanol: A mixture of (*S*)-N-methyl-1-(pyridin-2-yl)ethanamine (544 mg, 4.0 mmol), 5-((*tert*-butyldimethylsilyloxy)methyl)-6-chloro-2-methylpyrimidine-4-carbaldehyde (610 mg, 2.0 mmol) and AcOH (360 mg, 6.0 mmol) in dichloromethane (10 mL) was stirred for 1h. NaBH(OAc)₃ (1.3 g, 6.0 mmol) was then added to the reaction solution. The resulting suspension was stirred at room temperature overnight. The reaction mixture was added water (10 mL) and extracted with dichloromethane (10 mL). The combined organic layers was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 100/1 to 50/1) to give the desired product (480 mg, 80 %) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.66-

8.55 (m, 1H), 7.82-7.65 (m, 1H), 7.38-7.30 (m, 1H), 7.25-7.18 (m, 1H), 4.77 (s, 2H), 4.15-3.85 (m, 3H), 2.66 (s, 3H), 2.19 (s, 3H), 1.56 (d, $J = 7.2$ Hz, 3H).

[00350] Method AH-Step e. (*S*)-(2-methyl-4-((methyl(1-(pyridin-2-yl)ethyl)amino)methyl)-6-(4-methylpiperazin-1-yl)pyrimidin-5-yl)methanol: The mixture of (*S*)-(4-chloro-2-methyl-6-((methyl(1-(pyridin-2-yl)ethyl)amino)methyl)pyrimidin-5-yl)methanol (50 mg, 0.16 mmol), TEA (80 mg, 0.8 mmol) and 1-methylpiperazine (48 mg, 0.48 mmol) in ethanol (5 mL) was stirred at reflux overnight. The reaction solution was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/1 to 100/2/1) to give the desired product (26 mg, 80%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 8.62-8.56 (m, 1H), 7.73-7.63 (m, 1H), 7.31 (d, $J = 8.0$ Hz, 1H), 7.23-7.15 (m, 1H), 4.45-4.35 (m, 2H), 3.92 (q, $J = 6.8$ Hz, 1H), 3.87 (d, $J = 13.2$ Hz, 1H), 3.79 (s, 4H), 3.68 (d, $J = 13.2$ Hz, 1H), 2.70 (s, 4H), 2.48 (s, 3H), 2.45 (s, 3H), 2.07 (s, 3H), 1.55 (d, $J = 6.8$ Hz, 3H).

[00351] Example 9


[00352] Preparation of (3*R*,5*R*)-5-(2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)-1-((*S*)-5,6,7,8-tetrahydroquinolin-8-yl)pyrrolidin-3-ol (C16)



[00353] Method AI-Step a. (3*R*,5*R*)-5-(2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)-1-((*S*)-5,6,7,8-tetrahydroquinolin-8-yl)pyrrolidin-3-ol: The solution of (*S*)-8-((2*R*,4*R*)-4-(tert-butyldimethylsilyloxy)-2-(2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)pyrrolidin-1-yl)-5,6,7,8-tetrahydroquinoline (50 mg, 0.1 mmol) in 2M HCl aqueous solution (5 mL) was stirred at room temperature for 2h. The reaction mixture was added saturated NaHCO_3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na_2SO_4 , filtered and evaporated to give the desired product (35 mg, 86%) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 8.38 (d, $J = 4.8$ Hz, 1H), 7.12 (d, $J = 7.2$ Hz, 1H), 7.05-6.99 (m, 1H), 5.29 (s, 1H), 4.28 (s, 1H), 4.03 (d, $J = 10.0$ Hz, 1H), 3.89 (s, 1H), 3.55-3.38 (m, 4H), 3.30 (d, $J = 9.2$ Hz, 1H), 2.92-2.83 (m, 1H), 2.63-2.53 (m, 1H), 2.53-2.45 (m, 1H), 2.44-2.37 (m, 7H), 2.33 (s, 3H), 2.14-2.05 (m, 2H), 1.77 (d, $J = 13.6$ Hz, 1H), 1.62-1.51 (m, 3H).

[00354] Example 10


[00355] Preparation of (8-(methyl((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)amino)quinolin-6-yl)methanol (D55)



[00356] Method AJ-Step a. (8-(methyl((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)amino)quinolin-6-yl)methanol: The solution of methyl 8-(methyl((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)amino)quinoline-6-carboxylate (105 mg, 0.25 mmol) in THF (3 mL) was added LiAlH₄ (19 mg, 0.5 mmol) at 0°C, and stirred at room temperature for 20 min. Water and NaOH aqueous solution (15wt percent in water) was added to quench the reaction. The mixture was filtered and the filtrate was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/1) to give the desired product (60 mg, 61%) as a slight yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.76 (s, 1H), 8.07 (d, *J* = 8.0 Hz, 1H), 7.45-7.30 (m, 2H), 7.17 (s, 1H), 6.79 (s, 1H), 4.81 (s, 2H), 4.66 (s, 2H), 3.63 (s, 4H), 3.03 (s, 3H), 2.54 (s, 3H), 2.50-2.43 (m, 4H), 2.32 (s, 3H).

[00357] Example 11

[00358] Preparation of (*S*)-5-(4-methylpiperazin-1-yl)-2-((2-(3-methylpyridin-2-yl)pyrrolidin-1-yl)methyl)imidazo[1,2-*a*]pyridine (C38) and (*S*)-5-(4-methylpiperazin-1-yl)-2-((2-(3-methylpyridin-2-yl)pyrrolidin-1-yl)methyl)imidazo[1,2-*a*]pyridin-3-yl)methanol (C39)




[00359] Method AK-Step a. (*S*)-5-bromo-2-((2-(3-methylpyridin-2-yl)pyrrolidin-1-yl)methyl)imidazo[1,2-*a*]pyridine: The mixture of 5-bromo-2-(bromomethyl)imidazo[1,2-*a*]pyridine (48 mg, 0.17 mmol), (*S*)-3-methyl-2-(pyrrolidin-2-yl)pyridine (30 mg, 0.12 mmol), KI (3 mg, 0.017 mmol) and K₂CO₃ (46 mg, 0.34 mmol) in MeCN (15 mL) was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 50/1) to give the desired product (40 mg, 78%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.48 (s, 1H), 7.61 (s, 1H), 7.48 (d, *J* = 8.8 Hz, 1H), 7.31 (d, *J* = 7.6 Hz, 1H), 7.03-6.95 (m, 3H), 3.97-3.94 (m, 2H), 3.74 (s, 1H), 3.43 (s, 1H), 2.55 (s, 1H), 2.37 (s, 3H), 2.21-1.95 (m, 4H).

[00360] Method AK-Step b. (*S*)-5-(4-methylpiperazin-1-yl)-2-((2-(3-methylpyridin-2-yl)pyrrolidin-1-yl)methyl)imidazo[1,2-*a*]pyridine: The mixture of (*S*)-5-bromo-2-((2-(3-methylpyridin-2-yl)pyrrolidin-1-yl)methyl)imidazo[1,2-*a*]pyridine (40 mg, 0.11 mmol) in 1-methylpiperazine (3 mL) was stirred at 170°C under microwave for 1.5 h. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 60/1) to give the desired product (20 mg, 48%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.49 (d, *J* = 3.6 Hz, 1H), 7.33 (s, 2H), 7.28 (s, 1H), 7.13-7.09 (m, 1H), 7.01-6.98 (m, 1H), 6.24 (d, *J* = 7.2 Hz, 1H), 3.96 (d, *J* = 13.6 Hz, 1H), 3.84 (t, *J* = 8.0 Hz, 1H), 3.67 (d, *J* = 13.6 Hz, 1H), 3.39 (t, *J* = 8.0 Hz, 1H), 3.10 (s, 4H), 2.64 (s, 4H), 2.59-2.52 (m, 1H), 2.42 (s, 3H), 2.38 (s, 3H), 2.22-2.17 (m, 2H), 2.05-1.90 (m, 2H).

[00361] Method AK-Step c. (*S*)-5-(4-methylpiperazin-1-yl)-2-((2-(3-methylpyridin-2-yl)pyrrolidin-1-yl)methyl)imidazo[1,2-*a*]pyridin-3-yl)methanol: The mixture of (*S*)-5-(4-methylpiperazin-1-yl)-2-((2-(3-methylpyridin-2-yl)pyrrolidin-1-yl)methyl)imidazo[1,2-*a*]pyridine (46 mg, 0.12 mmol) and formaldehyde (37 wt percent in water, 5 mL) in a sealed tube was stirred at 50°C for 2 days. The reaction mixture was added saturated NaHCO₃ aqueous solution (10 mL) and extracted with dichloromethane (30 mL). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 50/1) to give the desired product (35 mg, 71%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, *J* = 3.6 Hz, 1H), 7.40 (d, *J* = 7.2 Hz, 1H), 7.29 (d, *J* = 8.8 Hz, 1H), 7.08-7.02 (m, 2H), 6.39 (d, *J* = 6.8 Hz, 1H), 6.19 (brs, 1H), 5.27 (d, *J* = 14.0 Hz, 1H), 5.07 (d, *J* = 14.0 Hz, 1H), 4.05 (d, *J* = 12.8 Hz, 1H), 3.86-3.84 (m, 1H), 3.50-3.47 (m, 2H), 3.26-3.23 (m, 1H), 3.18-3.15 (m, 1H), 3.01-2.91 (m, 3H), 2.85-2.80 (m, 1H), 2.54-2.46 (m, 3H), 2.41 (s, 3H), 2.38 (s, 3H), 2.28-2.24 (m, 1H), 1.91-1.82 (m, 3H).

[00362] Example 12

[00363] Preparation of 7-fluoro-*N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5,6-dihydroquinolin-8-amine (D1)




[00364] Method AL-Step a. 7,7-difluoro-6,7-dihydroquinolin-8(5H)-one: To a solution of NaH (60 wt percent moistened with oil, 511 mg, 12.8 mmol) in THF (20 mL) was added dropwise the THF solution (5 mL) containing 6,7-dihydroquinolin-8(5H)-one (588 mg, 4 mmol) at 0°C. The reaction was stirred at 0°C for 10 min followed by adding selectfluor (3.0 g, 8.4 mmol) in portions. The reaction mixture was stirred at room temperature for 1h. Water (20 mL) was added to quench the reaction. The water phase was extracted with diethyl ether (20 mL x 3). The combined organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 10/1) to give the desired product (380 mg, 52%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.81 (s, 1H), 7.73 (d, *J* = 7.6 Hz, 1H), 7.57-7.45 (m, 1H), 3.26-3.08 (m, 2H), 2.76-2.51 (m, 2H).

[00365] Method AL-Step b. 7,7-difluoro-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine: The solution of 7,7-difluoro-6,7-dihydroquinolin-8(5H)-one (18.3 mg, 0.1 mmol), MeNH₂ solution (30 wt percent in ethanol, 1 mL) and HOAc (5 mg, 0.083 mmol) in 1,2-dichloroethane (2 mL) was added NaBH₃CN (13 mg, 0.2 mmol). The resulting suspension was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 150/1) to give the desired product (15 mg, 75%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.47 (d, *J* = 4.0 Hz, 1H), 7.46 (d, *J* = 7.6 Hz, 1H), 7.19-7.15 (m, 1H), 3.89 (t, *J* = 10.0 Hz, 1H), 3.01-2.91 (m, 2H), 2.72 (s, 3H), 2.61-2.41 (m, 1H), 2.30-2.17 (m, 1H).

[00366] Method AL-Step c. 7-fluoro-*N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5,6-dihydroquinolin-8-amine: A mixture of 4-chloro-6-(chloromethyl)-2-methylpyrimidine (54 mg, 0.31 mmol), 7,7-difluoro-*N*-methyl-5,6,7,8-tetrahydroquinolin-8-amine (55 mg, 0.28 mmol), KI (5 mg, 0.028 mmol) and DIPEA (90 mg, 0.7 mmol) in CH₃CN (10 mL) was stirred at room temperature overnight. The reaction solution was evaporated to remove most of CH₃CN, diluted with dichloromethane (15 mL) and washed with saturated brine solution (10 mL). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was dissolved in ethanol (10 mL). TEA (252 mg, 2.5 mmol) and *N*-methylpiperazine (125 mg, 1.25 mmol) were added and stirred at reflux for 3h. The reaction mixture was cooled to room temperature and concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 50/1/1) to give the desired product (15 mg, 15%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.44 (d, *J* = 4.0 Hz, 1H), 7.40 (d, *J* = 7.2 Hz, 1H), 7.06-6.98 (m, 1H), 6.93 (s, 1H), 4.26 (s, 2H), 3.60 (s, 4H), 2.93 (s, 3H), 2.93-2.81 (m, 2H), 2.64-2.56 (m, 2H), 2.47 (s, 3H), 2.42 (s, 4H), 2.32 (s, 3H). MS (ESI/APCI) *m/z* 382.9 [M+H]⁺.

[00367] Example 13


[00368] Preparation of *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)quinolin-8-amine (D2)



[00369] Method AM-Step a. *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)quinolin-8-amine: A mixture of *N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)quinolin-8-amine (75 mg, 0.26 mmol) and formaldehyde (37 wt percent in water, 42 mg, 0.52 mmol) in methanol (3 mL) was added NaBH₃CN (25 mg, 0.4 mmol). The resulting suspension was stirred at room temperature overnight. Water (10 mL) was added to quench the reaction. The water phase was extracted with diethyl ether (10 mL x 3). The combined organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/1) to give the desired product (37 mg, 39%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.82 (d, *J* = 2.4 Hz, 1H), 8.11 (d, *J* = 8.4 Hz, 1H), 7.44-7.35 (m, 3H), 7.13 (d, *J* = 7.2 Hz, 1H), 6.68 (s, 1H), 4.69 (s, 2H), 3.57 (s, 4H), 3.06 (s, 3H), 2.51 (s, 3H), 2.39 (t, *J* = 4.8 Hz, 4H), 2.30 (s, 3H).

[00370] Example 14

[00371] Preparation of *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-1,7-naphthyridin-8-amine (D21)




[00372] Method AN-step a. *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-1,7-naphthyridin-8-amine: To the solution of 8-chloro-1,7-naphthyridine (56 mg, 0.34 mmol) and *N*-methyl-1-(2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methanamine (80 mg, 0.34 mmol) in DMSO (3 mL), was added K₂CO₃ (140 mg, 1.02 mmol). The resulting suspension was stirred at 110°C overnight. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 10/1/1) to give the desired product (17 mg, 11%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.66 (s, 1H), 8.10 (d, *J* = 5.2 Hz, 1H), 7.96 (d, *J* = 8.0 Hz, 1H), 7.43 (dd, *J* = 7.6,

4.0 Hz, 1H), 6.96 (d, $J = 5.6$ Hz, 1H), 6.46 (s, 1H), 5.26 (s, 2H), 3.57 (s, 4H), 3.36 (s, 3H), 2.52 (s, 3H), 2.45-2.34 (m, 4H), 2.29 (s, 3H).

[00373] Example 15


[00374] Preparation of *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-1,6-naphthyridin-8-amine (D22)



[00375] Method AO-step a. *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-1,6-naphthyridin-8-amine: The mixture of 8-bromo-1,6-naphthyridine (41 mg, 0.20 mmol), *N*-methyl-1-(2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methanamine (99 mg, 0.42 mmol), BINAP (13 mg, 0.02 mmol), Cs_2CO_3 (152 mg, 0.46 mol) and $\text{Pd}_2(\text{dba})_3$ (9 mg, 0.01 mmol) in toluene (5 mL) was stirred at 100°C overnight under N_2 atmosphere. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/1) to give the desired product (20 mg, 28%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.96 (s, 1H), 8.81 (s, 1H), 8.37-8.13 (m, 2H), 7.50 (s, 1H), 6.62 (s, 1H), 4.84 (s, 2H), 3.60 (s, 4H), 3.13 (s, 3H), 2.51 (s, 3H), 2.42 (s, 4H), 2.31 (s, 3H).

[00376] Example 16

[00377] Preparation of 4-(((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)(quinolin-8-yl)amino)butanoic acid (D30) and 4-(((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)(quinolin-8-yl)amino)butanamide (D31)




[00378] Method AP-Step a. 4-(((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)(quinolin-8-yl)amino)butanoic acid: The solution of *tert*-butyl 4-(((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)(quinolin-8-yl)amino)butanoate (55 mg, 0.112 mmol) in concentrated HCl aqueous solution (6 mL) was stirred at 50°C overnight. The reaction mixture was evaporated to give the desired product hydrochloride (535 mg, 96%) as a yellow oil. ^1H NMR (400 MHz, D_2O) δ 9.14 (d, $J = 8.4$ Hz, 1H), 9.07 (d, $J = 5.6$ Hz, 1H), 8.12 (d, $J =$

8.0 Hz, 1H), 8.09-8.06 (m, 1H), 8.02 (d, $J = 7.6$ Hz, 1H), 7.92-7.88 (m, 1H), 7.00 (s, 1H), 5.25 (s, 1H), 4.44 (s, 2H), 4.33 (s, 1H), 3.68-3.46 (m, 4H), 3.41-3.12 (m, 4H), 2.92 (s, 3H), 2.54 (s, 3H), 2.17 (t, $J = 6.8$ Hz, 2H), 1.61 (s, 2H).

[00379] Method AP-Step b. 4-(((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)(quinolin-8-yl)amino)butanamide: The mixture of 4-(((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)(quinolin-8-yl)amino)butanoic acid (50 mg, 0.098 mmol), NH_4Cl (27 mg, 0.51 mmol), HATU (47 mg, 0.122 mmol) and DIPEA (131 mg, 1.02 mmol) in DMF (3 mL) was stirred at 50°C overnight. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 20/1/0.1) to give the desired product (25 mg, 58%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.82 (d, $J = 4.4$ Hz, 1H), 8.18 (d, $J = 8.4$ Hz, 1H), 7.45-7.42 (m, 3H), 7.30-7.29 (m, 1H), 6.90 (s, 1H), 6.81 (s, 1H), 5.35 (s, 1H), 4.62 (s, 2H), 3.71 (s, 4H), 3.52 (t, $J = 7.2$ Hz, 2H), 2.58 (s, 3H), 2.50-2.48 (m, 4H), 2.34 (s, 3H), 2.26 (t, $J = 7.2$ Hz, 2H), 2.00-1.97 (m, 2H).

[00380] Example 17


[00381] Preparation of 8-(methyl((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)amino)quinoline-7-carbonitrile (D50)



[00382] Method AQ-Step a. 8-(methyl((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)amino)quinoline-7-carbonitrile: The mixture of 7-bromo-*N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)quinolin-8-amine (210 mg, 0.48 mmol), ZnCN_2 (112 mg, 0.95 mmol), dppf (53 mg, 0.1 mmol), $\text{Pd(PPh}_3)_4$ (110 mg, 0.1 mmol) and $\text{Pd}_2(\text{dba})_3$ (44 mg, 0.05 mmol) in DMAc (8 mL) was stirred at 150°C for 2 days under N_2 atmosphere. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/1/0.5) to give the crude product (80 mg). The crude product was further purified by Combi-Flash-C18 (MeCN/water, MeCN gradient 30% to 60% volume percent through 30 min) to give the desired product (13 mg, 7%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.91 (d, $J = 2.4$ Hz, 1H), 8.14 (d, $J = 8.0$ Hz, 1H), 7.58-7.46 (m, 3H), 7.06 (s, 1H), 4.91 (s, 2H), 3.75 (s, 4H), 3.31 (s, 3H), 2.49 (s, 7H), 2.34 (s, 3H).

[00383] Example 18


[00384] Preparation of *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5-(methylsulfonyl)quinolin-8-amine (D43)



[00385] Method AR-Step a. *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5-(methylsulfonyl)quinolin-8-amine: The mixture of 5-bromo-*N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)quinolin-8-amine (150 mg, 0.34 mmol), sodium methanesulfonate (70 mg, 0.68 mmol), L-Proline (47 mg, 0.41 mmol), K₂CO₃ (28 mg, 0.2 mmol) and CuI (40 mg, 0.2 mmol) in DMSO (2 mL) was stirred at 100°C for 2 days under N₂ atmosphere. The reaction mixture was cooled to room temperature and diluted with dichloromethane (20 mL). The mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 20/1/0.1) to give the a crude product (50 mg). The crude product was further purified by Combi-Flash-C18 (MeCN/water, MeCN gradient 30% to 70% volume percent through 30 min) to give the desired product (15 mg, 10%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 9.01 (dd, *J* = 8.8, 2.0 Hz, 1H), 8.75 (dd, *J* = 4.0, 2.0 Hz, 1H, 1H), 8.21 (d, *J* = 8.4 Hz, 1H), 7.52 (dd, *J* = 8.8, 4.0 Hz, 1H), 7.01 (d, *J* = 8.4 Hz, 1H), 6.55 (s, 1H), 4.97 (s, 2H), 3.68-3.55 (m, 4H), 3.20 (s, 3H), 3.14 (s, 3H), 2.52 (s, 3H), 2.46-2.38 (m, 4H), 2.31 (s, 3H). MS (ESI/APCI) *m/z* 441.2 [M+H]⁺.

[00386] Example 19

[00387] Preparation of *N*-(8-(methyl((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)amino)quinolin-5-yl)methanesulfonamide(D57)



[00388] Method AS-Step a. 8-fluoro-5-nitroquinoline: To the solution of concentrated sulfuric acid (2 mL) diluted with concentrated nitric acid (1 mL), was added dropwise 8-fluoroquinoline (3.76 g, 40.0 mmol) at 0°C. The resulting suspension was stirred at 0°C for 2h.

The reaction mixture was poured into ice-water and filtered. The filter cake was added saturated Na_2CO_3 aqueous solution to adjust pH to 7 and extracted with dichloromethane (20 mL x 2). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 30/1) to give the desired product (330 mg, 61%) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 9.16 (d, J = 8.4 Hz, 1H), 9.12 (s, 1H), 8.56-8.42 (m, 1H), 7.78-7.74(m, 1H), 7.53-7.48(m, 1H).


[00389] Method AS-step b. *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5- nitroquinolin-8-amine: To the solution of 8-fluoro-5-nitroquinoline (80 mg, 0.42 mmol) and *N*-methyl-1-(2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methanamine (100 mg, 0.42 mmol) in DMSO (3 mL), was added K_2CO_3 (58 mg, 0.42 mmol). The resulting suspension was stirred at 110°C overnight. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 50/1/0.5) to give the desired product (80 mg, 47%) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 9.32 (d, J = 8.4 Hz, 1H), 8.69 (s, 1H), 8.48 (d, J = 9.2 Hz, 1H), 7.58-7.50 (m, 1H), 6.92 (d, J = 8.8 Hz, 1H), 6.54 (s, 1H), 5.07 (s, 2H), 3.70-3.60 (s, 4H), 3.27 (s, 3H), 2.61 (s, 3H), 2.55 (s, 7H).

[00390] Method AS-step c. *N*⁸-methyl-*N*⁸-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)quinoline-5,8-diamine: To the solution of *N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-5- nitroquinolin-8-amine (80 mg, 0.2 mmol) in ethanol (4 mL), was added SnCl_2 (135 mg, 0.6 mmol). The resulting suspension was stirred at 80°C for 3h. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 50/1/0.5) to give the desired product (19 mg, 25%) as a yellow solid. MS (ESI/APCI) m/z 377.8 $[\text{M}+\text{H}]^+$.

[00391] Method AS-Step d. *N*-(8-(methyl((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)amino)quinolin-5-yl)methanesulfonamide: To the solution of *N*⁸-methyl-*N*⁸-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)quinoline-5,8-diamine (19 mg, 0.05 mmol) in Pyridine (3 mL) was added dropwise MsCl (10 mg, 0.09 mmol) at 0°C. The reaction mixture was stirred at room temperature for 1h. The saturated NaHCO_3 aqueous solution was added to adjust pH to 7, and extracted with dichloromethane (20 mL x 2). The organic layer was evaporated. The residue was purified by preparation TLC (dichloromethane/methanol/ammonium hydroxide = 30/1/0.3) to give the desired product (12 mg, 53%) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.76 (s, 1H), 8.61 (d, J = 8.0 Hz, 1H), 7.51-7.46 (m, 2H), 7.00 (d, J = 8.0 Hz, 1H), 6.87 (s, 1H), 4.69 (s, 2H), 3.78 (s, 4H), 3.05 (s, 3H), 3.01 (s, 3H), 2.61 (s, 7H), 2.43 (s, 3H). MS (ESI/APCI) m/z 455.9 $[\text{M}+\text{H}]^+$.

[00392] Example 20


[00393] Preparation of *N*-(8-(methyl((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)amino)quinolin-6-yl)methanesulfonamide(D58)



[00394] Method AT-Step a. *N*-(8-(methyl((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)amino)quinolin-6-yl)methanesulfonamide: To the solution of *N*⁸-methyl-*N*⁸-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)quinoline-6,8-diamine (crude 100 mg, 0.1 mmol) and TEA (101 mg, 1 mmol) in dichloromethane (10 mL) was added dropwise MsCl (23 mg, 0.2 mmol) at 0°C. The reaction mixture was stirred at room temperature for 1h. The 2M NaOH aqueous solution was added to adjust pH to 11 and stirred for 1h. The mixture was partitioned and the water phase was added 6M HCl aqueous solution to adjust pH to 5. The saturated NaHCO₃ aqueous solution was added to adjust pH to 8 and extracted with ethyl acetate (30 mL x 3). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 20/1/0.05) to give the desired product (10 mg, 22%) as a brown oil. ¹H NMR (400 MHz, CDCl₃) δ 8.70 (d, *J* = 4.0 Hz, 1H), 8.01 (d, *J* = 8.4 Hz, 1H), 7.38-7.30 (m, 1H), 7.27 (s, 1H), 6.91 (s, 1H), 6.67 (s, 1H), 4.68 (s, 2H), 3.77 (t, *J* = 4.4 Hz, 2H), 3.63 (t, *J* = 4.4 Hz, 2H), 3.07 (s, 3H), 3.04 (s, 3H), 2.48 (s, 3H), 2.44-2.34 (m, 4H), 2.29 (s, 3H). MS (ESI/APCI) *m/z* 455.7 [M+H]⁺.

[00395] Example 21

[00396] Preparation of (*S*)-*N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-1-(pyridin-2-yl)ethan-1-amine (A75)




[00397] Method AA-Step a. (*S*)-*N*-((6-chloro-2-methylpyrimidin-4-yl)methyl)-*N*-methyl-1-(pyridin-2-yl)ethan-1-amine: A mixture of (*S*)-*N*-methyl-1-(pyridin-2-yl)ethan-1-amine (150 mg, 1.1 mmol), 4-chloro-6-(chloromethyl)pyrimidine (195 mg, 1.1 mmol), KI (16 mg, 0.1 mmol) and DIPEA (426 mg, 3.3 mmol) in CH₃CN (20 mL) was stirred at room temperature

overnight. The reaction solution was evaporated to remove most of CH₃CN. The residue was added saturated NaHCO₃ aqueous solution (20 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 200/1/0.5) to give the desired product (280 mg, 92%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, *J* = 4.4 Hz, 1H), 7.72-7.63 (m, 1H), 7.46 (s, 1H), 7.42 (d, *J* = 7.6 Hz, 1H), 7.17 (dd, *J* = 7.6, 4.8 Hz, 1H), 3.91 (q, *J* = 6.8 Hz, 1H), 3.72 (d, *J* = 16.4 Hz, 1H), 3.59 (d, *J* = 16.4 Hz, 1H), 2.67(s, 3H), 2.28(s, 3H), 1.49 (d, *J* = 6.8 Hz, 3H).

[00398] Method AA-Step b. (*S*)-*N*-methyl-*N*-((2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl)methyl)-1-(pyridin-2-yl)ethan-1-amine: A mixture of (*S*)-*N*-((6-chloro-2-methylpyrimidin-4-yl)methyl)-*N*-methyl-1-(pyridin-2-yl)ethan-1-amine (90 mg, 0.33 mmol), TEA (333 mg, 3.3mmol) and *N*-methylpiperazine (163 mg, 1.6 mmol) in ethanol (10 mL) was stirred at reflux overnight. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol/ammonium hydroxide = 100/2/1) to give the desired product (70 mg, 63 %) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, *J* = 4.0 Hz, 1H), 7.69-7.58 (m, 1H), 7.41 (d, *J* = 7.6 Hz, 1H), 7.18-7.11 (m, 1H), 6.64(s, 1H), 3.92-3.80 (m, 1H), 3.68 (s, 4H), 3.57 (d, *J* = 15.6 Hz, 1H), 3.44 (d, *J* = 15.6 Hz, 1H), 2.55-2.40 (m, 7H), 2.34 (s, 3H), 2.27(s, 3H), 1.47(d, *J* = 6.4 Hz, 3H).

[00399] Example 22

[00400] Preparation of (*S*)-*N*-methyl-*N*-((5-(4-methylpiperazin-1-yl)imidazo[1,2-*a*]pyridin-2-yl)methyl)-1-(pyridin-2-yl)ethan-1-amine (A95) and (*S*)-(2-((methyl(1-(pyridin-2-yl)ethyl)amino)methyl)-5-(4-methylpiperazin-1-yl)imidazo[1,2-*a*]pyridin-3-yl)methanol (A96)



[00401] Method AK-Step a. (*S*)-*N*-((5-bromoimidazo[1,2-*a*]pyridin-2-yl)methyl)-*N*-methyl-1-(pyridin-2-yl)ethan-1-amine: The mixture of 5-bromo-2-(bromomethyl)imidazo[1,2-*a*]pyridine (127 mg, 0.4 mmol), (*S*)-*N*-methyl-1-(pyridin-2-yl)ethanamine (55 mg, 0.4 mmol), KI (7 mg, 0.04 mmol) and DIPEA (130 mg, 1 mmol) in MeCN (10 mL) was stirred at room temperature overnight. The reaction mixture was evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 100/1) to give the desired product (100 mg, 72%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, *J* = 4.0 Hz, 1H), 7.92 (s,


1H), 7.74-7.67 (m, 1H), 7.62-7.52(m, 2H), 7.24-7.18 (m, 1H), 7.13-7.01 (m, 2H), 4.17-4.05 (m, 1H), 4.04-3.96 (m, 1H), 3.96-3.87 (m, 1H), 2.44 (s, 3H), 1.64-1.59 (m, 3H)。










[00402] Method AK-Step b. (*S*)-*N*-methyl-*N*-((5-(4-methylpiperazin-1-yl)imidazo[1,2-*a*]pyridin-2-yl)methyl)-1-(pyridin-2-yl)ethan-1-amine: The mixture of (*S*)-*N*-((5-bromoimidazo[1,2-*a*]pyridin-2-yl)methyl)-*N*-methyl-1-(pyridin-2-yl)ethan-1-amine (100 mg, 0.29 mmol) in *N*-methylpiperazine (3 mL) was stirred at 190°C under microwave for 2 h. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 50/1) to give the desired product (60 mg, 57%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, *J* = 4.0 Hz, 1H), 7.72-7.62 (m, 1H), 7.54 (d, *J* = 7.6 Hz, 1H), 7.46 (s, 1H), 7.31 (d, *J* = 8.8 Hz, 1H), 7.20-7.11 (m, 2H), 6.26 (d, *J* = 7.2 Hz, 1H), 3.97-3.81 (m, 2H), 3.72 (d, *J* = 14.0 Hz, 1H), 3.14 (s, 4H), 2.67 (s, 4H), 2.41 (s, 3H), 2.32 (s, 3H), 1.50 (d, *J* = 6.4 Hz, 3H).









[00403] Method AK-Step c. (*S*)-(2-((methyl(1-(pyridin-2-yl)ethyl)amino)methyl)-5-(4-methylpiperazin-1-yl)imidazo[1,2-*a*]pyridin-3-yl)methanol: The mixture of (*S*)-*N*-methyl-*N*-((5-(4-methylpiperazin-1-yl)imidazo[1,2-*a*]pyridin-2-yl)methyl)-1-(pyridin-2-yl)ethan-1-amine (43 mg, 0.12 mmol) and formaldehyde (37 wt percent in water, 10 mL) in a sealed tube was stirred at 50°C for 3 days. The reaction mixture was added saturated NaHCO₃ aqueous solution (10 mL) and extracted with dichloromethane (20 mL). The organic layer was dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (dichloromethane/methanol = 50/1) to give the desired product (25 mg, 50%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.57 (s, 1H), 7.73-7.58 (m, 1H), 7.40 (d, *J* = 7.6 Hz, 1H), 7.29 (d, *J* = 8.8 Hz, 1H), 7.20-7.12 (m, 1H), 7.12-7.04 (m, 1H), 6.40 (d, *J* = 7.2 Hz, 1H), 5.24-5.11 (m, 2H), 3.95-3.85 (m, 1H), 3.84-3.73 (m, 2H), 3.73-3.62 (m, 1H), 3.42-3.29 (m, 2H), 3.00-2.86 (m, 4H), 2.50-2.42 (m, 2H), 2.39 (s, 3H), 2.13 (s, 3H), 1.52 (d, *J* = 6.4 Hz, 3H).









[00404] Table 1 shows a selection of the compounds prepared according to the methods discussed above in details and indicated in the third column of the table.

[00405] Table 1. Selected compounds (A1-A100, B1-B8, C1-C39 and D1-D59) of the present invention

Compd number	structure	method	¹ H NMR and MS
A1		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.45 (s, 2H), 7.33 (d, <i>J</i> = 6.8 Hz, 1H), 7.20 (s, 1H), 7.03 (s, 4.8 Hz, 1H), 3.99 (s, 1H), 3.68 (s, 4H), 3.62 (s, 2H), 2.77 (s, 1H), 2.68-2.64 (m, 1H), 2.44 (s, 4H), 2.35 (s, 3H), 2.30 (s, 3H), 1.97 (s, 1H), 1.91-1.88 (m, 1H), 1.85 (s, 1H), 1.67 (s, 1H). HRMS (ESI): calcd for C ₂₀ H ₂₉ N ₆ [M+H] ⁺ 353.2448, found 353.2451.

A2		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.0 Hz, 1H), 8.47 (s, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 6.98 (s, 1H), 4.04-4.01 (m, 1H), 3.69 (s, 2H), 3.65 (s, 2H), 3.09 (s, 3H), 2.81-2.80 (m, 1H), 2.78-2.71 (m, 1H), 2.47 (t, <i>J</i> = 7.2 Hz, 2H), 2.38 (s, 3H), 2.27 (s, 6H), 2.10-2.09 (m, 1H), 2.03-2.01 (m, 1H), 1.94-1.91 (m, 1H), 1.71-1.67 (m, 1H). MS (ESI/APCI) <i>m/z</i> 354.9 [M + H] ⁺ .
A3		B, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 3.9 Hz, 1H), 7.36 (d, <i>J</i> = 7.6 Hz, 1H), 7.06 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 6.96 (s, 1H), 4.09-3.98 (m, 1H), 3.72 (s, 4H), 3.58 (s, 2H), 2.86-2.75 (m, 1H), 2.74-2.65 (m, 1H), 2.49 (s, 3H), 2.47-2.43 (m, 4H), 2.39 (s, 3H), 2.33 (s, 3H), 2.10 (s, 1H), 2.03-2.00 (m, 1H), 1.91-1.87 (m, 1H), 1.65 (s, 1H).
A4		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.57 (d, <i>J</i> = 4.2 Hz, 1H), 8.51 (s, 1H), 7.65 (t, <i>J</i> = 7.2 Hz, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 7.19-7.13 (m, 1H), 6.78 (s, 1H), 3.90 (q, <i>J</i> = 6.8 Hz, 1H), 3.69 (s, 4H), 3.61 (d, <i>J</i> = 15.6 Hz, 1H), 3.46 (d, <i>J</i> = 15.6 Hz, 1H), 2.54-2.45 (m, 4H), 2.35 (s, 3H), 2.29 (s, 3H), 1.48 (d, <i>J</i> = 6.8 Hz, 3H).
A5		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.48 (s, 2H), 7.37 (d, <i>J</i> = 7.2 Hz, 1H), 7.26 (s, 1H), 7.07 (s, 1H), 4.02 (s, 1H), 3.71-3.65 (m, 8H), 2.81-2.78 (m, 1H), 2.71-2.67 (m, 2H), 2.57 (s, 6H), 2.39 (s, 3H), 2.11 (s, 1H), 2.00 (s, 1H), 1.97-1.88 (m, 1H), 1.70-1.68 (m, 1H). HRMS (ESI): calcd for C ₂₁ H ₃₁ N ₆ O [M+H] ⁺ 383.2554, found 383.2555.
A6		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.50-8.47 (m, 2H), 7.37 (d, <i>J</i> = 7.8 Hz, 1H), 7.20 (s, 1H), 7.07 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 4.03 (t, <i>J</i> = 7.4 Hz, 1H), 3.73 (s, 4H), 3.64 (s, 2H), 3.55 (t, <i>J</i> = 5.4 Hz, 2H), 3.38 (s, 3H), 2.85-2.77 (m, 1H), 2.72-2.68 (m, 1H), 2.62 (t, <i>J</i> = 5.4 Hz, 2H), 2.56 (t, <i>J</i> = 5.0 Hz, 4H), 2.39 (s, 3H), 2.17-2.07 (m, 1H), 2.07-1.98 (m, 1H), 1.99-1.88 (m, 1H), 1.76-1.67 (m, 1H).
A7		A, AB	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (s, 2H), 7.38 (d, <i>J</i> = 7.2 Hz, 1H), 7.21 (s, 1H), 7.08 (s, 1H), 4.05-4.04 (m, 1H), 3.80-3.70 (m, 6H), 3.02-2.98 (m, 4H), 2.81-2.79 (m, 1H), 2.72-2.68 (m, 1H), 2.58 (s, 1H), 2.41 (s, 3H), 2.13 (s, 1H), 2.01 (m, 1H), 1.95-1.89 (m, 1H), 1.71-1.69 (m, 1H). MS (ESI/APCI) <i>m/z</i> 338.9 [M + H] ⁺ .
A8		A, AB	¹ H NMR (400 MHz, CDCl ₃) δ 8.53-8.47 (m, 2H), 7.38 (d, <i>J</i> = 7.6 Hz, 1H), 7.25 (s, 1H), 7.08 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 4.09-3.97 (m, 1H), 3.73 (s, 4H), 3.65 (s, 2H), 2.86-2.78 (m, 1H), 2.75-2.71 (m, 3H), 2.58-2.53 (m, 6H), 2.40 (s, 3H), 2.16-2.08 (s, 1H), 2.05-1.97 (m, 1H), 1.93-1.88 (m, 1H), 1.75-1.69 (m, 1H).
A9		E, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.6 Hz, 1H), 7.35 (d, <i>J</i> = 8.0 Hz, 1H), 7.07-7.03 (m, 2H), 4.04 (t, <i>J</i> = 7.4 Hz, 1H), 3.71 (t, <i>J</i> = 5.2 Hz, 4H), 3.60 (s, 2H), 2.86-2.75 (m, 1H), 2.73-2.65 (m, 1H), 2.46-2.43 (m, 7H), 2.39 (s, 3H), 2.33 (s, 3H), 2.15-2.07 (m, 1H), 2.04-1.96 (m, 1H), 1.95-1.87 (m, 1H), 1.74-1.71 (m, 1H).
A10		E, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.48 (d, <i>J</i> = 4.4 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 6.87 (s, 1H), 4.03 (t, <i>J</i> = 7.4 Hz, 1H), 3.88 (s, 3H), 3.70 (d, <i>J</i> = 5.0 Hz, 4H), 3.58 (s, 2H), 2.84-2.78 (m, 1H), 2.74-2.65 (m, 1H), 2.44 (t, <i>J</i> = 5.6 Hz, 4H), 2.37 (s, 3H),

			2.32 (s, 3H), 2.15-2.06 (m, 1H), 2.05-1.96 (m, 1H), 1.97-1.87 (m, 1H), 1.72-1.66 (m, 1H).
A11		E, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.6 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 7.02 (s, 1H), 4.04 (s, 1H), 3.67 (t, <i>J</i> = 5.0 Hz, 4H), 3.61 (s, 2H), 2.85-2.75 (m, 1H), 2.73-2.65 (m, 1H), 2.44 (t, <i>J</i> = 5.0 Hz, 4H), 2.40 (s, 3H), 2.32 (s, 3H), 2.15-1.94 (m, 4H), 1.74-1.64 (m, 1H), 1.04-1.00 (m, 2H), 0.91-0.86 (m, 2H).
A12		F, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.6 Hz, 1H), 7.34 (d, <i>J</i> = 7.2 Hz, 1H), 7.04 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 6.49 (s, 1H), 4.06 (s, 1H), 3.65 (s, 4H), 3.55-4.49 (m, 2H), 3.11 (s, 6H), 2.83-2.76 (m, 1H), 2.74-2.64 (m, 1H), 2.46-2.40 (m, 4H), 2.38 (s, 3H), 2.32 (s, 3H), 2.12-2.07 (m, 1H), 2.03-1.97 (m, 1H), 1.95-1.91 (m, 1H), 1.72-1.64 (m, 1H).
A13		F, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.48 (d, <i>J</i> = 4.6 Hz, 1H), 7.34 (d, <i>J</i> = 7.6 Hz, 1H), 7.04 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 6.48 (s, 1H), 4.07 (t, <i>J</i> = 7.4 Hz, 1H), 3.65 (t, <i>J</i> = 5.2 Hz, 4H), 3.58-3.48 (m, 6H), 2.84-2.76 (m, 1H), 2.71-2.68 (m, 1H), 2.43 (t, <i>J</i> = 5.2 Hz, 4H), 2.35 (s, 3H), 2.31 (s, 3H), 2.13-2.08 (m, 1H), 2.03-1.98 (m, 1H), 1.96-1.87 (m, 5H), 1.70-1.64 (m, 1H).
A14		F, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.6 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 6.57 (s, 1H), 4.05 (t, <i>J</i> = 7.2 Hz, 1H), 3.72 (s, 8H), 3.64 (d, <i>J</i> = 5.0 Hz, 4H), 3.52 (d, <i>J</i> = 4.8 Hz, 2H), 2.84-2.76 (m, 1H), 2.72-2.64 (m, 1H), 2.44 (t, <i>J</i> = 5.0 Hz, 4H), 2.38 (s, 3H), 2.32 (s, 3H), 2.14-2.06 (m, 1H), 2.04-1.98 (m, 1H), 1.98-1.88 (m, 1H), 1.73-1.63 (m, 1H).
A15		F, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.6 Hz, 1H), 7.34 (s, 1H), 7.05 (s, 1H), 6.52 (s, 1H), 4.04 (s, 1H), 3.83 (t, <i>J</i> = 4.6 Hz, 2H), 3.69-3.63 (m, 6H), 3.50 (d, <i>J</i> = 8.0 Hz, 2H), 3.15 (s, 3H), 2.85-2.75 (m, 1H), 2.72-2.64 (s, 1H), 2.45-2.41 (m, 4H), 2.36 (s, 3H), 2.32 (s, 3H), 2.12-2.05 (m, 1H), 2.04-1.97 (m, 1H), 1.94-1.86 (m, 2H), 1.73-1.63 (m, 1H).
A16		F, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (s, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (s, 1H), 6.59 (s, 1H), 4.65 (s, 2H), 4.04 (s, 1H), 3.65 (s, 4H), 3.50 (s, 2H), 2.84-2.75 (m, 1H), 2.75-2.64 (m, 1H), 2.45-2.40 (m, 4H), 2.37 (s, 3H), 2.32 (s, 3H), 2.13-2.06 (m, 1H), 2.04-1.98 (m, 1H), 1.96-1.87 (m, 1H), 1.72-1.64 (m, 1H).
A17		H, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.52 (s, 1H), 8.37-8.32 (m, 2H), 7.42-7.40 (m, 3H), 7.37 (d, <i>J</i> = 7.2 Hz, 1H), 7.19 (s, 1H), 7.07 (s, 1H), 4.17-4.02 (m, 1H), 3.84-3.82 (m, 4H), 3.74 (s, 2H), 2.90-2.77 (m, 1H), 2.75-2.65 (m, 1H), 2.52-2.50 (m, 4H), 2.45 (s, 3H), 2.36 (s, 3H), 2.16-2.14 (m, 1H), 2.02-1.87 (m, 2H), 1.73-1.71 (m, 1H).
A18		F, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.8 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 6.51 (s, 1H), 4.79 (s, 1H), 4.12-0.02 (m, 1H), 3.67 (t, <i>J</i> = 5.0 Hz, 4H), 3.50 (d, <i>J</i> = 5.2 Hz, 2H), 2.92 (d, <i>J</i> = 4.8 Hz, 3H), 2.84-2.75 (m, 1H), 2.75-2.64 (m, 1H), 2.44 (t, <i>J</i> = 5.0 Hz, 4H), 2.36 (s, 3H), 2.32 (s, 3H), 2.13-1.04 (m, 1H), 2.03-1.97 (m, 1H), 1.93-1.87 (m, 1H), 1.74-1.63 (m, 1H).








A19		F, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.6 Hz, 1H), 7.35 (d, <i>J</i> = 7.8 Hz, 1H), 7.05 (t, <i>J</i> = 6.0 Hz, 1H), 6.49 (s, 1H), 4.77 (s, 1H), 4.05 (t, <i>J</i> = 7.6 Hz, 1H), 3.66 (d, <i>J</i> = 5.0 Hz, 4H), 3.49 (d, <i>J</i> = 4.4 Hz, 2H), 3.38 (t, <i>J</i> = 7.0 Hz, 2H), 2.83-2.75 (m, 1H), 2.72-2.64 (m, 1H), 2.43 (d, <i>J</i> = 5.2 Hz, 4H), 2.35 (s, 3H), 2.32 (s, 3H), 2.13-2.05 (m, 1H), 2.03-1.98 (m, 1H), 1.96-1.85 (m, 1H), 1.72-1.64 (s, 1H), 1.18 (t, <i>J</i> = 7.2 Hz, 3H).
A20		F, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.6 Hz, 1H), 7.34 (d, <i>J</i> = 7.6 Hz, 1H), 7.08-7.02 (m, 1H), 6.48 (s, 1H), 4.60 (s, 1H), 4.09-4.02 (m, 2H), 3.65 (d, <i>J</i> = 5.2 Hz, 4H), 3.47 (d, <i>J</i> = 7.8 Hz, 2H), 2.84-2.75 (m, 1H), 2.71-2.63 (m, 1H), 2.43 (t, <i>J</i> = 5.0 Hz, 4H), 2.36 (s, 3H), 2.32 (s, 3H), 2.13-2.05 (s, 1H), 2.03-1.95 (m, 1H), 1.92-1.86 (m, 1H), 1.68-1.62 (m, 1H), 1.18 (d, <i>J</i> = 6.4 Hz, 6H).
A21		H, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.50 (d, <i>J</i> = 2.8 Hz, 1H), 8.07 (s, 1H), 8.00 (s, 1H), 7.36 (d, <i>J</i> = 7.2 Hz, 1H), 7.06 (s, 2H), 4.10 – 4.09 (m, 1H), 3.92 (s, 3H), 3.77- 3.75 (m, 4H), 3.66 (s, 2H), 2.84-2.76 (m, 1H), 2.72-2.66 (m, 1H), 2.49-2.47 (m, 4H), 2.41 (s, 3H), 2.34 (s, 3H), 2.13-2.10 (m, 1H), 2.01-1.93 (m, 2H), 1.92-1.90 (m, 1H).
A22		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.47 (s, 2H), 7.35 (d, <i>J</i> = 7.2 Hz, 1H), 7.05 (s, 2H), 4.04 – 4.01 (m, 1H), 3.84 (s, 1H), 3.69 (s, 1H), 3.64 (s, 3H), 2.81-2.77 (m, 1H), 2.71-2.67 (m, 3H), 2.55 (s, 2H), 2.39 (s, 3H), 2.35 (s, 3H), 2.09 (s, 1H), 1.99 (s, 1H), 1.94-1.89 (m, 4H), 1.72 (s, 1H). MS (ESI/APCI) <i>m/z</i> 366.9 [M + H] ⁺ .
A23		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.48 (s, 2H), 7.36 (d, <i>J</i> = 7.2 Hz, 1H), 7.22 (s, 1H), 7.06 (s, 1H), 4.02 (t, <i>J</i> = 6.8 Hz, 1H), 3.72 (s, 4H), 3.64 (s, 2H), 2.81-2.78 (m, 1H), 2.71-2.67 (m, 1H), 2.50 (s, 4H), 2.46-2.42 (m, 2H), 2.40 (s, 3H), 2.10 (s, 1H), 2.00 (s, 1H), 1.94-1.88 (m, 1H), 1.71 (s, 1H), 1.12 (t, <i>J</i> = 6.8 Hz, 3H). MS (ESI/APCI) <i>m/z</i> 366.9 [M + H] ⁺ .
A24		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.49-8.47 (m, 2H), 7.36 (d, <i>J</i> = 7.2 Hz, 1H), 7.19 (s, 1H), 7.06 (s, 1H), 4.02 (s, 1H), 3.70 (s, 4H), 3.64 (s, 2H), 2.81-2.78 (m, 1H), 2.72 (s, 2H), 2.57 (s, 4H), 2.39 (s, 3H), 2.10 (s, 1H), 2.00 (s, 1H), 1.94-1.89 (m, 1H), 1.67 (s, 1H), 1.07 (d, <i>J</i> = 6.0 Hz, 6H). MS (ESI/APCI) <i>m/z</i> 380.9 [M + H] ⁺ .
A25		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.50-8.47 (m, 2H), 7.36 (d, <i>J</i> = 6.8 Hz, 1H), 7.23 (s, 1H), 7.06 (s, 1H), 4.53 (s, 2H), 4.02 (s, 1H), 3.72-3.71 (m, 1H), 3.63 (s, 2H), 2.90-2.84 (m, 3H), 2.71-2.67 (m, 1H), 2.38 (s, 4H), 2.29 (s, 6H), 2.10 (s, 1H), 2.01 (s, 1H), 1.91 (s, 3H), 1.43 (t, <i>J</i> = 11.0 Hz, 2H). MS (ESI/APCI) <i>m/z</i> 380.9 [M + H] ⁺ .
A26		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.50 (s, 1H), 8.42 (s, 1H), 7.35 (s, 1H), 7.05 (s, 1H), 6.90 (s, 1H), 4.03 (s, 1H), 3.71 (s, 4H), 3.57 (s, 2H), 3.41 (s, 2H), 2.78 (s, 1H), 2.71-2.68 (m, 1H), 2.58 (s, 2H), 2.46 (s, 4H), 2.38 (s, 3H), 2.11 (s, 1H), 2.00 (m, 1H), 1.95-1.89 (m, 1H), 1.68 (s, 1H). HRMS (ESI): calcd for C ₂₁ H ₃₁ N ₆ [M+H] ⁺ 383.2554, found 383.2553.









A27		E, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.46 (d, <i>J</i> = 4.0 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.09-7.02 (m, 1H), 3.99-3.94 (m, 1H), 3.76-3.66 (m, 2H), 3.45-3.30 (m, 4H), 2.88-2.77 (m, 1H), 2.72-2.65 (m, 1H), 2.53-2.47 (m, 7H), 2.33 (s, 3H), 2.28 (s, 3H), 2.09 (s, 3H), 2.06-2.00 (m, 2H), 1.96-1.88 (s, 1H), 1.75-1.64 (m, 1H).
A28		E, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.6 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (d, <i>J</i> = 6.9 Hz, 2H), 4.04 (t, <i>J</i> = 7.4 Hz, 1H), 3.72 (d, <i>J</i> = 5.2 Hz, 4H), 3.61 (s, 2H), 2.85-2.76 (m, 1H), 2.71 (dd, <i>J</i> = 7.8, 4.0 Hz, 3H), 2.46 (t, <i>J</i> = 4.6 Hz, 4H), 2.41 (s, 3H), 2.34 (s, 3H), 2.10 (s, 1H), 1.99 (d, <i>J</i> = 4.8 Hz, 1H), 1.97-1.90 (m, 1H), 1.75-1.63 (m, 1H), 1.28 (t, <i>J</i> = 7.6 Hz, 3H).
A29		E, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.6 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.07-7.00 (m, 2H), 4.04 (t, <i>J</i> = 7.6 Hz, 1H), 3.72 (d, <i>J</i> = 5.2 Hz, 4H), 3.61 (s, 2H), 2.94 (p, <i>J</i> = 6.8 Hz, 1H), 2.82 (dd, <i>J</i> = 15.8, 4.6 Hz, 1H), 2.69 (d, <i>J</i> = 16.4 Hz, 1H), 2.47 (t, <i>J</i> = 4.6 Hz, 4H), 2.40 (s, 3H), 2.34 (s, 3H), 2.14 (dd, <i>J</i> = 14.2, 7.8 Hz, 1H), 2.01 (d, <i>J</i> = 7.2 Hz, 1H), 1.93 (q, <i>J</i> = 12.0 Hz, 1H), 1.72-1.65 (m, 1H), 1.25 (dd, <i>J</i> = 6.4, 3.2 Hz, 6H).
A30		G, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.0 Hz, 1H), 7.36 (d, <i>J</i> = 7.6 Hz, 1H), 7.13-7.00 (m, 1H), 6.87 (s, 1H), 4.31 (q, <i>J</i> = 7.2 Hz, 2H), 4.08-3.96 (m, 1H), 3.69 (s, 4H), 3.57 (s, 2H), 2.88-2.76 (m, 1H), 2.74-2.65 (m, 1H), 2.49-2.42 (m, 4H), 2.39 (s, 3H), 2.32 (s, 3H), 2.14-2.06 (m, 1H), 2.05-1.98 (m, 1H), 1.98-1.87 (m, 1H), 1.37 (t, <i>J</i> = 7.2 Hz, 3H).
A31		G, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.48 (d, <i>J</i> = 4.8 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.08-7.02 (m, 1H), 6.86 (s, 1H), 5.25-5.12 (m, 1H), 4.10-3.99 (m, 1H), 3.75-3.64 (m, 4H), 3.56 (s, 2H), 2.85-2.76 (m, 1H), 2.74-2.65 (m, 1H), 2.44 (t, <i>J</i> = 5.0 Hz, 4H), 2.38 (s, 3H), 2.32 (s, 3H), 2.13-2.06 (m, 1H), 2.05-1.98 (m, 1H), 1.98-1.87 (m, 1H), 1.69-1.64 (m, 1H), 1.33 (d, <i>J</i> = 6.0 Hz, 6H).
A32		J, BC	¹ H NMR (400 MHz, CDCl ₃) δ 8.46 (d, <i>J</i> = 3.6 Hz, 1H), 7.33 (d, <i>J</i> = 7.2 Hz, 1H), 7.10-6.98 (m, 1H), 6.85 (s, 1H), 4.18-4.03 (m, 2H), 3.74-3.63 (m, 4H), 2.86-2.74 (m, 1H), 2.72-2.61 (m, 1H), 2.50 (s, 3H), 2.46 (t, <i>J</i> = 4.6 Hz, 4H), 2.33 (s, 3H), 2.15 (s, 3H), 1.98 (m, 4H), 1.68-1.60 (m, 1H), 1.42 (d, <i>J</i> = 6.4 Hz, 3H).
A33		J, BC	¹ H NMR (400 MHz, CDCl ₃) δ 8.53-8.46 (m, 1H), 7.33 (d, <i>J</i> = 8.0 Hz, 1H), 7.28-7.26 (m, 1H), 7.06-7.00 (m, 1H), 4.02-3.91 (m, 1H), 3.88-3.78 (m, 1H), 3.71 (s, 4H), 2.83-2.72 (m, 1H), 2.70-2.58 (m, 1H), 2.49 (s, 3H), 2.44-2.36 (m, 4H), 2.30 (s, 3H), 2.21 (s, 3H), 2.08-1.98 (m, 1H), 1.90-1.78 (m, 2H), 1.66-1.54 (m, 1H), 1.41 (d, <i>J</i> = 6.4 Hz, 3H).
A34		J, BC	¹ H NMR (400 MHz, CDCl ₃) δ 8.46 (d, <i>J</i> = 4.0 Hz, 1H), 7.34 (d, <i>J</i> = 7.6 Hz, 1H), 7.09-7.00 (m, 1H), 6.83 (s, 1H), 4.16-4.00 (m, 2H), 3.74-3.63 (m, 4H), 2.87-2.75 (m, 1H), 2.72-2.63 (m, 1H), 2.50 (s, 3H), 2.46 (t, <i>J</i> = 4.8 Hz, 4H), 2.34 (s, 3H), 2.14 (s, 3H), 2.05-1.90 (m, 4H), 1.43 (d, <i>J</i> = 6.8 Hz, 3H).

A35		J, BC	¹ H NMR (400 MHz, CDCl ₃) δ 8.52 (d, <i>J</i> = 3.6 Hz, 1H), 7.33 (d, <i>J</i> = 7.6 Hz, 1H), 7.30 (s, 1H), 7.08-7.01 (m, 1H), 4.02-3.92 (m, 1H), 3.90-3.80 (m, 1H), 3.72 (s, 4H), 2.83-2.73 (m, 1H), 2.72-2.63 (m, 1H), 2.50 (s, 3H), 2.47-2.37 (m, 4H), 2.31 (s, 3H), 2.22 (s, 3H), 2.15-1.85 (m, 4H), 1.42 (d, <i>J</i> = 6.8 Hz, 3H).
A36		K, BA, B, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.58 (d, <i>J</i> = 4.8 Hz, 1H), 7.70-7.61 (m, 1H), 7.26-7.21 (m, 1H), 7.20-7.13 (m, 1H), 6.46 (s, 1H), 4.59 (s, 1H), 3.75-3.65 (m, 5H), 3.58 (d, <i>J</i> = 15.6 Hz, 1H), 3.33 (d, <i>J</i> = 15.6 Hz, 1H), 3.13-3.00 (m, 2H), 2.54-2.43 (m, 7H), 2.34 (s, 3H), 2.23 (s, 3H), 2.04-1.90 (m, 2H), 1.53-1.45 (m, 2H), 1.42 (s, 9H), 1.33-1.27 (m, 1H), 1.22-1.12 (m, 1H).
A37		K, BA, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.58 (d, <i>J</i> = 4.8 Hz, 1H), 7.64 (t, <i>J</i> = 7.6 Hz, 1H), 7.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.20-7.13 (m, 1H), 6.59 (s, 1H), 4.80 (s, 1H), 3.74 (t, <i>J</i> = 7.2 Hz, 1H), 3.71-3.61 (m, 5H), 3.34 (d, <i>J</i> = 15.6 Hz, 1H), 3.18-3.08 (m, 2H), 2.52-2.44 (m, 7H), 2.34 (s, 3H), 2.22 (s, 3H), 2.07-1.96 (m, 2H), 1.59-1.51 (m, 1H), 1.42 (s, 10H).
A38		K, BA, C, AA, AD	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.99 (s, 1H), 8.82 (d, <i>J</i> = 4.8 Hz, 1H), 8.29 (t, <i>J</i> = 7.8 Hz, 1H), 8.19 (s, 3H), 7.99 (d, <i>J</i> = 7.6 Hz, 1H), 7.78 (t, <i>J</i> = 6.4 Hz, 1H), 7.64 (s, 1H), 5.06-4.50 (m, 3H), 4.25 (d, <i>J</i> = 14.8 Hz, 1H), 4.11 (d, <i>J</i> = 14.4 Hz, 1H), 3.81-3.45 (m, 4H), 3.25-3.11 (m, 2H), 2.79 (s, 5H), 2.61 (s, 3H), 2.46 (s, 3H), 2.38-2.21 (m, 2H), 1.58-1.44 (m, 1H), 1.41-1.29 (m, 1H).
A39		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.48 (s, 2H), 7.35 (d, <i>J</i> = 7.2 Hz, 1H), 7.05 (s, 1H), 6.90 (s, 1H), 4.03 (s, 1H), 3.92-3.84 (m, 1H), 3.66 (s, 3H), 3.44 (s, 1H), 3.26 (s, 1H), 2.83-2.78 (m, 2H), 2.71-2.67 (m, 1H), 2.40 (s, 3H), 2.31 (s, 6H), 2.23 (s, 1H), 2.10 (s, 1H), 2.01 (s, 1H), 1.93-1.88 (m, 2H), 1.69 (s, 1H). MS (ESI/APCI) <i>m/z</i> 366.9 [M + H] ⁺ .
A40		BD, BA, E, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.35 (d, <i>J</i> = 4.0 Hz, 1H), 7.41 (d, <i>J</i> = 8.0 Hz, 1H), 7.11-7.08 (m, 1H), 6.46 (s, 1H), 3.79-3.46 (m, 6H), 2.99 (s, 2H), 2.61-2.60 (m, 1H), 2.47-2.33 (m, 14H), 1.11-1.09 (m, 1H), 0.92-0.89 (m, 1H), 0.64-0.62 (m, 1H), 0.23-0.21 (m, 2H).
A41		BD, BA, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.36 (d, <i>J</i> = 4.4 Hz, 1H), 7.43 (d, <i>J</i> = 4.0 Hz, 1H), 7.15-7.04 (m, 1H), 6.63 (s, 1H), 3.88-3.58 (m, 6H), 3.01 (s, 1H), 2.95-2.80 (m, 1H), 2.48-2.35 (m, 14H), 1.15-1.10 (t, <i>J</i> = 4.0, 1Hz), 0.94-0.88 (t, <i>J</i> = 4.0, 1Hz), 0.66 (t, <i>J</i> = 4.0 Hz, 1H), 0.23 (t, <i>J</i> = 4.8 Hz, 2H).
A42		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.4 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.09-7.01 (m, 2H), 4.04 (t, <i>J</i> = 7.6 Hz, 1H), 3.71 (s, 4H), 3.60 (s, 2H), 2.88-2.75 (m, 1H), 2.74-2.65 (m, 1H), 2.48-2.44 (m, 7H), 2.39 (s, 3H), 2.33 (s, 3H), 2.16-2.06 (m, 1H), 2.04-1.98 (m, 1H), 1.95-1.84 (m, 1H), 1.77-1.68 (m, 1H).
A43		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.54-8.46 (m, 1H), 7.35 (d, <i>J</i> = 8.0 Hz, 1H), 7.10-7.02 (m, 2H), 4.10-4.00 (m, 1H), 3.72 (s, 4H), 3.60 (s, 2H), 2.87-2.76 (m, 1H), 2.75-2.64 (m, 1H), 2.53-2.42 (m, 9H), 2.40 (s, 3H), 2.16-2.07 (m, 1H), 2.05-1.98 (m, 1H), 1.96-1.89 (m, 1H), 1.76-1.66 (m, 1H), 1.12 (t, <i>J</i> = 7.4 Hz, 3H).








A44		BD, BA, C, AA	^1H NMR (400 MHz, CDCl_3) δ 8.36(s, 1H), 7.36(d, J = 6.8 Hz), 7.05(s, 1H), 6.75(s, 1H), 3.66(s, 4H), 3.60(s, 2H), 3.47(s, 1H), 3.15-3.07(m, 1H), 2.90-2.86(m, 1H), 2.8-2.70(m, 2H), 2.48(s, 4H), 2.42(s, 3H), 2.35(s, 3H), 2.10-2.04(m, 1H), 1.28-1.20(m, 1H), 1.01(t, J = 6.8 Hz, 3H), 0.89-0.82(m, 1H), 0.51-0.46(m, 1H), 0.42-0.38(m, 1H), 0.27-0.23(m, 1H).
A45		BD, BA, C, AA	^1H NMR (400 MHz, CDCl_3) δ 8.36(s, 1H), 7.42(d, J = 8.0 Hz, 1H), 7.11(d, J = 4.8 Hz, 1H), 6.61(s, 1H), 3.86-3.56(m, 6H), 3.00(s, 2H), 2.86-2.83(m, 1H), 2.50-2.36(m, 12H), 1.15-1.11 (m, 4H), 0.93-0.88(m, 1H), 0.68-0.60(m, 1H), 0.28-0.19(m, 1H).
A46		BE, BC, C, AA	^1H NMR (400 MHz, CDCl_3) δ 8.51(s, 1H), 7.30(d, J = 7.2 Hz, 1H), 7.07-7.01(m, 2H), 4.17-4.13(m, 1H), 3.71(s, 4H), 3.60(d, J = 5.2 Hz, 2H), 3.23(d, J = 16.8 Hz, 1H), 2.47(s, 7H), 2.42 (s, 3H), 2.34(s, 3H), 2.26-2.17(m, 1H), 2.01(d, J = 16.0 Hz, 1H), 1.52-1.45(m, 1H), 0.57-0.48(m, 2H), 0.37-0.30(m, 2H).
A47		BB, C, AA	^1H NMR (400 MHz, CDCl_3) δ 8.49 (d, J = 3.6 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.07-7.03 (m, 2H), 4.08-4.01 (m, 1H), 3.70-3.63 (m, 4H), 3.61 (s, 2H), 2.83-2.74 (m, 1H), 2.73-2.69 (m, 1H), 2.68-2.63 (m, 4H), 2.47 (s, 3H), 2.40 (s, 3H), 2.16-2.07 (m, 1H), 2.05-1.96 (m, 1H), 1.95-1.86 (m, 1H), 1.69-1.66 (m, 1H), 1.65-1.59 (m, 1H), 0.51-0.43 (m, 4H).
A48		E, BB, AC	^1H NMR (400 MHz, CDCl_3) δ 8.47 (d, J = 3.6 Hz, 1H), 7.46 (s, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.08-7.04 (m, 1H), 4.06-3.96 (m, 1H), 3.84-3.72 (m, 4H), 3.72-3.60 (m, 2H), 2.87-2.75 (m, 1H), 2.74-2.61 (m, 1H), 2.53-2.42 (m, 4H), 2.42 (s, 3H), 2.34 (s, 3H), 2.16-2.08 (m, 1H), 2.07-1.96 (m, 1H), 1.96-1.86 (m, 1H), 1.76-1.64 (m, 1H).
A49		BB, C, AA	^1H NMR (400 MHz, CDCl_3) δ 8.49 (d, J = 4.0 Hz, 1H), 7.36 (d, J = 7.2 Hz, 1H), 7.10-7.01 (m, 2H), 4.713-4.60 (m, 4H), 4.10-3.95 (m, 1H), 3.74 (s, 4H), 3.61 (s, 2H), 3.55-3.46 (m, 1H), 2.86-2.75 (m, 1H), 2.713-2.673 (m, 1H), 2.47 (s, 3H), 2.38 (s, 7H), 2.20-2.07 (m, 1H), 2.06-1.96 (m, 1H), 1.93-1.88 (m, 1H), 1.78-1.65 (m, 1H).
A50		L, AE	^1H NMR (400 MHz, CDCl_3) δ 8.46 (s, 1H), 8.18 (d, J = 6.0 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.05-7.02 (m, 1H), 6.32 (d, J = 6.4 Hz, 1H), 4.15-4.12 (m, 1H), 3.81 (s, 2H), 3.65 (s, 4H), 2.87-2.77 (m, 1H), 2.72-2.69 (m, 1H), 2.65-2.44 (m, 7H), 2.32 (s, 3H), 2.11-1.98 (m, 3H), 1.73-1.64 (m, 1H).
A51		I, BC	^1H NMR (400 MHz, CDCl_3) δ 8.48 (d, J = 4.0 Hz, 1H), 7.34(d, J = 7.6 Hz, 1H), 7.06-7.02 (m, 1H), 4.11-4.00 (m, 1H), 3.81-3.73 (m, 4H), 3.73-3.69 (m, 2H), 3.68-3.60 (m, 1H), 2.89-2.75 (m, 1H), 2.75-2.62 (m, 1H), 2.50-2.45 (m, 4H), 2.46-2.42 (m, 3H), 2.40 (s, 3H), 2.32 (s, 3H), 2.07-2.01 (m, 2H), 1.76-1.680 (m, 1H).
A52		C, AA	^1H NMR (400 MHz, CDCl_3) δ 8.57 (d, J = 4.8 Hz, 1H), 7.70-7.60 (m, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.15 (dd, J = 7.6, 4.8 Hz, 1H), 6.65 (s, 1H), 3.90 (q, J = 6.6 Hz, 1H), 3.69 (t, J = 5.0 Hz, 4H), 3.57 (d, J = 15.6 Hz, 1H), 3.44 (d, J = 15.6 Hz, 1H), 2.48 (d, J = 5.0 Hz, 7H), 2.35 (s, 3H), 2.28 (s, 3H), 1.47 (d, J = 6.8 Hz, 3H).

A53		BA, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.40 (d, <i>J</i> = 4.8 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 6.44 (s, 1H), 4.12 (q, <i>J</i> = 6.8 Hz, 1H), 3.62 (t, <i>J</i> = 5.0 Hz, 4H), 3.53 (s, 2H), 2.48-2.40 (m, 10H), 2.33 (s, 3H), 2.26 (s, 3H), 1.45 (d, <i>J</i> = 6.6 Hz, 3H).
A54		BA, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.41 (d, <i>J</i> = 4.8 Hz, 1H), 7.24 (s, 1H), 6.97 (d, <i>J</i> = 4.8 Hz, 1H), 6.65 (s, 1H), 3.90-3.83 (m, 1H), 3.75-3.64 (m, 4H), 3.57 (d, <i>J</i> = 15.6 Hz, 1H), 3.43 (d, <i>J</i> = 15.6 Hz, 1H), 2.50-2.45 (m, 7H), 2.36-2.32 (m, 6H), 2.29 (s, 3H), 1.46 (d, <i>J</i> = 6.8 Hz, 3H).
A55		BA, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.38 (s, 1H), 7.45 (d, <i>J</i> = 8.0 Hz, 1H), 7.30 (d, <i>J</i> = 8.0 Hz, 1H), 6.65 (s, 1H), 3.87 (d, <i>J</i> = 6.9 Hz, 1H), 3.69-3.67 (m, 4H), 3.56 (d, <i>J</i> = 15.6 Hz, 1H), 3.42 (d, <i>J</i> = 15.6 Hz, 1H), 2.50-2.46 (m, 7H), 2.35 (s, 3H), 2.31 (s, 3H), 2.27 (s, 3H), 1.45 (d, <i>J</i> = 6.8 Hz, 3H).
A56		BA, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 7.56-7.48 (m, 1H), 7.21 (d, <i>J</i> = 7.8 Hz, 1H), 6.99 (d, <i>J</i> = 7.6 Hz, 1H), 6.67 (s, 1H), 3.83 (q, <i>J</i> = 6.6 Hz, 1H), 3.69 (s, 4H), 3.57 (d, <i>J</i> = 15.6 Hz, 1H), 3.42 (d, <i>J</i> = 15.6 Hz, 1H), 2.53 (s, 3H), 2.47 (d, <i>J</i> = 6.4 Hz, 7H), 2.34 (s, 3H), 2.28 (s, 3H), 1.44 (d, <i>J</i> = 6.8 Hz, 3H).
A57		C, BC, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.43 (s, 1H), 7.38-7.29 (m, 1H), 7.21 (s, 1H), 7.03 (s, 1H), 4.13 (s, 1H), 3.73 (s, 4H), 3.64-3.45 (m, 2H), 2.90-2.60 (m, 4H), 2.55-2.40 (m, 7H), 2.34 (s, 3H), 2.20-2.06 (m, 1H), 2.06-1.90 (m, 1H), 1.90-1.78 (m, 1H), 1.78-1.70 (m, 1H), 1.10-0.98 (m, 3H).
A58		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.42 (s, 1H), 7.31 (d, <i>J</i> = 7.2 Hz, 1H), 7.22 (s, 1H), 7.04-6.99 (m, 1H), 4.18-4.05 (m, 1H), 3.72 (s, 4H), 3.64-3.48 (m, 2H), 2.90-2.65 (m, 4H), 2.53-2.39 (m, 7H), 2.34 (s, 3H), 2.20-2.03 (s, 1H), 2.05-1.90 (m, 1H), 1.90-1.73 (m, 1H), 1.75-1.68 (m, 1H), 1.10-0.94 (m, 3H).
A59		C, BC, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.42 (s, 1H), 7.32 (d, <i>J</i> = 7.2 Hz, 2H), 7.02 (s, 1H), 4.30-4.18 (m, 1H), 3.80-3.55 (m, 6H), 2.85-2.52 (m, 4H), 2.52-2.40 (m, 7H), 2.35 (s, 3H), 2.20-2.10 (m, 1H), 2.02-1.90 (m, 1H), 1.88-1.76 (m, 2H), 0.90-0.78 (m, 1H), 0.45-0.30 (m, 2H), 0.12-0.03 (m, 2H).
A60		A, E, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.54-8.46 (m, 2H), 7.37 (d, <i>J</i> = 7.6 Hz, 1H), 7.21 (s, 1H), 7.12-7.03 (m, 1H), 4.03 (t, <i>J</i> = 7.2 Hz, 1H), 3.74 (s, 4H), 3.65 (s, 2H), 2.88-2.76 (m, 1H), 2.74-2.66 (m, 1H), 2.59 (s, 4H), 2.39 (s, 3H), 2.30 (d, <i>J</i> = 6.4 Hz, 2H), 2.17-2.08 (m, 1H), 2.06-1.98 (m, 1H), 1.98-1.87 (m, 1H), 1.76-1.741 (m, 1H), 0.94-0.84 (m, 1H), 0.60-0.50 (m, 2H), 0.17-0.06 (m, 2H). MS (ESI/APCI) <i>m/z</i> 392.9 [M + H] ⁺ .
A61		E, BB, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.07-7.01 (m, 1H), 4.02-3.92 (m, 1H), 3.80-3.69 (m, 2H), 3.39-3.25 (m, 4H), 2.88-2.76 (m, 1H), 2.73-2.65 (m, 1H), 2.51 (s, 7H), 2.33 (s, 3H), 2.23 (s, 3H), 2.08-1.98 (m, 3H), 1.74-1.63 (m, 1H).
A62		C, BS, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.53 (d, <i>J</i> = 4.8 Hz, 1H), 7.73 (d, <i>J</i> = 8.4 Hz, 1H), 7.65-7.55 (m, 1H), 7.13-7.08 (m, 1H), 6.70 (s, 1H), 3.71 (t, <i>J</i> = 5.0 Hz, 4H), 3.40 (s, 2H), 2.51 (t, <i>J</i> = 5.0 Hz, 4H), 2.45 (s, 3H), 2.36 (s, 3H),

			2.27 (s, 3H), 1.48 (s, 6H).
A63		BB, C, AA , AD	¹ H NMR (400 MHz, CDCl ₃) δ 8.48 (s, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.09-6.92 (m, 2H), 4.62 (s, 1H), 4.35-4.28 (m, 1H), 4.09-3.98 (m, 1H), 3.74-3.49 (m, 2H), 3.23-3.08 (m, 1H), 2.91-2.83 (m, 1H), 2.82-2.75 (m, 1H), 2.74-2.65 (m, 2H), 2.46 (s, 3H), 2.42-2.36 (m, 3H), 2.28 (s, 3H), 2.22-2.17 (m, 1H), 2.14-2.07 (m, 1H), 2.05-1.91 (m, 3H), 1.74-1.63 (m, 1H), 1.29-1.23 (m, 3H).
A64		BB, C, AA , AD	¹ H NMR (400 MHz, CDCl ₃) δ 8.51-8.44 (m, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.09-7.02 (m, 1H), 7.02-6.89 (m, 1H), 4.61 (s, 1H), 4.31 (d, <i>J</i> = 13.2 Hz, 1H), 4.05 (q, <i>J</i> = 7.8 Hz, 1H), 3.63 (d, <i>J</i> = 8.0 Hz, 1H), 3.56 (s, 1H), 3.21 - 3.10 (m, 1H), 2.89-2.83 (m, 1H), 2.81-2.74 (m, 1H), 2.74-2.67 (m, 2H), 2.46 (s, 3H), 2.37 (d, <i>J</i> = 6.0 Hz, 3H), 2.23 (s, 3H), 2.21-2.15 (m, 1H), 2.15-2.05 (m, 1H), 2.04-1.95 (m, 2H), 1.95-1.92 (m, 1H), 1.74-1.63 (m, 1H), 1.30-1.25 (m, 2H), 1.18 (d, <i>J</i> = 6.8 Hz, 1H).
A65		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.52-8.47 (m, 1H), 7.36 (d, <i>J</i> = 7.6 Hz, 1H), 7.09-7.00 (m, 2H), 4.35 (s, 1H), 4.25 (s, 1H), 4.04 (t, <i>J</i> = 7.6 Hz, 1H), 3.68-3.55 (m, 2H), 3.14-3.03 (m, 1H), 2.88-2.82 (m, 1H), 2.82-2.76 (m, 1H), 2.74-2.63 (m, 2H), 2.46 (s, 3H), 2.37 (s, 3H), 2.31 (s, 3H), 2.29-2.18 (m, 1H), 2.14-2.06 (m, 2H), 2.04-1.97 (m, 1H), 1.93-1.87 (m, 1H), 1.73-1.64 (m, 1H), 1.17-1.09 (m, 3H).
A66		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.50 (d, <i>J</i> = 4.4 Hz, 1H), 7.36 (d, <i>J</i> = 7.6 Hz, 1H), 7.09-7.01 (m, 2H), 4.35 (s, 1H), 4.25 (s, 1H), 4.05 (t, <i>J</i> = 7.6 Hz, 1H), 3.68-3.55 (m, 2H), 3.14-3.02 (m, 1H), 2.89-2.82 (m, 1H), 2.80-2.74 (m, 1H), 2.74-2.63 (m, 2H), 2.46 (s, 3H), 2.37 (s, 3H), 2.31 (s, 3H), 2.28-2.19 (m, 1H), 2.14-2.06 (m, 2H), 2.04-1.98 (m, 1H), 1.97-1.87 (m, 1H), 1.73-1.64 (m, 1H), 1.16-1.10 (m, 3H).
A67		BB, C, AA , AD	¹ H NMR (400 MHz, CDCl ₃) δ 8.52 (s, 1H), 7.36 (d, <i>J</i> = 7.2 Hz, 1H), 7.06 (s, 2H), 4.32 (s, 2H), 4.05 (t, <i>J</i> = 7.6 Hz, 1H), 3.63 (s, 2H), 2.85-2.76 (m, 1H), 2.75-2.62 (m, 3H), 2.47 (s, 3H), 2.39 (s, 3H), 2.29 (s, 3H), 2.24-2.16 (m, 2H), 2.13-2.07 (m, 1H), 2.05-1.96 (m, 1H), 1.95-1.87 (m, 1H), 1.71-1.65 (m, 1H), 1.18 (t, <i>J</i> = 6.0 Hz, 6H).
A68		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.55-8.48 (m, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.14-7.02 (m, 2H), 4.75-4.35 (m, 2H), 4.11-3.97 (m, 1H), 3.61 (s, 2H), 3.15-3.08 (m, 2H), 3.05-2.96 (m, 1H), 2.86-2.76 (m, 1H), 2.74-2.57 (m, 2H), 2.46 (s, 3H), 2.38 (s, 3H), 2.23-1.83 (m, 9H), 1.74-1.63 (m, 2H), 1.55-1.42 (m, 1H).
A69		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (s, 1H), 7.36 (d, <i>J</i> = 7.6 Hz, 1H), 7.11-7.03 (m, 2H), 4.68-4.37 (m, 2H), 4.09-3.99 (m, 1H), 3.68-3.55 (m, 2H), 3.17-3.07 (m, 2H), 3.06-2.97 (m, 1H), 2.84-2.74 (m, 1H), 2.71-2.60 (m, 2H), 2.47 (s, 3H), 2.38 (s, 3H), 2.28-2.06 (m, 3H), 2.04-1.82 (m, 6H), 1.71-1.59 (m, 1H), 1.54-1.43 (m, 1H).
A70		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.50 (s, 1H), 7.37 (d, <i>J</i> = 6.8 Hz, 1H), 7.12-7.02 (m, 1H), 6.73 (s, 1H), 5.50 (s, 1H), 4.13-3.95 (m, 1H), 3.72 (s, 4H), 3.59 (s, 2H), 3.44 (s, 2H), 2.88-2.76 (m, 1H), 2.75-2.63 (m, 1H), 2.50-2.40 (m, 9H), 2.38 (s, 3H), 2.18-2.08 (m, 1H), 2.06-1.96 (m,








			1H), 1.96-1.88 (m, 2H), 1.76-1.73 (m, 2H).
A71		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.53-8.48 (m, 1H), 7.36 (d, <i>J</i> = 7.6 Hz, 1H), 7.10-7.02 (m, 1H), 6.75 (s, 1H), 5.52 (s, 1H), 4.08-4.02 (m, 1H), 3.72 (s, 4H), 3.56 (s, 2H), 3.42 (s, 2H), 2.84-2.77 (m, 1H), 2.74-2.65 (m, 1H), 2.62-2.56 (m, 2H), 2.46 (s, 7H), 2.38 (s, 3H), 2.15-2.08 (m, 1H), 2.06-1.98 (m, 1H), 1.96-1.85 (m, 1H), 1.80-1.75 (m, 1H).
A72		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.51-8.47 (m, 1H), 7.36 (d, <i>J</i> = 7.6 Hz, 1H), 7.11-7.02 (m, 2H), 4.58 (d, <i>J</i> = 12.0 Hz, 2H), 4.03 (t, <i>J</i> = 7.2 Hz, 1H), 3.72 (s, 4H), 3.61 (s, 2H), 2.88-2.76 (m, 3H), 2.74-2.65 (m, 1H), 2.56 (s, 4H), 2.46 (s, 4H), 2.38 (s, 3H), 2.15-1.96 (m, 2H), 1.95-1.85 (m, 3H), 1.76-1.65 (m, 1H), 1.55-1.42 (m, 2H).
A73		C, BB, AA, AD	¹ H NMR (400 MHz, CDCl ₃) δ 8.52-8.45 (m, 1H), 7.37 (d, <i>J</i> = 7.6 Hz, 1H), 7.115-7.04 (m, 2H), 4.63 (s, 1H), 4.29 (s, 1H), 4.08-3.83 (m, 3H), 3.62-3.58 (m, 2H), 3.48-3.36 (m, 1H), 3.06 (d, <i>J</i> = 11.6 Hz, 1H), 2.90 (d, <i>J</i> = 10.8 Hz, 1H), 2.85-2.75 (m, 1H), 2.74-2.63 (m, 1H), 2.45 (d, <i>J</i> = 5.2 Hz, 3H), 2.38 (d, <i>J</i> = 14.0 Hz, 3H), 2.30 (s, 3H), 2.17-2.07 (m, 2H), 2.06-1.97 (m, 2H), 1.96-1.88 (m, 1H), 1.75-1.63 (m, 1H).
A74		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (d, <i>J</i> = 4.4 Hz, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.10-7.02 (m, 2H), 4.59 (d, <i>J</i> = 13.2 Hz, 2H), 4.04 (t, <i>J</i> = 7.2 Hz, 1H), 3.60 (s, 2H), 2.90-2.75 (m, 3H), 2.71-2.55 (m, 5H), 2.54-2.43 (m, 7H), 2.39 (s, 3H), 2.29 (s, 3H), 2.17-1.84 (m, 7H), 1.56-1.40 (m, 2H).
A75		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.56 (d, <i>J</i> = 4.0 Hz, 1H), 7.64 (t, <i>J</i> = 7.2 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 1H), 7.15 (t, <i>J</i> = 6.4 Hz, 1H), 6.64 (s, 1H), 3.92-3.80 (m, 1H), 3.68 (s, 4H), 3.59-3.42 (m, 2H), 2.55-2.40 (m, 7H), 2.34 (s, 3H), 2.27 (s, 3H), 1.47 (d, <i>J</i> = 6.4 Hz, 3H).
A76		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.56 (d, <i>J</i> = 4.0 Hz, 1H), 7.70-7.56 (m, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 1H), 7.21-7.11 (m, 1H), 6.64 (s, 1H), 3.92-3.80 (m, 1H), 3.68 (s, 4H), 3.59-3.42 (m, 2H), 2.55-2.40 (m, 7H), 2.34 (s, 3H), 2.27 (s, 3H), 1.47 (d, <i>J</i> = 6.4 Hz, 3H).
A77		M, AD	¹ H NMR (400 MHz, CDCl ₃) δ 8.44 (d, <i>J</i> = 4.0 Hz, 1H), 7.35 (d, <i>J</i> = 7.2 Hz, 1H), 7.04 (dd, <i>J</i> = 8.0, 4.8 Hz, 1H), 4.15-4.08 (m, 1H), 4.08-3.93 (m, 6H), 2.87-2.75 (m, 1H), 2.75-2.62 (m, 1H), 2.55-2.45 (m, 7H), 2.33 (s, 3H), 2.23 (s, 3H), 2.08-1.90 (m, 3H), 1.77-1.64 (m, 1H).
A78		BB, C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.54 (d, <i>J</i> = 4.8 Hz, 1H), 7.67-7.57 (m, 1H), 7.40 (d, <i>J</i> = 8.0 Hz, 1H), 7.18-7.08 (m, 1H), 6.65 (s, 1H), 4.63-4.50 (m, 1H), 4.46-4.30 (m, 1H), 3.89 (q, <i>J</i> = 6.8 Hz, 1H), 3.56 (d, <i>J</i> = 15.6 Hz, 1H), 3.43 (d, <i>J</i> = 15.6 Hz, 1H), 3.17-3.07 (m, 2H), 3.07-2.95 (m, 1H), 2.69-2.58 (m, 1H), 2.45 (s, 3H), 2.26 (s, 3H), 2.23-2.11 (m, 2H), 2.00-1.71 (m, 4H), 1.54-1.39 (m, 4H).

A79		BB, C, AA	^1H NMR (400 MHz, CDCl_3) δ 8.57 (d, J = 4.8 Hz, 1H), 7.67-7.57 (m, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.18-7.10 (m, 1H), 6.70 (s, 1H), 4.63-4.50 (m, 1H), 4.46-4.30 (m, 1H), 3.91 (q, J = 6.8 Hz, 1H), 3.58 (d, J = 15.6 Hz, 1H), 3.45 (d, J = 15.6 Hz, 1H), 3.19-3.10 (m, 2H), 3.09-2.98 (m, 1H), 2.73-2.61 (m, 1H), 2.47 (s, 3H), 2.28 (s, 3H), 2.26-2.13 (m, 2H), 2.03-1.76 (m, 4H), 1.57-1.42 (m, 4H).
A80		BB, C, AA	^1H NMR (400 MHz, CDCl_3) δ 8.53 (d, J = 4.8 Hz, 1H), 7.68-7.54 (m, 1H), 7.42 (d, J = 7.6 Hz, 1H), 7.16-7.06 (m, 1H), 6.72 (s, 1H), 4.08 (q, J = 6.8 Hz, 1H), 3.73-3.60 (m, 5H), 3.54 (d, J = 16.8 Hz, 1H), 2.75-2.63 (m, 1H), 2.60-2.51 (m, 1H), 2.49-2.40 (m, 7H), 2.33 (s, 3H), 1.44 (d, J = 6.8 Hz, 3H), 1.03 (t, J = 6.8 Hz, 3H).
A81		E, BB, AC	^1H NMR (400 MHz, CDCl_3) δ 8.56 (s, 1H), 7.68-7.62 (m, 1H), 7.41 (d, J = 7.6 Hz, 1H), 7.18-7.14 (m, 1H), 6.69 (s, 1H), 4.55 (s, 2H), 3.95-3.83 (m, 2H), 3.77-3.65 (m, 4H), 3.60 (d, J = 16.0 Hz, 1H), 3.47 (d, J = 16.0 Hz, 1H), 2.55-2.42 (m, 4H), 2.35 (s, 3H), 2.29 (s, 3H), 1.47 (d, J = 6.8 Hz, 3H). MS (ESI/APCI) m/z 356.9 $[\text{M}+\text{H}]^+$.
A82		E, BB, AC	^1H NMR (400 MHz, CDCl_3) δ 8.51 (s, 1H), 7.61-7.57 (m, 1H), 7.35 (d, J = 7.6 Hz, 1H), 7.11-7.06 (m, 1H), 6.64 (s, 1H), 4.58-4.42 (m, 3H), 4.41-4.26 (m, 1H), 3.98-3.72 (m, 2H), 3.55 (d, J = 15.6 Hz, 1H), 3.41 (d, J = 15.6 Hz, 1H), 3.08-2.95 (m, 3H), 2.71-2.56 (m, 1H), 2.24 (s, 3H), 2.21-2.09 (m, 2H), 1.98-1.72 (m, 4H), 1.51-1.47 (m, 1H), 1.42 (d, J = 6.4 Hz, 3H). MS (ESI/APCI) m/z 382.9 $[\text{M}+\text{H}]^+$.
A83		F, BB, AC	^1H NMR (400 MHz, CDCl_3) δ 8.55 (s, 1H), 7.68-7.58 (m, 1H), 7.47-7.37 (m, 1H), 7.18-7.09 (m, 1H), 6.22 (s, 1H), 4.66 (s, 2H), 3.95-3.76 (m, 1H), 3.61 (s, 4H), 3.44 (d, J = 15.2 Hz, 1H), 3.29 (d, J = 15.2 Hz, 1H), 2.45 (s, 4H), 2.33 (s, 3H), 2.26 (s, 3H), 1.46 (d, J = 6.8 Hz, 1H).
A84		C, BB, AA, AD	^1H NMR (400 MHz, CDCl_3) δ 8.58 (s, 1H), 7.80-7.60 (m, 1H), 7.44 (d, J = 7.6 Hz, 1H), 7.25-7.05 (m, 2H), 4.66-4.27 (m, 2H), 4.10-3.88 (m, 3H), 3.87-3.60 (m, 3H), 3.41 (s, 1H), 3.15-3.00 (m, 1H), 2.94 (d, J = 10.8 Hz, 1H), 2.49 (d, J = 6.0 Hz, 3H), 2.40 (s, 3H), 2.35-2.30 (m, 4H), 2.20-2.10 (m, 1H), 1.60-1.50 (m, 3H).
A85		BB, AH	^1H NMR (400 MHz, CDCl_3) δ 8.62-8.56 (m, 1H), 7.73-7.63 (m, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.23-7.15 (m, 1H), 4.45-4.35 (m, 2H), 3.92 (q, J = 6.8 Hz, 1H), 3.87 (d, J = 13.2 Hz, 1H), 3.79 (s, 4H), 3.68 (d, J = 13.2 Hz, 1H), 2.70 (s, 4H), 2.48 (s, 3H), 2.45 (s, 3H), 2.07 (s, 3H), 1.55 (d, J = 6.8 Hz, 3H).








A86		BB, AH	¹ H NMR (400 MHz, CDCl ₃) δ 8.59 (d, <i>J</i> = 4.8 Hz, 1H), 7.73-7.63 (m, 1H), 7.31 (d, <i>J</i> = 8.0 Hz, 1H), 7.22-7.15 (m, 1H), 6.81 (br s, 1H), 4.48-4.32 (m, 3H), 4.28 (d, <i>J</i> = 12.0 Hz, 1H), 4.00-3.83 (m, 2H), 3.61 (d, <i>J</i> = 13.2 Hz, 1H), 3.20-3.05 (m, 3H), 2.79 (t, <i>J</i> = 11.4 Hz, 1H), 2.47 (s, 3H), 2.40-2.30 (m, 1H), 2.24-2.16 (m, 1H), 2.15-2.10 (m, 1H), 2.08 (s, 3H), 1.92-1.83 (m, 2H), 1.80-1.74 (m, 2H), 1.55 (d, <i>J</i> = 6.8 Hz, 3H).
A87		BB, AH	¹ H NMR (400 MHz, CDCl ₃) δ 8.60 (d, <i>J</i> = 4.8 Hz, 1H), 7.71-7.65 (m, 1H), 7.33 (d, <i>J</i> = 8.0 Hz, 1H), 7.22-7.15 (m, 1H), 6.80 (br s, 1H), 4.43-4.35 (m, 3H), 4.28 (d, <i>J</i> = 12.8 Hz, 1H), 3.93 (q, <i>J</i> = 6.8 Hz, 1H), 3.78 (d, <i>J</i> = 13.2 Hz, 1H), 3.70 (d, <i>J</i> = 13.2 Hz, 1H), 3.25-3.05 (m, 3H), 2.79 (t, <i>J</i> = 11.4 Hz, 1H), 2.47 (s, 3H), 2.40-2.30 (m, 1H), 2.24-2.16 (m, 1H), 2.15-2.10 (m, 1H), 2.08 (s, 3H), 1.93-1.83 (m, 2H), 1.80-1.72 (m, 2H), 1.55 (d, <i>J</i> = 6.8 Hz, 3H).
A88		BB, AH	¹ H NMR (400 MHz, CDCl ₃) δ 8.60 (d, <i>J</i> = 5.2 Hz, 1H), 7.72-7.63 (m, 1H), 7.32 (d, <i>J</i> = 8.0 Hz, 1H), 7.22-7.16 (m, 1H), 4.48-4.35 (m, 2H), 4.21-4.13 (m, 1H), 4.12-4.04 (m, 1H), 3.93 (q, <i>J</i> = 6.8 Hz, 1H), 3.86 (d, <i>J</i> = 12.8 Hz, 1H), 3.63 (d, <i>J</i> = 13.2 Hz, 1H), 3.28-3.16 (m, 1H), 2.91-2.84 (m, 1H), 2.84-2.77 (m, 1H), 2.48 (s, 3H), 2.41-2.35 (m, 1H), 2.33 (s, 3H), 2.27-2.21 (m, 1H), 2.08 (s, 3H), 1.55 (d, <i>J</i> = 6.8 Hz, 3H), 1.13 (d, <i>J</i> = 6.4 Hz, 3H).
A89		BB, AH	¹ H NMR (400 MHz, CDCl ₃) δ 8.60 (s, 1H), 7.74-7.64 (m, 1H), 7.38-7.30 (m, 1H), 7.22-7.14 (m, 1H), 6.75 (br s, 1H), 4.40 (s, 2H), 4.16 (d, <i>J</i> = 13.2 Hz, 1H), 4.08 (d, <i>J</i> = 13.2 Hz, 1H), 3.97-3.85 (m, 1H), 3.80 (d, <i>J</i> = 13.2 Hz, 1H), 3.68 (d, <i>J</i> = 13.2 Hz, 1H), 3.20 (t, <i>J</i> = 12.8 Hz, 1H), 2.92-2.83 (m, 1H), 2.82-2.75 (m, 1H), 2.48 (s, 3H), 2.42-2.36 (m, 1H), 2.33 (s, 3H), 2.23 (s, 1H), 2.08 (s, 3H), 1.55 (d, <i>J</i> = 6.8 Hz, 3H), 1.13 (d, <i>J</i> = 5.6 Hz, 3H).
A90		D, BC	¹ H NMR (400 MHz, CDCl ₃) δ 8.21 (s, 1H), 7.08 (s, 2H), 6.88 (s, 1H), 4.39 (s, 1H), 4.17 (s, 1H), 4.06 (s, 1H), 3.81-3.60 (m, 6H), 2.55-2.40 (m, 7H), 2.38 (s, 3H), 2.33 (s, 3H), 2.26 (s, 1H), 2.13 (s, 1H).
A91		C, BB, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.22 (s, 1H), 7.09 (s, 2H), 6.89 (s, 1H), 4.44-4.37 (m, 1H), 4.17 (t, <i>J</i> = 8.4 Hz, 1H), 4.06 (t, <i>J</i> = 6.4 Hz, 1H), 3.75-3.63 (m, 6H), 2.47 (s, 7H), 2.39 (s, 3H), 2.33 (s, 3H), 2.30-2.21 (m, 1H), 2.18-2.10 (m, 1H).
A92		C, BB, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.19 (d, <i>J</i> = 2.4 Hz, 1H), 7.12 (s, 2H), 6.59 (s, 1H), 4.50-4.46 (m, 1H), 3.79 (s, 3H), 3.66 (s, 4H), 3.58-3.47 (m, 2H), 2.46 (s, 7H), 2.32 (s, 3H), 2.26 (s, 3H), 1.47-1.45 (m, 3H).









A93		C, BF, BB, AA	^1H NMR (400 MHz, CDCl_3) δ 11.18 (s, 1H), 8.49 (d, J = 8.0 Hz, 1H), 8.23 (d, J = 4.8 Hz, 1H), 7.24-7.12 (m, 1H), 6.19 (s, 1H), 4.13-4.00 (m, 1H), 3.82-3.72 (m, 1H), 3.73-3.60 (m, 5H), 2.54-2.42 (m, 7H), 2.38-2.26 (m, 6H), 2.13 (s, 3H), 1.48 (d, J = 6.8 Hz, 3H). MS (ESI/APCI) m/z 398.1 $[\text{M}+\text{H}]^+$.
A94		C, BG, BB, AA	^1H NMR (400 MHz, CDCl_3) δ 8.21 (d, J = 4.8 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.18-7.13 (m, 1H), 6.39 (s, 1H), 4.12-3.98 (m, 1H), 3.74-3.61 (m, 4H), 3.52 (s, 2H), 2.98 (s, 3H), 2.50-2.37 (m, 7H), 2.28 (s, 3H), 2.16 (s, 3H), 1.48 (d, J = 6.4 Hz, 3H).
A95		N, BB, AK	^1H NMR (400 MHz, CDCl_3) δ 8.56 (d, J = 4.0 Hz, 1H), 7.72-7.62 (m, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.46 (s, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.20-7.11 (m, 2H), 6.26 (d, J = 7.2 Hz, 1H), 3.97-3.81 (m, 2H), 3.72 (d, J = 14.0 Hz, 1H), 3.14 (s, 4H), 2.67 (s, 4H), 2.41 (s, 3H), 2.32 (s, 3H), 1.50 (d, J = 6.4 Hz, 3H).
A96		N, BB, AK	^1H NMR (400 MHz, CDCl_3) δ 8.57 (s, 1H), 7.73-7.58 (m, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.29 (d, J = 8.8 Hz, 1H), 7.20-7.12 (m, 1H), 7.12-7.04 (m, 1H), 6.40 (d, J = 7.2 Hz, 1H), 5.24-5.11 (m, 2H), 3.95-3.85 (m, 1H), 3.84-3.73 (m, 2H), 3.73-3.62 (m, 1H), 3.42-3.29 (m, 2H), 3.00-2.86 (m, 4H), 2.50-2.42 (m, 2H), 2.39 (s, 3H), 2.13 (s, 3H), 1.52 (d, J = 6.4 Hz, 3H).
A97		N, BB, AK	^1H NMR (400 MHz, CDCl_3) δ 8.56 (d, J = 2.8 Hz, 1H), 7.68-7.63 (m, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.21-7.08 (m, 2H), 6.29 (d, J = 6.8 Hz, 1H), 4.00-3.82 (m, 2H), 3.80-3.68 (m, 1H), 3.59-3.49 (m, 1H), 3.45-3.37 (m, 1H), 3.22-3.11 (m, 2H), 3.00-2.89 (m, 1H), 2.70-2.48 (m, 2H), 2.40-2.25 (m, 5H), 1.93-1.75 (m, 3H), 1.58-1.40 (m, 4H).
A98		N, BB, AK	^1H NMR (400 MHz, CDCl_3) δ 8.56 (d, J = 4.0 Hz, 1H), 7.73-7.61 (m, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.46 (s, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.18-7.06 (m, 2H), 6.28 (d, J = 6.8 Hz, 1H), 3.93-3.81 (m, 3H), 3.72 (d, J = 14.0 Hz, 1H), 3.58-3.48 (m, 1H), 3.47-3.38 (m, 1H), 3.22-3.11 (m, 2H), 3.00-2.87 (m, 1H), 2.66-2.59 (m, 1H), 2.56-2.51 (m, 1H), 2.36-2.26 (m, 5H), 1.93-1.76 (m, 3H), 1.57-1.44 (m, 4H).
A99		N, BB, AK	^1H NMR (400 MHz, CDCl_3) δ 8.57 (s, 1H), 7.80-7.60 (m, 1H), 7.48-7.36 (m, 1H), 7.35-7.28 (m, 1H), 7.20-7.16 (m, 1H), 7.15-7.06 (m, 1H), 6.45-6.30 (m, 1H), 6.00 (brs, 1H), 5.36-5.00 (m, 2H), 4.00-3.70 (m, 3H), 3.55-3.35 (m, 2H), 3.20-3.07 (m, 2H), 2.97-2.80 (m, 1H), 2.70-2.50 (m, 2H), 2.34-2.21 (m, 2H), 2.15 (d, J = 3.6 Hz, 3H), 1.95-1.70 (m, 3H), 1.56-1.40 (m, 4H).








A100		N, BB, AK	¹ H NMR (400 MHz, CDCl ₃) δ 8.59 (s, 1H), 7.69 (d, <i>J</i> = 6.4 Hz, 1H), 7.42 (d, <i>J</i> = 6.0 Hz, 1H), 7.33 (d, <i>J</i> = 8.8 Hz, 1H), 7.21-7.14 (m, 1H), 7.14-7.06 (m, 1H), 6.46 (d, <i>J</i> = 6.4 Hz, 1H), 5.30-5.07 (m, 2H), 3.99-3.72 (m, 3H), 3.53 (d, <i>J</i> = 9.6 Hz, 1H), 3.44 (d, <i>J</i> = 10.8 Hz, 1H), 3.25-3.09 (s, 2H), 3.00-2.83 (m, 1H), 2.71-2.53 (m, 2H), 2.47-2.26 (m, 2H), 2.17 (s, 3H), 2.03-1.84 (m, 3H), 1.60-1.45 (m, 4H).
B1		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.39 (d, <i>J</i> = 4.6 Hz, 1H), 8.22 (s, 1H), 7.37 (d, <i>J</i> = 7.8 Hz, 1H), 7.04 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 5.80 (s, 1H), 4.00-3.82 (m, 1H), 3.66-3.56 (m, 4H), 3.31-3.23 (m, 1H), 3.11 (s, 3H), 2.83-2.70 (m, 2H), 2.48 (t, <i>J</i> = 5.2 Hz, 4H), 2.33 (s, 3H), 2.03-1.91 (m, 1H), 1.91-1.85 (m, 2H), 1.76-1.70 (m, 2H).
B2		A, AA, AG	¹ H NMR (400 MHz, CDCl ₃) δ 9.06 (s, 1H), 8.65 (d, <i>J</i> = 4.8 Hz, 1H), 8.50 (s, 1H), 7.80 (d, <i>J</i> = 4.4 Hz, 1H), 7.37 (d, <i>J</i> = 7.2 Hz, 1H), 7.08-7.05 (m, 1H), 4.04-4.01 (m, 1H), 3.82-3.72 (m, 2H), 2.82-2.78 (m, 1H), 2.73-2.69 (m, 1H), 2.39 (s, 3H), 2.13 (s, 1H), 2.03 (s, 1H), 1.97-1.88 (m, 1H), 1.72 (s, 1H). MS (ESI/APCI) <i>m/z</i> 254.9 [M + H] ⁺ .
B3		A, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.49 (s, 2H), 7.36 (s, 1H), 7.06 (s, 2H), 4.04 (s, 1H), 3.67 (s, 2H), 3.12 (s, 6H), 2.81 (s, 1H), 2.71-2.67 (m, 1H), 2.40 (s, 3H), 2.16-2.12 (m, 1H), 2.04-2.01 (m, 1H), 1.94-1.92 (m, 1H), 1.69 (s, 1H).
B4		L, AE	¹ H NMR (400 MHz, CDCl ₃) δ 8.50 (d, <i>J</i> = 4.4 Hz, 1H), 8.24 (d, <i>J</i> = 5.2 Hz, 1H), 7.36 (d, <i>J</i> = 8.0 Hz, 1H), 7.06 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 6.93 (d, <i>J</i> = 4.8 Hz, 1H), 4.06-3.98 (m, 1H), 3.82 (t, <i>J</i> = 5.0 Hz, 4H), 3.59 (q, <i>J</i> = 13.8 Hz, 2H), 2.87-2.77 (m, 1H), 2.74-2.66 (m, 1H), 2.45 (t, <i>J</i> = 5.2 Hz, 4H), 2.38 (s, 3H), 2.33 (s, 3H), 2.14-1.99 (m, 2H), 1.98-1.89 (m, 1H), 1.73-1.66 (m, 1H).
B5		AF	¹ H NMR (400 MHz, CDCl ₃) δ 8.51 (d, <i>J</i> = 4.0 Hz, 1H), 8.07 (d, <i>J</i> = 5.2 Hz, 1H), 7.35 (d, <i>J</i> = 7.2 Hz, 1H), 7.06 (dd, <i>J</i> = 7.2, 4.8 Hz, 1H), 6.86 (s, 1H), 6.67 (d, <i>J</i> = 4.8 Hz, 1H), 3.99-3.96 (m, 1H), 3.67-3.64 (m, 1H), 3.56 (s, 4H), 3.52-3.48 (m, 1H), 2.84-2.78 (m, 1H), 2.71-2.67 (m, 1H), 2.51 (t, <i>J</i> = 4.6 Hz, 4H), 2.34 (s, 3H), 2.31 (s, 3H), 2.04-2.02 (m, 2H), 1.96-1.90 (m, 1H), 1.73-1.69 (m, 1H).
B6		AF	¹ H NMR (400 MHz, CDCl ₃) δ 8.51 (d, <i>J</i> = 4.4 Hz, 1H), 7.43 (t, <i>J</i> = 7.8 Hz, 1H), 7.34 (d, <i>J</i> = 7.6 Hz, 1H), 7.05 (d, <i>J</i> = 4.8 Hz, 1H), 7.00 (d, <i>J</i> = 7.2 Hz, 1H), 6.46 (d, <i>J</i> = 8.4 Hz, 1H), 4.03 (s, 1H), 3.64 (q, <i>J</i> = 15.0 Hz, 2H), 3.53 (s, 4H), 2.82-2.78 (m, 1H), 2.71-2.66 (m, 1H), 2.50 (t, <i>J</i> = 4.4 Hz, 5H), 2.37 (s, 3H), 2.33 (s, 3H), 2.07 (s, 1H), 2.02-2.98 (m, 1H), 1.95-1.92 (m, 1H), 1.65 (s, 1H).
B7		WO2009121063	¹ H NMR (400 MHz, CDCl ₃) δ 8.63 (s, 1H), 8.47 (d, <i>J</i> = 4.8 Hz, 1H), 7.61 (s, 1H), 7.40 (d, <i>J</i> = 7.6 Hz, 1H), 7.14-7.04 (m, 1H), 6.30 (s, 1H), 4.08-3.96 (m, 1H), 3.75-3.59 (m, 2H), 3.49-3.32 (m, 3H), 3.24 (d, <i>J</i> = 12.8 Hz, 1H), 3.13 (s, 6H), 2.86-2.68 (m, 2H), 2.19 (s, 3H), 2.14-2.08 (m, 1H), 2.06-1.99 (m, 1H), 1.90-1.79 (m, 1H), 1.77-1.66 (m, 1H), 1.37 (s, 9H).









B8		WO20091 21063	^1H NMR (400 MHz, CDCl_3) δ 13.27 (s, 1H), 9.35 (s, 1H), 8.59 (s, 1H), 8.40 (s, 3H), 8.12 (s, 1H), 7.76 (d, J = 7.2 Hz, 1H), 7.44 (s, 1H), 4.91 (s, 1H), 4.61 (d, J = 14.0 Hz, 1H), 4.31 (d, J = 13.2 Hz, 2H), 3.86-3.72 (m, 3H), 3.21 (s, 6H), 3.10 (s, 2H), 2.86-2.77 (m, 2H), 2.69 (s, 3H), 2.42 (s, 1H), 2.09-1.99 (m, 2H).
C1		J, BC	^1H NMR (400 MHz, CDCl_3) δ 8.39 (d, J = 4.4 Hz, 1H), 7.30-7.26 (m, 1H), 7.07-6.95 (m, 2H), 4.05-3.93 (m, 2H), 3.74-3.61 (m, 4H), 3.01-2.90 (m, 1H), 2.82-2.72 (m, 2H), 2.72-2.64 (m, 1H), 2.48 (s, 3H), 2.44 (t, J = 5.0 Hz, 4H), 2.32 (s, 3H), 2.30-2.24 (m, 1H), 2.12-2.01 (m, 1H), 2.00-1.90 (m, 2H), 1.83-1.69 (m, 4H).
C2		J, BC	^1H NMR (400 MHz, CDCl_3) δ 8.37 (d, J = 4.4 Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 7.04-6.96 (m, 1H), 6.57 (s, 1H), 4.65-4.53 (m, 1H), 4.06-3.98 (m, 1H), 3.72-3.58 (m, 4H), 2.98-2.89 (m, 1H), 2.84-2.73 (m, 1H), 2.69-2.58 (m, 2H), 2.51-2.44 (m, 7H), 2.34 (s, 3H), 2.33-2.26 (m, 1H), 2.00-1.90 (m, 3H), 1.66-1.55 (m, 1H).
C3		J, BC	^1H NMR (400 MHz, CDCl_3) δ 8.38 (d, J = 4.4 Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 7.04-6.97 (m, 1H), 6.57 (s, 1H), 4.57 (s, 1H), 4.01 (s, 1H), 3.67 (s, 4H), 2.98-2.90 (m, 1H), 2.85-2.74 (m, 1H), 2.69-2.58 (m, 2H), 2.51-2.45 (m, 7H), 2.35 (s, 3H), 2.33-2.23 (m, 2H), 1.95 (s, 3H), 1.72 (s, 3H).
C4		J, BC	^1H NMR (400 MHz, CDCl_3) δ 8.39 (d, J = 4.4 Hz, 1H), 7.31-7.27 (m, 1H), 7.06-6.96 (m, 2H), 3.98 (s, 2H), 3.68 (s, 4H), 2.96 (s, 1H), 2.83-2.73 (m, 2H), 2.72-2.63 (m, 1H), 2.49 (s, 3H), 2.47-2.42 (m, 4H), 2.32 (s, 5H), 2.11-2.01 (s, 1H), 2.01-1.90 (m, 2H), 1.82-1.74 (m, 3H).
C5		J, BA	^1H NMR (400 MHz, CDCl_3) δ 8.39 (d, J = 4.4 Hz, 1H), 7.30-7.26 (m, 1H), 7.11 (s, 1H), 7.02-6.92 (m, 1H), 4.06-3.92 (m, 2H), 3.67 (s, 4H), 3.03-2.89 (m, 1H), 2.81-2.62 (m, 3H), 2.45 (s, 7H), 2.32 (s, 3H), 2.30-2.23 (m, 1H), 2.10-2.01 (m, 3H), 2.00-1.87 (m, 3H), 1.71-1.60 (m, 1H).
C6		J, BC	^1H NMR (400 MHz, CDCl_3) δ 8.53-8.47 (m, 1H), 7.30 (d, J = 7.2 Hz, 1H), 7.05-6.95 (m, 2H), 4.08-3.97 (m, 1H), 3.69 (s, 4H), 3.58 (d, J = 10.4 Hz, 1H), 2.77-2.65 (m, 1H), 2.64-2.56 (m, 1H), 2.49 (s, 3H), 2.43 (s, 4H), 2.38-2.34 (m, 1H), 2.30 (s, 3H), 1.97-1.85 (m, 4H), 1.83-1.56 (m, 4H), 1.55-1.45 (m, 2H), 1.40-1.28 (m, 1H).

C7		J, BC	¹ H NMR (400 MHz, CDCl ₃) δ 8.45 (d, <i>J</i> = 4.4 Hz, 1H), 7.22 (d, <i>J</i> = 7.6 Hz, 1H), 7.01-6.91 (m, 1H), 6.55 (s, 1H), 4.54 (d, <i>J</i> = 10.8 Hz, 1H), 3.91 (t, <i>J</i> = 8.6 Hz, 1H), 3.63 (s, 4H), 2.75-2.60 (m, 2H), 2.57-2.53 (m, 1H), 2.51 (s, 3H), 2.48-2.44 (m, 4H), 2.34 (s, 3H), 2.20-2.02 (m, 2H), 1.93-1.84 (m, 2H), 1.82-1.67 (m, 2H), 1.67-1.44 (m, 4H), 1.38-1.28 (m, 1H).
C8		J, BC	¹ H NMR (400 MHz, CDCl ₃) δ 8.53 (d, <i>J</i> = 4.8 Hz, 1H), 7.38 (d, <i>J</i> = 7.6 Hz, 1H), 7.22 (s, 1H), 7.14-7.08 (m, 1H), 4.08-4.00 (m, 1H), 3.88-3.61 (m, 5H), 2.76-2.70 (m, 1H), 2.68-2.62 (m, 1H), 2.57-2.53 (m, 1H), 2.52-2.47 (m, 7H), 2.35 (s, 3H), 2.08-1.92 (m, 4H), 1.84-1.75 (m, 2H), 1.70-1.62 (m, 2H), 1.62-1.50 (m, 2H), 1.33-1.26 (m, 1H).
C9		J, BC	¹ H NMR (400 MHz, CDCl ₃) δ 8.45 (d, <i>J</i> = 4.8 Hz, 1H), 7.22 (d, <i>J</i> = 7.6 Hz, 1H), 6.98-6.91 (m, 1H), 6.55 (s, 1H), 4.53 (d, <i>J</i> = 10.8 Hz, 1H), 3.91 (t, <i>J</i> = 8.4 Hz, 1H), 3.63 (s, 4H), 2.75-2.67 (m, 1H), 2.67-2.59 (m, 1H), 2.55 (s, 1H), 2.51 (s, 3H), 2.46 (d, <i>J</i> = 4.6 Hz, 4H), 2.34 (s, 3H), 2.13-2.05 (m, 1H), 1.95-1.85 (m, 4H), 1.80-1.68 (m, 2H), 1.68-1.59 (m, 1H), 1.60-1.50 (m, 2H), 1.53-1.40 (m, 1H).
C10		E, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.50 (d, <i>J</i> = 4.4 Hz, 1H), 7.67-7.55 (m, 1H), 7.44 (d, <i>J</i> = 8.0 Hz, 1H), 7.16-7.07 (m, 1H), 6.45 (s, 1H), 3.70 (s, 4H), 3.50-3.42 (m, 2H), 3.09-3.02 (m, 2H), 2.50-2.45 (m, 7H), 2.45 (s, 3H), 2.36 (s, 2H), 1.90-1.25 (m, 5H).
C11		E, AC	¹ H NMR (400 MHz, CDCl ₃) δ 8.53 (d, <i>J</i> = 4.0 Hz, 1H), 7.67-7.57 (m, 1H), 7.46 (d, <i>J</i> = 8.0 Hz, 1H), 7.17-7.06 (m, 1H), 6.32 (s, 1H), 3.73-3.64 (m, 6H), 3.36-3.31 (m, 2H), 2.47-1.95 (m, 15H).
C12		C, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.52 (d, <i>J</i> = 4.0 Hz, 1H), 7.65-7.54 (m, 1H), 7.45 (d, <i>J</i> = 8.0 Hz, 1H), 7.16-7.05 (m, 1H), 6.45 (s, 1H), 3.72-3.68 (m, 2H), 3.63 (s, 4H), 3.40-3.31 (m, 2H), 2.46-2.40 (m, 8H), 2.34-2.29 (m, 4H), 2.05-1.95 (m, 1H), 1.93-1.90 (m, 2H).
C13		J, BA	¹ H NMR (400 MHz, CDCl ₃) δ 7.94 (d, <i>J</i> = 4.8 Hz, 1H), 7.26 (s, 1H), 6.90-6.81 (m, 1H), 5.84 (s, 1H), 4.66 (t, <i>J</i> = 8.6 Hz, 1H), 3.58 (s, 1H), 3.48-3.42 (m, 1H), 3.41-3.28 (m, 4H), 3.13 (q, <i>J</i> = 8.2 Hz, 1H), 2.89-2.72 (m, 2H), 2.52-2.43 (m, 1H), 2.40 (s, 3H), 2.39-2.33 (m, 4H), 2.34-2.30 (m, 4H), 2.13-2.05 (m, 1H), 1.92-1.83 (m, 1H), 1.75-1.65 (m, 2H).

C14		J, BA	^1H NMR (400 MHz, CDCl_3) δ 8.39 (d, $J = 4.4$ Hz, 1H), 7.39 (d, $J = 7.6$ Hz, 1H), 7.13-7.07 (m, 1H), 6.81 (s, 1H), 4.25 (t, $J = 8.2$ Hz, 1H), 3.69 (s, 4H), 3.66-3.58 (m, 2H), 3.27 (t, $J = 8.0$ Hz, 1H), 2.88-2.75 (m, 1H), 2.75 - 2.62 (m, 1H), 2.50 (s, 3H), 2.49-2.43 (m, 4H), 2.42-2.36 (m, 1H), 2.34 (s, 3H), 2.04-1.89 (m, 2H), 1.78-1.71 (m, 1H), 1.66-1.56 (m, 1H), 1.53-1.42 (m, 1H).
C15		J, BA	^1H NMR (400 MHz, CDCl_3) δ 8.30 (d, $J = 4.8$ Hz, 1H), 7.23 (s, 1H), 7.19 (s, 1H), 7.00-6.93 (m, 1H), 4.36 (s, 1H), 4.05 (s, 1H), 3.94-3.88 (m, 1H), 3.66 (s, 4H), 3.07-3.01 (m, 1H), 2.99-2.93 (m, 1H), 2.79-2.63 (m, 2H), 2.61-2.51 (m, 1H), 2.45-2.42 (m, 7H), 2.32 (s, 3H), 2.12-2.06 (m, 1H), 1.93-1.88 (m, 2H), 1.81-1.75 (m, 1H), 1.71-1.62 (m, 1H), 0.79 (s, 9H), 0.01 (s, 6H).
C16		J, BA, AI	^1H NMR (400 MHz, CDCl_3) δ 8.38 (d, $J = 4.8$ Hz, 1H), 7.12 (d, $J = 7.2$ Hz, 1H), 7.05-6.99 (m, 1H), 5.29 (s, 1H), 4.28 (s, 1H), 4.03 (d, $J = 10.0$ Hz, 1H), 3.89 (s, 1H), 3.55-3.38 (m, 4H), 3.30 (d, $J = 9.2$ Hz, 1H), 2.92-2.83 (m, 1H), 2.63-2.53 (m, 1H), 2.53-2.45 (m, 1H), 2.44-2.37 (m, 7H), 2.33 (s, 3H), 2.14-2.05 (m, 2H), 1.77 (d, $J = 13.6$ Hz, 1H), 1.62-1.51 (m, 3H).
C17		J, AI, BA	^1H NMR (400 MHz, CDCl_3) δ 8.33 (d, $J = 4.8$ Hz, 1H), 7.39 (d, $J = 8.0$ Hz, 1H), 7.11 (dd, $J = 7.6, 4.8$ Hz, 1H), 6.74 (s, 1H), 4.31 (s, 1H), 4.22 (dd, $J = 11.6, 5.2$ Hz, 1H), 4.04 (t, $J = 8.4$ Hz, 1H), 3.86 (dd, $J = 11.2, 4.0$ Hz, 1H), 3.68 (s, 4H), 3.43 (d, $J = 11.2$ Hz, 1H), 2.71-2.63 (m, 2H), 2.48 (t, $J = 5.2$ Hz, 4H), 2.44 (s, 3H), 2.35 (s, 3H), 2.02-1.98 (m, 1H), 1.89-1.83 (m, 2H), 1.72-1.63 (m, 2H), 1.54-1.45 (m, 1H).
C18		C, AA	^1H NMR (400 MHz, CDCl_3) δ 8.50 (s, 1H), 7.63-7.59 (m, 1H), 7.45 (d, $J = 7.2$ Hz, 1H), 7.13 (t, $J = 6.4$ Hz, 1H), 6.64 (s, 1H), 3.70 (s, 4H), 3.56-3.48 (m, 2H), 3.14-3.07 (m, 2H), 2.51 (s, 4H), 2.45 (s, 3H), 2.36 (s, 3H), 2.21 (s, 1H), 2.06 (s, 4H), 1.86 (t, $J = 16.0$ Hz, 2H).
C19		J, BA	^1H NMR (400 MHz, CDCl_3) δ 8.40 (s, 1H), 7.30 (d, $J = 8.0$ Hz, 1H), 7.18 (s, 1H), 7.07-6.99 (m, 1H), 4.26 (t, $J = 8.4$ Hz, 1H), 4.05-3.95 (m, 1H), 3.70 (s, 4H), 3.41-3.23 (m, 1H), 3.23-3.06 (m, 1H), 2.83-2.62 (m, 4H), 2.49-2.43 (m, 7H), 2.33 (s, 3H), 2.30-2.18 (m, 1H), 1.91-1.78 (m, 2H), 1.75-1.58 (m, 1H).
C20		J, BA	^1H NMR (400 MHz, CDCl_3) δ 8.43 (d, $J = 4.8$ Hz, 1H), 7.30 (d, $J = 7.6$ Hz, 1H), 7.22 (s, 1H), 7.06-6.99 (m, 1H), 4.17 (t, $J = 8.0$ Hz, 1H), 4.03-3.96 (m, 1H), 3.95-3.87 (m, 1H), 3.70 (s, 4H), 3.27 (s, 3H), 3.25-3.16 (m, 1H), 2.85-2.71 (m, 1H), 2.71-2.61 (m, 2H), 2.48 (s, 3H), 2.46-2.41 (m, 4H), 2.41-2.34 (m, 1H), 2.32 (s, 3H), 2.20-2.06 (m, 1H), 1.97-1.90 (m, 2H), 1.86-1.77 (m, 1H), 1.72-1.59 (m, 1H).

C21		J, BA	^1H NMR (400 MHz, CDCl_3) δ 8.34 (d, J = 4.8 Hz, 1H), 7.32-7.27 (m, 1H), 7.17 (s, 1H), 7.03-6.97 (m, 1H), 4.07-3.96 (m, 1H), 3.97-3.85 (m, 2H), 3.73-3.65 (m, 4H), 3.21 (s, 3H), 3.09-2.96 (m, 1H), 2.938-2.82 (m, 1H), 2.80-2.57 (m, 4H), 2.46-2.43 (m, 7H), 2.35-2.28 (m, 4H), 2.14-2.02 (m, 1H), 1.87-1.78 (m, 1H), 1.70-1.60 (m, 1H).
C22		J, BA	^1H NMR (400 MHz, CDCl_3) δ 8.58-8.42 (m, 1H), 7.68-7.40 (m, 1H), 7.36-7.25 (m, 1H), 7.18-6.98 (m, 1H), 6.82-6.45 (m, 1H), 3.95-3.85 (m, 1H), 3.83-3.74 (m, 1H), 3.70 (s, 2H), 3.60 (s, 2H), 3.15-3.03 (m, 1H), 2.78-2.2 (m, 1H), 2.51-2.48 (m, 4H), 2.44 (s, 3H), 2.38-2.30 (m, 3H), 2.28-2.15 (m, 1H), 1.87-1.73 (m, 2H), 1.68-1.57 (m, 1H), 1.45-1.30 (m, 3H).
C23		C, BH, AA	^1H NMR (400 MHz, CDCl_3) δ 8.51 (s, 1H), 7.61-7.57 (m, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.17-7.05 (m, 1H), 6.45 (s, 1H), 3.71-3.67 (m, 2H), 3.63 (s, 4H), 3.39-3.32 (m, 2H), 2.46-2.43 (m, 8H), 2.40-2.31 (m, 4H), 2.01-1.95 (m, 1H), 1.97-1.86 (m, 2H).
C24		C, BI, AA	^1H NMR (400 MHz, CDCl_3) δ 8.52 (d, J = 4.0 Hz, 1H), 7.65-7.54 (m, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.15-7.08 (m, 1H), 6.45 (s, 1H), 3.72-3.68 (m, 2H), 3.63 (s, 4H), 3.40-3.31 (m, 2H), 2.46-2.40 (m, 8H), 2.40-2.31 (m, 4H), 2.05-1.95 (m, 1H), 1.91-1.83 (m, 2H).
C25		C, BH, AA	^1H NMR (400 MHz, CDCl_3) δ 8.46 (s, 1H), 7.34 (d, J = 6.8 Hz, 1H), 7.01 (s, 1H), 6.39 (s, 1H), 3.92-3.78 (m, 1H), 3.71-3.48 (m, 5H), 3.41-3.29 (m, 2H), 2.43 (s, 8H), 2.33 (d, J = 7.6 Hz, 6H), 2.25-1.83 (m, 4H).
C26		C, BH, AA	^1H NMR (400 MHz, CDCl_3) δ 8.36 (s, 1H), 7.26 (s, 1H), 6.93 (s, 1H), 6.42 (s, 1H), 3.74-3.54 (m, 6H), 3.41-3.27 (m, 2H), 2.57-2.38 (m, 8H), 2.38-2.32 (s, 3H), 2.31-2.25 (m, 4H), 2.00-1.90 (m, 1H), 1.90-1.86 (m, 2H).
C27		C, BH, AA	^1H NMR (400 MHz, CDCl_3) δ 8.35 (s, 1H), 7.41 (d, J = 7.6 Hz, 1H), 7.33 (d, J = 7.6 Hz, 1H), 6.46 (s, 1H), 3.71-3.54 (m, 6H), 3.37-3.25 (m, 2H), 2.54-2.38 (m, 8H), 2.34 (s, 3H), 2.29 (s, 4H), 2.07-1.94 (m, 1H), 1.89-1.78 (m, 2H).
C28		C, BH, AA	^1H NMR (400 MHz, CDCl_3) δ 7.56-7.44 (m, 1H), 7.31 (d, J = 7.6 Hz, 1H), 6.97 (d, J = 7.6 Hz, 1H), 6.48 (s, 1H), 3.74-3.55 (m, 6H), 3.38-3.15 (m, 2H), 2.52 (s, 3H), 2.49-2.30 (m, 8H), 2.30-2.26 (m, 4H), 1.99-1.75 (m, 3H).

C29		C, BJ, AA	^1H NMR (400 MHz, CDCl_3) δ 8.54 (d, J = 3.6 Hz, 1H), 7.62-7.58 (m, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.14-7.11 (m, 1H), 6.44 (s, 1H), 3.65-3.61 (m, 5H), 3.35-3.31 (m, 2H), 3.22 (d, J = 7.6 Hz, 1H), 2.47-2.43 (m, 8H), 2.35 (s, 3H), 2.27-2.21 (m, 2H), 1.52 (s, 1H), 1.05 (d, J = 8.0 Hz, 3H).
C30		C, BK, AA	^1H NMR (400 MHz, CDCl_3) δ 8.53 (d, J = 4.4 Hz, 1H), 7.62-7.58 (m, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.15-7.12 (m, 1H), 6.51 (s, 1H), 4.18 (d, J = 9.6 Hz, 1H), 3.75-3.66 (m, 5H), 3.56-3.38 (m, 4H), 2.54-2.48 (m, 5H), 2.45 (s, 3H), 2.37 (s, 3H), 2.11-2.07 (m, 1H), 0.81 (t, J = 7.2 Hz, 3H). MS (ESI/APCI) m/z 424.8 $[\text{M}+\text{H}]^+$.
C31		C, BK, AA, AJ	^1H NMR (400 MHz, CD_3OD) δ 8.43 (d, J = 4.8 Hz, 1H), 7.75-7.71 (m, 1H), 7.57-7.55 (m, 1H), 7.26-7.23 (m, 1H), 6.58 (s, 1H), 3.94-3.92 (m, 1H), 3.71-3.58 (m, 6H), 3.44-3.41 (m, 1H), 3.35-3.33 (m, 1H), 3.04 (d, J = 7.2 Hz, 1H), 2.71-2.65 (m, 1H), 2.50-2.48 (m, 6H), 2.35 (s, 3H), 2.33 (s, 3H), 2.13-2.06 (m, 1H), 1.88-1.78 (m, 1H). MS (ESI/APCI) m/z 382.9 $[\text{M}+\text{H}]^+$.
C32		C, BK, AA	^1H NMR (400 MHz, CDCl_3) δ 8.53 (d, J = 4.8 Hz, 1H), 7.65-7.58 (m, 1H), 7.46-7.31 (m, 1H), 7.19-7.14 (m, 1H), 6.33-6.22 (m, 1H), 4.59-4.29 (m, 2H), 3.92-3.40 (m, 9H), 3.04-2.84 (m, 1H), 2.49-2.30 (m, 11H), 0.91-0.80 (m, 3H). MS (ESI/APCI) m/z 450.1 $[\text{M}+\text{H}]^+$.
C33		BH, I	^1H NMR (400 MHz, CDCl_3) δ 8.45 (s, 1H), 7.35 (s, 1H), 7.00 (s, 1H), 4.03-3.65 (m, 6H), 3.62-3.43 (m, 1H), 3.41-3.24 (m, 1H), 2.67-2.45 (m, 5H), 2.39 (s, 6H), 2.33 (s, 3H), 2.26-2.12 (m, 1H), 2.09-1.96 (m, 1H), 1.95-1.77 (m, 2H).
C34		M, BH, AD	^1H NMR (400 MHz, CDCl_3) δ 8.43 (s, 1H), 7.35 (d, J = 6.4 Hz, 1H), 7.01 (s, 1H), 4.11-3.93 (m, 1H), 3.92 (s, 4H), 3.87-3.78 (m, 1H), 3.71-3.58 (m, 1H), 3.48-3.34 (m, 1H), 2.64-2.55 (m, 1H), 2.49 (s, 4H), 2.45 (s, 3H), 2.41 (s, 3H), 2.33 (s, 3H), 2.26-2.14 (m, 1H), 2.14-2.01 (m, 1H), 2.01-1.93 (m, 1H), 1.91-1.81 (m, 1H).
C35		C, BH, AA	^1H NMR (400 MHz, CDCl_3) δ 8.47 (d, J = 4.0 Hz, 1H), 7.36 (d, J = 7.2 Hz, 1H), 7.03-6.98 (m, 1H), 6.33 (s, 1H), 5.42 (s, 1H), 3.86 (s, 1H), 3.73 (s, 4H), 3.66-3.57 (m, 1H), 3.44-3.19 (m, 4H), 2.56 (t, J = 6.0 Hz, 2H), 2.47 (s, 4H), 2.43 (s, 3H), 2.40-2.30 (m, 4H), 2.25-2.12 (m, 1H), 2.12-1.95 (m, 2H), 1.95-1.83 (m, 1H).

C36		C, BH, AA	^1H NMR (400 MHz, CDCl_3) δ 8.45 (d, $J = 3.2$ Hz, 1H), 7.35 (d, $J = 7.2$ Hz, 1H), 7.01 (t, $J = 6.0$ Hz, 1H), 6.30 (s, 1H), 3.83-3.87 (m, 3H), 3.63-3.66 (m, 3H), 3.35 (d, $J = 14.2$ Hz, 2H), 2.62 (s, 2H), 2.53 (s, 2H), 2.41 (s, 3H), 2.36 (d, $J = 2.8$ Hz, 6H), 2.17-2.19 (m, 1H), 1.96-2.06 (m, 6H).
C37		C, BH, AA	^1H NMR (400 MHz, CDCl_3) δ 8.46 (s, 1H), 7.45-7.30 (m, 1H), 7.09-6.95 (m, 1H), 6.39 (s, 1H), 4.40 (s, 2H), 3.84 (s, 1H), 3.72-3.58 (m, 1H), 3.47-3.28 (m, 2H), 2.77 (s, 2H), 2.55-2.40 (m, 5H), 2.40-2.33 (s, 3H), 2.29 (s, 6H), 2.08-1.95 (m, 2H), 1.95-1.80 (m, 4H), 1.40 (s, 2H).
C38		N, BH, AK	^1H NMR (400 MHz, CDCl_3) δ 8.49 (d, $J = 3.6$ Hz, 1H), 7.33 (s, 2H), 7.28 (s, 1H), 7.13-7.09 (m, 1H), 7.01-6.98 (m, 1H), 6.24 (d, $J = 7.2$ Hz, 1H), 3.96 (d, $J = 13.6$ Hz, 1H), 3.84 (t, $J = 8.0$ Hz, 1H), 3.67 (d, $J = 13.6$ Hz, 1H), 3.39 (t, $J = 8.0$ Hz, 1H), 3.10 (s, 4H), 2.64 (s, 4H), 2.59-2.52 (m, 1H), 2.42 (s, 3H), 2.38 (s, 3H), 2.22-2.17 (m, 2H), 2.05-1.90 (m, 2H).
C39		N, BH, AK	^1H NMR (400 MHz, CDCl_3) δ 8.50 (d, $J = 3.6$ Hz, 1H), 7.40 (d, $J = 7.2$ Hz, 1H), 7.29 (d, $J = 8.8$ Hz, 1H), 7.02-7.08 (m, 2H), 6.39 (d, $J = 6.8$ Hz, 1H), 6.19 (d, $J = 14.4$ Hz, 1H), 5.27 (d, $J = 14.0$ Hz, 1H), 5.07 (d, $J = 14.0$ Hz, 1H), 4.05 (d, $J = 12.8$ Hz, 1H), 3.85 (d, $J = 8.0$ Hz, 1H), 3.49 (d, $J = 12.8$ Hz, 2H), 3.24 (d, $J = 10.8$ Hz, 1H), 3.16 (t, $J = 7.8$ Hz, 1H), 2.91-3.01 (m, 3H), 2.83 (t, $J = 11.0$ Hz, 1H), 2.46-2.51 (m, 3H), 2.41 (s, 3H), 2.38 (s, 3H), 2.24 (s, 1H), 1.84-1.91 (m, 3H).
D1		C, AL	^1H NMR (400 MHz, CDCl_3) δ 8.44 (d, $J = 4.0$ Hz, 1H), 7.40 (d, $J = 7.2$ Hz, 1H), 7.06-6.98 (m, 1H), 6.93 (s, 1H), 4.26 (s, 2H), 3.60 (s, 4H), 2.93 (s, 3H), 2.93-2.81 (m, 2H), 2.64-2.56 (m, 2H), 2.47 (s, 3H), 2.42 (s, 4H), 2.32 (s, 3H). MS (ESI/APCI) m/z 382.9 $[\text{M}+\text{H}]^+$.
D2		C, AA, AM	^1H NMR (400 MHz, CDCl_3) δ 8.82 (d, $J = 2.4$ Hz, 1H), 8.11 (d, $J = 8.4$ Hz, 1H), 7.44-7.35 (m, 3H), 7.13 (d, $J = 7.2$ Hz, 1H), 6.68 (s, 1H), 4.69 (s, 2H), 3.57 (s, 4H), 3.06 (s, 3H), 2.51 (s, 3H), 2.39 (t, $J = 4.8$ Hz, 4H), 2.30 (s, 3H).
D3		C, BM, AA	^1H NMR (400 MHz, CDCl_3) δ 8.82 (d, $J = 2.4$ Hz, 1H), 8.10 (d, $J = 8.0$ Hz, 1H), 7.42-7.32 (m, 3H), 7.11 (d, $J = 7.2$ Hz, 1H), 6.44 (s, 1H), 4.72 (s, 2H), 4.10-3.22 (m, 4H), 3.08 (s, 3H), 2.50-2.42 (m, 7H), 2.30 (s, 3H), 1.82 (s, 2H).
D4		C, BM, AA	^1H NMR (400 MHz, CDCl_3) δ 8.82 (s, 1H), 8.12 (d, $J = 7.6$ Hz, 1H), 7.42-7.36 (m, 3H), 7.14 (d, $J = 6.0$ Hz, 1H), 6.67 (s, 1H), 4.71 (s, 2H), 4.14-4.03 (m, 2H), 3.06 (s, 4H), 2.82-2.78 (m, 1H), 2.65-2.62 (m, 1H), 2.52 (s, 3H), 2.03-2.17 (m, 1H), 1.08 (d, $J = 4.4$ Hz, 3H).

D5		C, BM, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.82 (d, <i>J</i> = 2.8 Hz, 1H), 8.12 (d, <i>J</i> = 7.2 Hz, 1H), 7.42-7.36 (m, 3H), 7.13 (d, <i>J</i> = 6.8 Hz, 1H), 6.68 (s, 1H), 4.69 (s, 2H), 3.63 (t, <i>J</i> = 5.2 Hz, 2H), 3.56 (s, 4H), 3.06 (s, 3H), 2.75-2.45 (m, 10H).
D6		C, BM, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.82 (s, 1H), 8.11 (d, <i>J</i> = 6.8 Hz, 1H), 7.50-7.30 (m, 3H), 7.13-7.11 (m, 1H), 6.68 (s, 1H), 4.71 (s, 2H), 4.37 (s, 2H), 3.07 (s, 3H), 2.76 (s, 2H), 2.52 (s, 4H), 2.34 (s, 6H), 1.86 (s, 2H), 1.49-1.30 (m, 2H).
D7		C, BM, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.82 (s, 1H), 8.11 (d, <i>J</i> = 7.6 Hz, 1H), 7.44-7.29 (m, 3H), 7.12 (d, <i>J</i> = 6.8 Hz, 1H), 6.32 (s, 1H), 4.74 (s, 2H), 4.20-3.10 (m, 4H), 3.08 (s, 3H), 2.69 (s, 1H), 2.52 (s, 3H), 2.26 (s, 6H), 2.20-2.12 (m, 1H), 1.80 (s, 1H).
D8		C, BM, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.82 (s, 1H), 8.12 (d, <i>J</i> = 8 Hz, 1H), 7.41-7.32 (m, 3H), 7.12 (d, <i>J</i> = 6.8 Hz, 1H), 6.65 (s, 1H), 4.69 (s, 2H), 3.50 (m, 4H), 3.06 (s, 3H), 2.59 (s, 4H), 2.51 (s, 3H), 1.59 (s, 1H), 0.46-0.43 (m, 4H).
D9		C, BM, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.82 (s, 1H), 8.10 (d, <i>J</i> = 8.0 Hz, 1H), 7.41-7.35 (m, 3H), 7.12 (d, <i>J</i> = 7.2 Hz, 1H), 6.65 (s, 1H), 4.71 (s, 2H), 3.57 (s, 4H), 3.07 (s, 3H), 2.76 (d, <i>J</i> = 7.6 Hz, 2H), 2.39 (s, 4H), 2.29 (s, 3H), 1.30 (t, <i>J</i> = 7.6 Hz, 3H).
D10		C, BM, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.83 (s, 1H), 8.16 (s, 1H), 7.42 (s, 3H), 7.18 (s, 1H), 6.72 (s, 1H), 4.65 (s, 2H), 3.61 (s, 4H), 3.07 (s, 3H), 2.42 (s, 4H), 2.31 (s, 3H), 2.04 (s, 1H), 1.10 (s, 2H), 1.00 (s, 2H).
D11		F, AC, AM	¹ H NMR (400 MHz, CDCl ₃) δ 8.85 (s, 1H), 8.11 (s, 1H), 7.38 (s, 3H), 7.13 (s, 1H), 5.92 (s, 1H), 4.69 (s, 2H), 3.75-3.27 (m, 4H), 3.08 (s, 9H), 2.44 (s, 4H), 2.33 (s, 3H).
D12		B, BM, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.83 (s, 1H), 8.11 (d, <i>J</i> = 8.0 Hz, 1H), 7.43-7.33 (m, 3H), 7.11 (d, <i>J</i> = 7.2 Hz, 1H), 6.47 (s, 1H), 4.71 (s, 2H), 3.56 (s, 4H), 3.06 (s, 3H), 2.44 (s, 3H), 2.42-2.35 (m, 4H), 2.30 (s, 3H).
D13		G, AC, AM	¹ H NMR (400 MHz, CDCl ₃) δ 8.84 (s, 1H), 8.11 (d, <i>J</i> = 7.6 Hz, 1H), 7.40-7.37 (m, 3H), 7.12 (d, <i>J</i> = 5.6 Hz, 1H), 6.39 (s, 1H), 4.71 (s, 2H), 3.85 (s, 3H), 3.55 (s, 4H), 3.08 (s, 3H), 2.37 (s, 4H), 2.29 (s, 3H).
D14		C, BL, BM, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.92-8.90 (m, 1H), 8.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.58-7.55 (m, 1H), 7.44-7.41 (m, 1H), 7.38-7.34 (m, 1H), 7.22 (s, 1H), 4.62 (s, 2H), 3.76-3.73 (m, 4H), 3.10 (s, 3H), 2.65 (s, 3H), 2.56-2.51 (m, 7H), 2.39 (s, 3H).



D15		C, BL, BM, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.75 (d, <i>J</i> = 4.4 Hz, 1H), 8.01 (d, <i>J</i> = 8.0 Hz, 1H), 7.33-7.30 (m, 1H), 7.15 (s, 1H), 6.96 (s, 1H), 6.69 (s, 1H), 4.68 (s, 2H), 3.58-3.55 (m, 4H), 3.04 (s, 3H), 2.52 (s, 3H), 2.47 (s, 3H), 2.41-2.38 (m, 4H), 2.30 (s, 3H). MS (ESI/APCI) <i>m/z</i> 377.0 [M+H] ⁺ .
D16		C, BN, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.83 (d, <i>J</i> = 4.8 Hz, 1H), 8.29-8.25 (m, 1H), 7.41-7.38 (m, 1H), 7.25-7.21 (m, 1H), 7.075-7.03 (m, 1H), 6.75 (s, 1H), 4.60 (s, 2H), 3.59-3.58 (m, 4H), 3.01 (s, 3H), 2.57 (s, 3H), 2.51 (s, 3H), 2.41-2.39 (m, 4H), 2.30 (s, 3H).
D17		C, BN, BO, AA, AM	¹ H NMR (400 MHz, CDCl ₃) δ 8.80 (d, <i>J</i> = 4.4 Hz, 1H), 8.09 (d, <i>J</i> = 8.4 Hz, 1H), 7.42-7.39 (m, 1H), 7.23-7.13 (m, 2H), 6.69 (s, 1H), 4.70 (s, 2H), 3.96-3.94 (m, 4H), 3.73-3.69 (m, 4H), 3.63-3.61 (m, 6H), 2.53 (s, 3H).
D18		C, BN, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.71 (s, 1H), 8.02 (d, <i>J</i> = 8.4 Hz, 1H), 7.37-7.34 (m, 1H), 6.95-6.92 (m, 1H), 6.85-6.82 (m, 1H), 6.64 (s, 1H), 4.80 (s, 2H), 3.59 (s, 4H), 3.05 (s, 3H), 2.51 (s, 3H), 2.41 (s, 4H), 2.31 (s, 3H).
D19		C, BN, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.90 (s, 1H), 8.40 (d, <i>J</i> = 9.2 Hz, 1H), 7.47-7.44 (m, 1H), 7.10-7.05 (m, 2H), 6.72 (s, 1H), 4.58 (s, 2H), 3.60 (s, 4H), 3.02 (s, 3H), 2.51 (s, 3H), 2.42-2.40 (m, 4H), 2.31 (s, 3H). MS (ESI/APCI) <i>m/z</i> 381.0 [M+H] ⁺ .
D20		C, BN, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.77 (s, 1H), 8.39-8.35 (m, 1H), 7.44 (s, 1H), 6.92 (s, 1H), 6.70 (s, 1H), 4.67 (s, 2H), 3.63 (s, 4H), 3.01 (s, 3H), 2.53-2.45 (m, 7H), 2.30 (s, 3H). MS (ESI/APCI) <i>m/z</i> 399.2 [M+H] ⁺ .
D21		D, BP, AN	¹ H NMR (400 MHz, CDCl ₃) δ 8.66 (s, 1H), 8.10 (d, <i>J</i> = 5.2 Hz, 1H), 7.96 (d, <i>J</i> = 8.0 Hz, 1H), 7.43 (dd, <i>J</i> = 7.6, 4.0 Hz, 1H), 6.96 (d, <i>J</i> = 5.6 Hz, 1H), 6.46 (s, 1H), 5.26 (s, 2H), 3.57 (s, 4H), 3.36 (s, 3H), 2.52 (s, 3H), 2.45-2.34 (m, 4H), 2.29 (s, 3H).
D22		D, BQ, AO	¹ H NMR (400 MHz, CDCl ₃) δ 8.96 (s, 1H), 8.81 (s, 1H), 8.37-8.13 (m, 2H), 7.50 (s, 1H), 6.62 (s, 1H), 4.84 (s, 2H), 3.60 (s, 4H), 3.13 (s, 3H), 2.51 (s, 3H), 2.42 (s, 4H), 2.31 (s, 3H).
D23		D, BR, AN	¹ H NMR (400 MHz, CDCl ₃) δ 8.67 (s, 1H), 8.59 (d, <i>J</i> = 5.2 Hz, 1H), 8.28 (d, <i>J</i> = 8.8 Hz, 1H), 7.54-7.52 (m, 1H), 6.75 (d, <i>J</i> = 5.6 Hz, 1H), 6.40 (s, 1H), 5.24 (s, 2H), 3.58 (s, 4H), 3.26 (s, 3H), 2.53 (s, 3H), 2.41 (s, 4H), 2.31 (s, 3H). MS (ESI/APCI) <i>m/z</i> 364.2 [M+H] ⁺ .
D24		D, AN	¹ H NMR (400 MHz, CDCl ₃) δ 8.64 (s, 2H), 8.09 (d, <i>J</i> = 7.6 Hz, 1H), 7.58 (s, 1H), 6.20 (s, 1H), 5.49 (s, 2H), 3.55 (s, 7H), 2.51 (s, 3H), 2.39 (s, 4H), 2.28 (s, 3H).

D25		C, AA, AM	^1H NMR (400 MHz, CDCl_3) δ 8.86 (d, J = 2.0 Hz, 1H), 8.11 (d, J = 7.6 Hz, 1H), 7.38 (s, 3H), 7.14 (s, 1H), 6.58 (s, 1H), 4.62 (s, 2H), 3.65 (q, J = 6.8 Hz, 2H), 3.46 (s, 4H), 2.50 (s, 3H), 2.31 (s, 4H), 2.26 (s, 3H), 1.12 (t, J = 6.8 Hz, 3H).
D26		C, AO, AA	^1H NMR (400 MHz, CDCl_3) δ 8.80 (s, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.47-7.44k (m, 2H), 7.41-7.36 (m, 2H), 6.21 (s, 1H), 5.16 (s, 2H), 3.44 (s, 4H), 2.81 (s, 1H), 2.46 (s, 3H), 2.35 (s, 4H), 2.29 (s, 3H), 0.80 (d, J = 5.6 Hz, 2H), 0.68 (s, 2H).
D27		C, AO, AA	^1H NMR (400 MHz, CDCl_3) δ 8.86 (s, 1H), 8.11 (s, 1H), 7.37 (s, 3H), 7.11 (s, 1H), 6.57 (s, 1H), 4.62 (s, 3H), 3.57 (s, 2H), 3.47 (s, 4H), 3.05 (s, 2H), 2.49 (s, 3H), 2.33 (s, 3H), 2.29 (s, 4H), 1.63 (s, 2H), 1.40 (s, 11H).
D28		C, AO, AA, AD	^1H NMR (400 MHz, CDCl_3) δ 8.86 (s, 1H), 8.11 (d, J = 8.0 Hz, 2H), 7.37 (s, 3H), 7.12 (s, 1H), 6.58 (s, 1H), 4.62 (s, 2H), 3.57 (t, J = 7.2 Hz, 2H), 3.47 (s, 4H), 2.63 (t, J = 6.4 Hz, 2H), 2.49 (s, 3H), 2.33 (s, 4H), 2.26 (s, 3H), 1.68-1.60 (m, 4H), , 1.42- 1.40 (m, 2H).
D29		C, AO, AA	^1H NMR (400 MHz, CDCl_3) δ 8.84-8.82 (m, 1H), 8.11-8.09 (m, 1H), 7.38-7.35 (m, 3H), 7.19-7.17 (m, 1H), 6.75 (s, 1H), 4.64 (s, 2H), 3.58-3.53 (m, 6H), 2.50 (s, 3H), 2.38-2.35 (m, 4H), 2.29 (s, 3H), 2.18 (t, J = 7.6 Hz, 2H), 1.90-1.83 (m, 2H), 1.34 (s, 9H).
D30		C, AO, AA, AP	^1H NMR (400 MHz, D_2O) δ 9.14 (d, J = 8.4 Hz, 1H), 9.07 (d, J = 5.6 Hz, 1H), 8.12 (d, J = 8.0 Hz, 1H), 8.09-8.06 (m, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.92-7.88 (m, 1H), 7.00 (s, 1H), 5.25 (s, 1H), 4.44 (s, 2H), 4.33 (s, 1H), 3.68-3.46 (m, 4H), 3.41-3.12 (m, 4H), 2.92 (s, 3H), 2.54 (s, 3H), 2.17 (t, J = 6.8 Hz, 2H), 1.61 (s, 2H).
D31		C, AO, AA, AP	^1H NMR (400 MHz, CDCl_3) δ 8.82 (d, J = 4.4 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 7.45-7.42 (m, 3H), 7.30-7.29 (m, 1H), 6.90 (s, 1H), 6.81 (s, 1H), 5.35 (s, 1H), 4.62 (s, 2H), 3.71 (s, 4H), 3.52 (t, J = 7.2 Hz, 2H), 2.58 (s, 3H), 2.50-2.48 (m, 4H), 2.34 (s, 3H), 2.26 (t, J = 7.2 Hz, 2H), 2.00-1.97 (m, 2H).
D32		C, BL, AA, AM	^1H NMR (400 MHz, CDCl_3) δ 8.76 (d, J = 4.0 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.36-7.33 (m, 1H), 7.20 (s, 1H), 7.07 (s, 1H), 6.91 (s, 1H), 4.64 (s, 2H), 3.74-3.55 (m, 6H), 2.57 (s, 3H), 2.53-2.45 (m, 7H), 2.34 (s, 3H), 1.11 (t, J = 7.2 Hz, 3H).

D33		E, AC, AM	^1H NMR (400 MHz, CDCl_3) δ 8.87 (s, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.43-7.30 (m, 3H), 7.11 (d, J = 4.4 Hz, 1H), 4.85 (s, 2H), 3.24 (s, 4H), 3.05 (s, 3H), 2.53 (s, 3H), 2.47 (s, 4H), 2.31 (s, 3H), 1.86 (s, 3H).
D34		I, BM	^1H NMR (400 MHz, CDCl_3) δ 8.90 (s, 1H), 8.11 (d, J = 7.6 Hz, 1H), 7.38 (s, 3H), 7.03 (s, 1H), 4.95 (s, 2H), 3.60 (s, 4H), 3.07 (s, 3H), 2.40 (s, 7H), 2.29 (s, 3H).
D35		B, BM, AA	^1H NMR (400 MHz, CDCl_3) δ 8.83 (d, J = 2.4 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.41-7.33 (m, 3H), 7.11 (d, J = 6.8 Hz, 1H), 5.10 (s, 2H), 3.53 (s, 4H), 3.16 (s, 3H), 2.49 (s, 4H), 2.45 (s, 3H), 2.32 (s, 3H).
D36		M, BM, AD	^1H NMR (400 MHz, CDCl_3) δ 8.83 (s, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.46-7.30 (m, 3H), 7.09 (s, 1H), 5.10 (s, 2H), 3.87 (s, 4H), 3.17 (s, 3H), 2.46 (s, 7H), 2.31 (s, 3H).
D37		AH, AM	^1H NMR (400 MHz, CDCl_3) δ 8.87 (d, J = 4.0 Hz, 1H), 8.19 (d, J = 8.4 Hz, 1H), 7.62-7.31 (m, 4H), 4.51 (s, 2H), 4.46 (s, 2H), 4.38-3.96 (m, 4H), 3.36-3.11 (m, 4H), 2.83 (s, 3H), 2.79 (s, 3H), 2.59 (s, 3H). MS (ESI/APCI) m/z 392.8 $[\text{M}+\text{H}]^+$.
D38		N, BM, AK	^1H NMR (400 MHz, CDCl_3) δ 8.99 (s, 1H), 8.19 (d, J = 8.0 Hz, 1H), 7.48-7.44 (m, 3H), 7.36 (d, J = 8.8 Hz, 1H), 7.20-7.15 (m, 2H), 7.09 (s, 1H), 6.28 (d, J = 7.2 Hz, 1H), 5.07 (s, 2H), 3.14 (s, 3H), 3.03 (s, 4H), 2.56 (s, 4H), 2.42 (s, 3H).
D39		N, BM, AK	^1H NMR (400 MHz, CDCl_3) δ 8.93 (s, 1H), 8.18 (d, J = 8.0 Hz, 1H), 7.50 (s, 2H), 7.44-7.38 (m, 2H), 7.32 (s, 1H), 7.15-7.12 (m, 1H), 6.45 (d, J = 7.2 Hz, 1H), 5.81 (s, 1H), 5.21 (s, 2H), 4.75 (s, 2H), 3.44 (d, J = 11.2 Hz, 2H), 2.99-2.91 (m, 7H), 2.53-2.49 (m, 2H), 2.41 (s, 3H).
D40		D, BN	^1H NMR (400 MHz, CDCl_3) δ 8.79 (d, J = 2.8 Hz, 1H), 8.44 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.47 (dd, J = 8.8, 4.0 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.61 (s, 1H), 4.84 (s, 2H), 3.59 (s, 4H), 3.13 (s, 3H), 2.52 (s, 3H), 2.46-2.37 (m, 4H), 2.30 (s, 3H).
D41		C, BN, AA	^1H NMR (400 MHz, CDCl_3) δ 8.81-8.79 (m, 1H), 8.48 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.48-7.45 (m, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.63 (s, 1H), 4.66 (s, 2H), 3.58-3.55 (s, 4H), 3.05 (s, 3H), 2.50 (s, 3H), 2.40-2.38 (s, 4H), 2.29 (s, 3H).

D42		C, BN, AA, AQ	¹ H NMR (400 MHz, CDCl ₃) δ 8.74 (d, <i>J</i> = 3.2 Hz, 1H), 8.43 (d, <i>J</i> = 8.4 Hz, 1H), 7.79 (d, <i>J</i> = 8.4 Hz, 1H), 7.50 (dd, <i>J</i> = 8.4, 4.0 Hz, 1H), 6.94 (d, <i>J</i> = 8.4 Hz, 1H), 6.51 (s, 1H), 4.99 (s, 2H), 3.61-3.52 (m, 4H), 3.19 (s, 3H), 2.50 (s, 3H), 2.43-2.37 (m, 4H), 2.29 (s, 3H). MS (ESI/APCI) <i>m/z</i> 388.2 [M+H] ⁺ .
D43		C, BN, AA, AR	¹ H NMR (400 MHz, CDCl ₃) δ 9.01 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 8.75 (dd, <i>J</i> = 4.0, 2.0 Hz, 1H, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 1H), 7.52 (dd, <i>J</i> = 8.8, 4.0 Hz, 1H), 7.01 (d, <i>J</i> = 8.4 Hz, 1H), 6.55 (s, 1H), 4.97 (s, 2H), 3.68-3.55 (m, 4H), 3.20 (s, 3H), 3.14 (s, 3H), 2.52 (s, 3H), 2.46-2.38 (m, 4H), 2.31 (s, 3H). MS (ESI/APCI) <i>m/z</i> 441.2 [M+H] ⁺ .
D44		D, BN	¹ H NMR (400 MHz, CDCl ₃) δ 8.85 (s, 1H), 8.17 (d, <i>J</i> = 8.0 Hz, 1H), 7.63 (s, 1H), 7.44 (dd, <i>J</i> = 7.6 Hz, <i>J</i> = 3.6 Hz, 1H), 7.20 (s, 1H), 6.60 (s, 1H), 4.84 (s, 2H), 3.58 (s, 4H), 3.09 (s, 3H), 2.50 (s, 3H), 2.44-2.38 (m, 4H), 2.30 (s, 3H).
D45		C, BN, AA	¹ H NMR (400 MHz, CDCl ₃) δ 8.74 (s, 1H), 8.00 (d, <i>J</i> = 8.4 Hz, 1H), 7.51 (s, 1H), 7.39-7.36 (m, 1H), 7.16 (s, 1H), 6.72 (s, 1H), 4.78 (s, 2H), 3.66 (s, 4H), 3.03 (s, 3H), 2.54 (s, 3H), 2.49 (s, 4H), 2.35 (s, 3H).
D46		C, BN, AA, AQ	¹ H NMR (400 MHz, CDCl ₃) δ 8.85 (dd, <i>J</i> = 4.4, 2.0 Hz, 1H), 8.13 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.70 (s, 1H), 7.46 (dd, <i>J</i> = 8.4, 4.4 Hz, 1H), 7.14 (s, 1H), 6.63 (s, 1H), 4.80 (s, 2H), 3.67-3.54 (m, 4H), 3.08 (s, 3H), 2.51 (s, 3H), 2.46-2.40 (m, 4H), 2.31 (s, 3H).
D47		C, BN, AA, AR	¹ H NMR (400 MHz, CDCl ₃) δ 8.87 (d, <i>J</i> = 4.0 Hz, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 1H), 7.97 (s, 1H), 7.52-7.43 (m, 2H), 6.65 (s, 1H), 4.86 (s, 2H), 3.67-3.58 (m, 4H), 3.12 (s, 6H), 2.51 (s, 3H), 2.47-2.42 (m, 4H), 2.32 (s, 3H). MS (ESI/APCI) <i>m/z</i> 441.1 [M+H] ⁺ .
D48		D, BN	¹ H NMR (400 MHz, CDCl ₃) δ 8.98 (s, 1H), 8.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.76 (s, 2H), 7.49 (dd, <i>J</i> = 8.4, 4.0 Hz, 1H), 7.15 (s, 1H), 4.64 (s, 2H), 3.81 (s, 4H), 3.03 (s, 3H), 2.61-2.58 (m, 4H), 2.52 (s, 3H), 2.40 (s, 3H).
D49		C, BN, AA	¹ H NMR (400 MHz, CDCl ₃): δ 8.89 (s, 1H), 8.12 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.8 Hz, 1H), 7.47 (d, <i>J</i> = 8.8 Hz, 1H), 7.41 (s, 2H), 4.68 (s, 2H), 3.74 (s, 4H), 3.05 (s, 3H), 2.49 (s, 7H), 2.35 (s, 3H). MS (ESI/APCI) <i>m/z</i> 441.1 [M+H] ⁺ .
D50		C, BN, AA, AQ	¹ H NMR (400 MHz, CDCl ₃) δ 8.91 (d, <i>J</i> = 2.4 Hz, 1H), 8.14 (d, <i>J</i> = 8.0 Hz, 1H), 7.58-7.46 (m, 3H), 7.06 (s, 1H), 4.91 (s, 2H), 3.75 (s, 4H), 3.31 (s, 3H), 2.49 (s, 7H), 2.34 (s, 3H).

D51		C, BN, AA, AR	^1H NMR (400 MHz, CDCl_3) δ 9.00 (d, J = 3.2 Hz, 1H), 8.23 (dd, J = 8.4, 1.6 Hz, 1H), 8.18 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.52 (dd, J = 8.8, 4.4 Hz, 1H), 7.16 (s, 1H), 5.15 (brs, 1H), 4.21 (brs, 1H), 3.86-3.70 (m, 4H), 3.36 (s, 3H), 3.07 (s, 3H), 2.57-2.42 (m, 7H), 2.35 (s, 3H). MS (ESI/APCI) m/z 441.2 $[\text{M}+\text{H}]^+$.
D52		C, BN, AA	^1H NMR (400 MHz, CDCl_3) δ 8.70 (s, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.40-8.32 (m, 1H), 6.94 (d, J = 7.6 Hz, 1H), 6.84 (d, J = 11.2 Hz, 1H), 6.65 (s, 1H), 4.79 (s, 2H), 4.10-3.95 (m, 2H), 3.80-3.76 (m, 1H), 3.52 (d, J = 10.8 Hz, 1H), 3.32 (t, J = 10.8 Hz, 1H), 3.13-2.95 (m, 4H), 2.81 (d, J = 10.4 Hz, 1H), 2.51 (s, 3H), 2.38-2.20 (m, 5H).
D53		C, BN, AA, AD	^1H NMR (400 MHz, CDCl_3) δ 8.70 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.36 (dd, J = 7.2, 3.6 Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 6.96-6.70 (m, 2H), 4.78 (s, 2H), 4.56 (s, 1H), 4.10-3.88 (m, 3H), 3.42 (t, J = 10.4 Hz, 1H), 3.10-3.00 (m, 4H), 2.86 (d, J = 10.4 Hz, 1H), 2.51 (s, 3H), 2.35-2.24 (m, 4H), 2.09 (t, J = 9.2 Hz, 1H).
D54		E, AC, AM	^1H NMR (400 MHz, CDCl_3) δ 8.82 (s, 1H), 8.12 (d, J = 8.0 Hz, 1H), 7.45-7.36 (m, 3H), 7.12 (d, J = 7.2 Hz, 1H), 6.70 (s, 1H), 4.75 (s, 2H), 4.56 (s, 2H), 3.86 (br s, 1H), 3.68-3.51 (m, 4H), 3.05 (s, 3H), 2.47-2.35 (m, 4H), 2.30 (s, 3H). MS (ESI/APCI) m/z 378.9 $[\text{M}+\text{H}]^+$.
D55		D, BN, AO, AJ	^1H NMR (400 MHz, CDCl_3) δ 8.76 (s, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.45-7.30 (m, 2H), 7.17 (s, 1H), 6.79 (s, 1H), 4.81 (s, 2H), 4.66 (s, 2H), 3.63 (s, 4H), 3.03 (s, 3H), 2.54 (s, 3H), 2.50-2.43 (m, 4H), 2.32 (s, 3H).
D56		D, BN, AN, AJ	^1H NMR (400 MHz, CDCl_3) δ 8.90 (s, 1H), 8.14 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.37-7.30 (m, 1H), 6.36 (s, 1H), 5.30 (s, 1H), 4.70-4.20 (m, 3H), 3.69 (s, 4H), 2.96 (s, 3H), 2.53 (s, 3H), 2.48 (s, 4H), 2.34 (s, 3H).
D57		D, AS	^1H NMR (400 MHz, CDCl_3) δ 8.76 (s, 1H), 8.61 (d, J = 8.0 Hz, 1H), 7.51-7.46 (m, 2H), 7.00 (d, J = 8.0 Hz, 1H), 6.87 (s, 1H), 4.69 (s, 2H), 3.78 (s, 4H), 3.05 (s, 3H), 3.01 (s, 3H), 2.61 (s, 7H), 2.43 (s, 3H). MS (ESI/APCI) m/z 455.9 $[\text{M}+\text{H}]^+$.

D58		C, BN, AA, AO, BO, AT	¹ H NMR (400 MHz, CDCl ₃) δ 8.70 (d, <i>J</i> = 4.0 Hz, 1H), 8.01 (d, <i>J</i> = 8.4 Hz, 1H), 7.38-7.30 (m, 1H), 7.27 (s, 1H), 6.91 (s, 1H), 6.67 (s, 1H), 4.68 (s, 2H), 3.77 (t, <i>J</i> = 4.4 Hz, 2H), 3.63 (t, <i>J</i> = 4.4 Hz, 2H), 3.07 (s, 3H), 3.04 (s, 3H), 2.48 (s, 3H), 2.44-2.34 (m, 4H), 2.29 (s, 3H). MS (ESI/APCI) <i>m/z</i> 455.7 [M+H] ⁺ .
D59		C, BN, AA, AO, BO, AT	¹ H NMR (400 MHz, CDCl ₃) δ 8.89 (d, <i>J</i> = 5.2 Hz, 1H), 8.11 (d, <i>J</i> = 8.4 Hz, 1H), 7.96 (d, <i>J</i> = 8.8 Hz, 1H), 7.67 (d, <i>J</i> = 9.2 Hz, 1H), 7.34-7.31 (m, 1H), 6.25 (s, 1H), 4.61-4.34 (m, 1H), 4.24-3.98 (m, 1H), 3.77 (t, <i>J</i> = 4.4 Hz, 2H), 3.62 (t, <i>J</i> = 4.4 Hz, 2H), 3.03 (s, 3H), 2.98 (s, 3H), 2.64 (s, 3H), 2.56-2.49 (m, 4H), 2.37 (s, 3H). MS (ESI/APCI) <i>m/z</i> 455.7 [M+H] ⁺ .

BIOLOGICAL ACTIVITIES

[00406] Example 22: HPB-ALL CXCR4 competitive binding assay

[00407] HPB-ALL cells were maintained in RPMI-1640 (Gibico) supplemented with 10% FBS (Hyclone). APC-conjugated anti-human CXCR4 was from Sungene. EC₈₀ was first determined for 12G5 binding to CXCR4. Then the compounds for testing were added into 96-well plates serially diluted at a ratio of 1:3. Cells were washed once with ice-cold assay buffer (DPBS+2% HI-FBS) and then re-suspended in the same buffer at a final concentration of 1 x 10⁶/mL. Cell suspension was then added into the wells and with the addition of APC-conjugated anti-human CXCR4 clone 12G5 at its EC₈₀ determined. The mix of cell, compounds and APC-conjugated anti-human CXCR4 were incubated at 4 °C for 3 h before addition of 100 μL of 4% PFA. Cells were then washed once and resuspended in assay buffer and examined by FACS. The percent (%) effect at each concentration of compound was calculated and relative to the amount of calcium produced in the positive and negative control wells contained within each assay plate. The concentrations and % effect values for tested compounds were plotted and the concentration of compound required for 50% effect (IC₅₀) was determined. Tables 2 summarize results of the CXCR4 competitive binding assay for selected compounds disclosed in the present disclosure. Table 3 summarizes results of the CXCR4 competitive binding assay for control compounds. FIGs. 1-2 depict the IC₅₀ curves of compounds A42 and A43.

[00408] Table 2. Results of selected compounds of the present invention tested by the 12G5 binding assay

Compound number	IC ₅₀ (nM)	Compound number	IC ₅₀ (nM)	Compound number	IC ₅₀ (nM)
A1	45	A2	228	A3	19
A4	229	A5	113	A6	1138
A7	393	A8	242	A9	14
A10	23	A11	26	A12	8000
A13	8000	A14	2253	A15	606
A16	17	A17	2689	A18	43
A19	67	A20	210	A21	790
A22	32	A23	34	A24	42
A25	100	A26	41	A27	7.9
A28	21	A29	78	A30	65
A31	77	A32	22	A33	268
A34	47	A35	106	A36	5735
A37	4432	A38	6940	A39	94
A40	110	A41	97	A42	9.8
A43	11	A44	296	A45	886
A46	161	A47	58	A48	240
A49	123	A50	211	A51	16
A52	27	A53	33	A54	356
A55	44	A56	131	A57	21
A58	19	A59	63	A60	464
A61	8.8	A62	2288	A63	29
A64	21	A65	13	A66	20
A67	12	A68	46	A69	27
A70	54	A71	90	A72	146
A73	32	A74	100	A75	15
A76	220	A77	9	C1	93
C2	9000	C3	9000	C4	2324
C5	20	C6	3235	C7	9000
C8	6957	C9	9000	C10	248
C11	142	C12	165	C13	62
C14	8105	C15	500	C16	7.74

C17	9000	C18	429	C19	1709
C20	9000	C21	82	C22	9000
C23	144	C24	9000	C25	68
C26	206	C27	279	C28	2283
C29	1200	C30	9000	C31	9000
C32	9000	D1	18	D2	65
D4	55	D14	57	D20	675
D25	151	D28	338	D30	3822
D36	1171				

[00409] Table 3. Results of selected control compounds tested by the 12G5 binding assay

Compound number	IC ₅₀ (nM)	Compound number	IC ₅₀ (nM)	Compound number	IC ₅₀ (nM)
B1	>10000	B2	>10000	B3	>10000
B4	>10000	B5	>10000	B6	>10000
B7	>10000	B8	>10000		

[00410] Example 23: FLIPR Tetra calcium mobilization assay

[00411] The FLIPR Tetra calcium mobilization assay was performed by HD Bioscience. Briefly, The Molecular Devices, Fluorescent Imaging Plate Reader (FLIPR) Tetra was used in this assay. Excitation was achieved through unique placement of LED's within the instrument and emission captured by a CCD camera (EMCCD camera for FI and ICCD camera for luminescence). The homogeneous FLIPR Calcium 4 assay kit from Molecular Devices was used as the fluorescence reagent. Compounds were solubilized in 100% dimethyl sulfoxide (DMSO) to a concentration of 30 mM. A 10-point, 4-fold, intermediate dilution series was created in 100% DMSO with a top concentration of 4 mM and a bottom concentration of 0.01 μ M. A near assay ready, direct dilution plate (ddNARP) was prepared from this compound dilution plate by transferring 1 μ L of each dilution of compound in 100% DMSO to a Greiner#781201 plate. In addition, each ddNARP plate also contained positive and negative control wells to define the upper and lower limits for the assay signal. The final assay concentration range of compound was 10 μ M to 0.035 nM in 0.5% DMSO. Human CD⁴⁺ T-Cells were isolated from human whole blood and subsequently activated and expanded using a CD3/CD28 expansion kit (Life

Technologies). The cells were frozen in ThermoFisher-formulated Recovery Cell Culture Freezing Medium containing 10% Dimethyl sulfoxide (DMSO) and 10% Fetal Bovine Serum (FBS) (ThermoFisher Catalog No. 10100147). When used, cells were resuspended using room temperature 1X HBSS/20mM HEPES/0.005% P-104 assay buffer, adjusted the volume of the suspension to achieve a cell concentration of 2.5×10^6 cells/mL. 2X Calcium 4 dye (20 μ L/well) were added and the mixture were centrifuged briefly (~10s) and stopped when it reached 1000 rpm. The plates were allowed to equilibrate before compounds and CXCL12 were added to the plates. The raw data were analyzed using Abase. The percent (%) effect at each concentration of compound was calculated by Abase and was based on and relative to the amount of calcium produced in the positive and negative control wells contained within each assay plate. The concentrations and % effect values for tested compounds were plotted by Abase and the concentration of compound required for 50% effect (IC_{50}) was determined with a four-parameter logistic dose response equation. Table 4 summarizes the results of selected compounds in the calcium mobilization assay. FIGs. 3 and 4 summarize the results of Compounds A78 and A83 in the calcium mobilization assay.


[00412] Table 4. Results of selected compounds of the present invention tested by the calcium mobilization assay

Compound number	IC_{50} (nM)	Compound number	IC_{50} (nM)	Compound number	IC_{50} (nM)
A1	4.5	A22	3.4	A42	0.021
A61	0.024	A75	0.090	A78	0.062
A79	0.22	A80	0.18	A81	4.5
A82	2.5	A83	0.93	A84	3.0
A85	0.99	A86	0.13	A87	0.18
A88	0.30	A89	0.13	A90	0.046
A91	0.032	A92	118	A93	20000
A94	20000	A95	0.13	A96	0.086
A97	0.25	A98	0.15	A99	0.39
A100	0.29	C33	1.1	C34	1.8
C35	2.7	C36	0.5	C37	12
C38	0.2	C39	0.1	D1	1.2

D2	0.24	D3	0.63	D4	0.14
D5	2.1	D6	2.4	D7	0.75
D8	1.4	D9	0.59	D10	2.9
D11	1700	D12	0.61	D13	2.9
D14	0.3	D15	0.4	D16	2.7
D17	74	D18	0.79	D19	0.4
D20	3.1	D21	1581	D22	965
D23	20000	D24	12400	D25	016
D26	2.3	D27	1.7	D28	0.21
D29	12.7	D30	9.3	D31	1.25
D32	0.53	D33	0.51	D34	0.83
D35	1.2	D36	3.6	D37	0.95
D38	0.18	D39	0.088	D40	2850
D41	6.3	D42	96	D43	3380
D44	104	D45	3.0	D46	53
D47	13	D48	928	D49	4.5
D50	14	D51	2087	D52	4.5
D53	6.7	D54	7.2	D55	39
D56	5.5	D57	2880	D58	55
D59	450				

What is claimed is:


1. A compound of Formula I:





or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof,


wherein


Ar is 5-10 membered heteroaryl comprising one N and 1-3 additional heteroatoms independently selected from the group consisting of N, O, and S, and Ar is unsubstituted or substituted with 1-4 R_{31} ;




W is , each X is independently a bond, $CR_{32}R_{33}$, O, NR_{34} , S, $S(=O)$ or $S(=O)_2$; n is 0, 1, 2 or 3; o and p are different integers with values of 0 or 1; wherein when o is 0, p is 1, B_1 is CR_{11} , B_2 is N, and B_1 is bonded with Ar; wherein when o is 1, p is 0, B_1 is N, B_2 is CR_{11} , and the carbon bearing R'_5 and R'_6 is bonded with Ar;




or W is , wherein the carbon bonded with R_5 and R_6 is connected the ring carbon bonded with Y;



Y is , wherein the carbon bonded with R₃ is bonded with the carbon bonded with R₂;




or Y is ;



U is

or



;

Q is a bond or CR₂₉R₃₀;


each of R₁, R₂, R₃, and R₄ is independently selected from the group consisting of H, deuterium, -CN, halide, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), -NHS(=O)₂(C₁₋₆ alkyl), -S(=O)₂(C₁₋₆ alkyl), C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, -OH, methanesulfonyl, and deuterium;

or R₄ together with the atoms it attached to forms a carbocyclic, aryl, heterocyclic, or heteroaryl ring;




each of R₅ and R₆ is independently selected from the group consisting of H, deuterium, -CN, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group

consisting of halide, deuterium, $-\text{OH}$, amino, $-\text{NH}(\text{C}_{1-6} \text{ alkyl})$, $-\text{N}(\text{C}_{1-6} \text{ alkyl})_2$, $-\text{NHC}(=\text{O})(\text{C}_{1-6} \text{ alkyl})$, $-\text{NHC}(=\text{O})\text{O}(\text{C}_{1-6} \text{ alkyl})$, and C_{1-3} alkoxy;

or R_5 and R_6 together forms



, and D_3 bonded with R_4 to form:



wherein each R'_4 is independently selected from the group consisting of H, deuterium, $-\text{CN}$, halide, $-\text{OH}$, amino, C_{1-6} alkyl, $-\text{NH}(\text{C}_{1-6} \text{ alkyl})$, $-\text{N}(\text{C}_{1-6} \text{ alkyl})_2$, $-\text{S}(=\text{O})_2(\text{C}_{1-6} \text{ alkyl})$, C_{3-6} cycloalkyl, C_{1-8} alkoxy, C_{2-6} alkenyl, and C_{2-6} alkynyl, wherein each of $-\text{NH}(\text{C}_{1-6} \text{ alkyl})$, $-\text{N}(\text{C}_{1-6} \text{ alkyl})_2$, $-\text{S}(=\text{O})_2(\text{C}_{1-6} \text{ alkyl})$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-8} alkoxy, C_{2-6} alkenyl, and C_{2-6} alkynyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, $-\text{OH}$, methanesulfonyl, and deuterium;

R_7 is selected from the group consisting of H, deuterium, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} heterocycloalkyl, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected

from the group consisting of halide, deuterium, amino, $-OH$, acyl, $-CN$, C_{1-6} alkoxy, $-NH(C_{1-6} \text{ alkyl})$, $-N(C_{1-6} \text{ alkyl})_2$, $-C(=O)O(C_{1-6} \text{ alkyl})$, $-C(=O)NH_2$, $-C(=O)NH(C_{1-6} \text{ alkyl})$, $-C(=O)N(C_{1-6} \text{ alkyl})_2$, $-NHC(=O)O(C_{1-6} \text{ alkyl})$, $-S(=O)_2(C_{1-6} \text{ alkyl})$, and C_{3-6} cycloalkyl;

each of R_8 and R_9 is independently selected from the group consisting of H, deuterium, $-CN$, C_{1-6} alkyl, and C_{3-6} cycloalkyl, wherein each of C_{1-6} alkyl and C_{3-6} cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, and C_{1-3} alkoxy; or R_7 and R_8 , and atoms attached thereto, form a ring;

or R_8 and R_9 , together with atoms they attached to, form a ring;

each of R'_5 , R'_6 , R'_7 , R'_8 , R'_9 , R'_{10} , R_{11} , R_{32} , and R_{33} is independently selected from the group consisting of H, deuterium, $-CN$, halide, C_{1-6} alkyl, $-C(=O)O(C_{1-6} \text{ alkyl})$, C_{3-6} cycloalkyl, C_{1-6} alkoxy, and $-OSi(C_{1-6} \text{ alkyl})_3$, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-6} alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, amino, C_{3-6} cycloalkyl, C_{1-6} alkyl, $-NHC(=O)(C_{1-6} \text{ alkyl})$, $-NHC(=O)O(C_{1-6} \text{ alkyl})$, $-NHC(=O)NH(C_{1-6} \text{ alkyl})$, $-NHC(=O)N(C_{1-6} \text{ alkyl})_2$, $-NHS(=O)_2(C_{1-6} \text{ alkyl})$, and C_{1-6} alkoxy;

each of R_{19} , R_{20} , R_{21} , R_{22} , R_{25} , R_{26} , R_{27} , R_{28} , R_{29} , and R_{30} is independently selected from the group consisting of H, deuterium, $-CN$, $-OH$, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3} alkoxy, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3} alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, amino, $-NH(C_{1-6} \text{ alkyl})$, $-N(C_{1-6} \text{ alkyl})_2$, $-NHC(=O)(C_{1-6} \text{ alkyl})$, $-NHC(=O)O(C_{1-6} \text{ alkyl})$, C_{1-6} alkyl, and C_{1-3} alkoxy; or R_{21} and R_{23} , together with atoms they attached to, form a ring; or R_{19} and R_{27} , together with atoms they attached to, form a ring; or R_{21} and R_{27} , together with atoms they attached to, form a ring; or R_{19} and R_{26} , together with atoms they attached to, form a ring; or R_{21} and R_{26} , together with atoms they attached to, form a ring;

R₂₃ is selected from the group consisting of H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, C₁₋₆ alkyl, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), and C₁₋₃ alkoxy; or R₂₂ and R₂₃, together with atoms they attached to, form a 5-7 membered heterocycle;

R₂₄ is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ heterocycloalkyl comprising N or O, -C(=O)(C₁₋₆ alkyl), -C(=O)O(C₁₋₆ alkyl), and -C(=O)NH(C₁₋₆ alkyl), wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ heterocycloalkyl comprising N or O, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), and C₁₋₃ alkoxy; or R and R₂₄, together with atoms they attached to, form a 5-7 membered heterocycle;

R₃₁ is selected from the group consisting of deuterium, halide, -CN, -OH, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkynyl, C₂₋₆ alkenyl, -S(C₁₋₆ alkyl), -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of deuterium, halide, -CN, -OH, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₆ alkoxy;


R₃₄ is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, -C(=O)(C₁₋₈ alkyl), -S(=O)₂(C₁₋₈ alkyl), -C(=O)O(C₁₋₆ alkyl), and -C(=O)NH(C₁₋₆ alkyl), wherein each of C₁₋₆ alkyl, C₁₋₈ alkyl, and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH,

amino, C₁₋₆ alkyl, -NH(C₁₋₆ alkyl), -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), and C₁₋₃ alkoxy;

R is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O; or R and R₂₄, together with N atom they attached to, form a 5-7 membered heterocycle; or R and R₂₁, together with N atom they attached to, form a 5-7 membered heterocycle; and

R' is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O; or R' and R₂₁, together with atoms they attached to, form a 5-7 membered heterocycle.


2. The compound of claim 1 according to Formula Ia:



Ia

or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof,
wherein

Ar is unsubstituted or substituted with 1-4 groups of R_{31} , and Ar is selected from the group consisting of:



each X is independently a bond, $CR_{32}R_{33}$, O, or NR_{34} ;

each of R_{19} , R_{20} , R_{21} , R_{22} , R_{25} , R_{26} , R_{27} , R_{28} , R_{29} , and R_{30} is independently selected from the group consisting of H, deuterium, $-CN$, $-OH$, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3} alkoxy, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3} alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, amino, C_{1-6} alkyl, and C_{1-3} alkoxy; or R_{19} and R_{27} , together with atoms they attached to, form a ring; or R_{21} and R_{27} , together with atoms they attached to, form a ring;


each of R_{23} and R_{24} is independently selected from the group consisting of H, C_{1-6} alkyl, and C_{3-6} cycloalkyl, wherein each of C_{1-6} alkyl and C_{3-6} cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, amino, C_{1-6} alkyl, and C_{1-3} alkoxy; or R_{22} and R_{23} , together with atoms they attached to, form a 5-7 membered heterocycle;

R₃₁ is selected from the group consisting of deuterium, halide, -CN, -OH, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, C₂₋₆ alkynyl, C₂₋₆ alkenyl, -S(C₁₋₆ alkyl), -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of deuterium, halide, -CN, -OH, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₆ alkoxy;

R is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₈ heterocycloalkyl comprising N or O, -C(=O)(C₁₋₆ alkyl), -C(=O)O(C₁₋₆ alkyl), and -C(=O)NH(C₁₋₆ alkyl) wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O; or R and R₂₄, together with N atom they attached to, form a 5-7 membered heterocycle; and

R' is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O; or R' and R₂₁, together with N atom they attached to, form a 5-7 membered heterocycle.


3. The compound of claim 1 according to Formula Ib:



Ib

or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof,
wherein

Ar is unsubstituted or substituted with 1-4 groups of R_{31} , and Ar is selected from the group consisting of:



each X is independently a bond, $CR_{32}R_{33}$, O, or NR_{34} ;

each of R_{19} , R_{20} , R_{21} , R_{22} , R_{25} , R_{26} , R_{27} , R_{28} , R_{29} , and R_{30} is independently selected from the group consisting of H, deuterium, $-CN$, $-OH$, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3} alkoxy, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3} alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, amino, C_{1-6} alkyl, and C_{1-3} alkoxy; or R_{19} and R_{27} , together with atoms

they attached to, form a ring; or R₂₁ and R₂₇, together with atoms they attached to, form a ring;

each of R₂₃ and R₂₄ is independently selected from the group consisting of H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, C₁₋₆ alkyl, and C₁₋₃ alkoxy; or R₂₂ and R₂₃, together with atoms they attached to, form a 5-7 membered heterocycle;


R₃₁ is selected from the group consisting of deuterium, halide, -CN, -OH, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, C₂₋₆ alkynyl, C₂₋₆ alkenyl, -S(C₁₋₆ alkyl), -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of deuterium, halide, -CN, -OH, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₆ alkoxy;

R is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O; or R and R₂₄, together with N atom they attached to, form a 5-7 membered heterocycle; and

R' is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₁₋₆ alkyl, C₃₋₆ cycloalkyl,

C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O; or R' and R₂₁, together with N atom they attached to, form a 5-7 membered heterocycle.

4. The compound of claim 2 according to Formula Ic:




Ic

or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof, wherein

each of Z1, Z2 and Z3 is independently selected from the group consisting of O and CR₄₁R₄₂; and

each of R₄₁ and R₄₂ is independently selected from the group consisting of H, deuterium, halide and C₁₋₃ alkyl.

5. The compound of claim 1 according to Formula II:



II

wherein

W_1 is D_1 , D_1-D_2 , or $D_1=D_2$, and D_1 is bonded with the pyridine ring;

each of R_1 , R_2 , and R_3 is independently selected from the group consisting of H,

deuterium, $-CN$, halide, $-OH$, amino, C_{1-6} alkyl, $-NH(C_{1-6} \text{ alkyl})$, $-N(C_{1-6} \text{ alkyl})_2$,

$-S(=O)_2(C_{1-6} \text{ alkyl})$, C_{3-6} cycloalkyl, C_{1-8} alkoxy, C_{2-6} alkenyl, and C_{2-6} alkynyl, wherein

each of C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-8} alkoxy, C_{2-6} alkenyl, and C_{2-6} alkynyl is

unsubstituted or substituted with 1-3 groups independently selected from the group

consisting of halide, $-OH$, methanesulfonyl, and deuterium;

R_7 is selected from the group consisting of H, deuterium, C_{1-6} alkyl, and C_{3-6} cycloalkyl,

wherein each of C_{1-6} alkyl, and C_{3-6} cycloalkyl is unsubstituted or substituted with 1-3

groups independently selected from the group consisting of halide, deuterium, amino,

$-OH$, acyl, $-CN$, C_{1-6} alkoxy, $-NH(C_{1-6} \text{ alkyl})$, $-N(C_{1-6} \text{ alkyl})_2$, $-C(=O)O(C_{1-6} \text{ alkyl})$,

$-C(=O)NH_2$, $-C(=O)NH(C_{1-6} \text{ alkyl})$, $-C(=O)N(C_{1-6} \text{ alkyl})_2$, $-NHC(=O)O(C_{1-6} \text{ alkyl})$,

$-S(=O)_2(C_{1-6} \text{ alkyl})$, and C_{3-6} cycloalkyl;

R_{23} is selected from the group consisting of H, C_{1-6} alkyl and C_{3-6} cycloalkyl, wherein

each of C_{1-6} alkyl and C_{3-6} cycloalkyl is unsubstituted or substituted with 1-3 groups

independently selected from the group consisting of halide, deuterium, $-OH$, amino,

$-NH(C_{1-6} \text{ alkyl})$, $-N(C_{1-6} \text{ alkyl})_2$, and C_{1-3} alkoxy;

each of R_{19} , R_{20} , R_{21} , R_{22} , R_{25} , R_{26} , R_{27} , R_{28} , R_{29} , and R_{30} is independently selected from

the group consisting of H, deuterium, $-CN$, $-OH$, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3}

alkoxy, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3} alkoxy is unsubstituted or

substituted with 1-3 groups independently selected from the group consisting of halide,

deuterium, $-OH$, amino, $-NH(C_{1-6} \text{ alkyl})$, $-N(C_{1-6} \text{ alkyl})_2$, $-NHC(=O)(C_{1-6} \text{ alkyl})$,


$-NHC(=O)O(C_{1-6} \text{ alkyl})$, and C_{1-3} alkoxy; or R_{22} and R_{23} , together with atoms they

attached to, form a ring; or R_{19} and R_{26} , together with atoms they attached to, form a

ring; or R_{21} and R_{26} , together with atoms they attached to, form a ring;

each of R and R₂₄ is independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ heterocycloalkyl comprising N or O, -C(=O)(C₁₋₆ alkyl), -C(=O)O(C₁₋₆ alkyl), and -C(=O)NH(C₁₋₆ alkyl), wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, and C₃₋₆ heterocycloalkyl comprising N or O; or R and R₂₄, together with N atom they attached to, form a 5-7 membered heterocycle; and R' is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O; or R' and R₂₁, together with N atom they attached to, form a 5-7 membered heterocycle.

6. The compound of claim 5 according to Formula IIa:




IIa

or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof,


wherein

Ar is unsubstituted or substituted with 1-4 groups of R₃₁, and Ar is selected from the group consisting of:



each of R_1 , R_2 , R_3 , and R_{43} is independently selected from the group consisting of H, deuterium, $-CN$, halide, $-OH$, amino, C_{1-6} alkyl, $-NH(C_{1-6} \text{ alkyl})$, $-N(C_{1-6} \text{ alkyl})_2$, $-S(=O)_2(C_{1-6} \text{ alkyl})$, C_{3-6} cycloalkyl, C_{1-8} alkoxy, C_{2-6} alkenyl, and C_{2-6} alkynyl, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-8} alkoxy, C_{2-6} alkenyl, and C_{2-6} alkynyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, $-OH$, methanesulfonyl, and deuterium.

7. The compound of claim 5 according to Formula IIb:




IIb

or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof,
wherein


each of D_1 , D_2 and D_3 is independently selected from the group consisting of N and CR'₄;

Ar is unsubstituted or substituted with 1-4 groups of R₃₁, and Ar is selected from the group consisting of:



each of R₁, R₂, R₃, and R'₄ is independently selected from the group consisting of H, deuterium, -CN, halide, -OH, amino, C₁₋₆ alkyl, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -S(=O)₂(C₁₋₆ alkyl), C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, -OH, methanesulfonyl, and deuterium.


8. The compound of claim 1 according to Formula III:



III

wherein

each of A_1 , A_2 , and A_3 is independently selected from the group consisting of N and CR_{44} , wherein at least one of A_1 , A_2 , and A_3 is N;



W_2 is

or

;

each of R_1 , R_2 , R_3 , and R_4 is independently selected from the group consisting of H, deuterium, $-CN$, halide, $-OH$, amino, $-NH(C_{1-6} \text{ alkyl})$, $-N(C_{1-6} \text{ alkyl})_2$, $-NHC(=O)(C_{1-6} \text{ alkyl})$, $-NHC(=O)O(C_{1-6} \text{ alkyl})$, $-NHS(=O)_2(C_{1-6} \text{ alkyl})$, $C_{1-6} \text{ alkyl}$, $C_{3-6} \text{ cycloalkyl}$, $C_{1-8} \text{ alkoxy}$, $C_{2-6} \text{ alkenyl}$, and $C_{2-6} \text{ alkynyl}$, wherein each of $C_{1-6} \text{ alkyl}$, $C_{3-6} \text{ cycloalkyl}$, and $C_{1-8} \text{ alkoxy}$ is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide and deuterium;

each of R_5 and R_6 is independently selected from the group consisting of H, deuterium, $-CN$, $C_{1-6} \text{ alkyl}$, and $C_{3-6} \text{ cycloalkyl}$, wherein each of $C_{1-6} \text{ alkyl}$ and $C_{3-6} \text{ cycloalkyl}$ is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, amino, $-NH(C_{1-6} \text{ alkyl})$, $-N(C_{1-6} \text{ alkyl})_2$, $-NHC(=O)(C_{1-6} \text{ alkyl})$, $-NHC(=O)O(C_{1-6} \text{ alkyl})$, and $C_{1-3} \text{ alkoxy}$; or R_5 is O or $CR_{45}R_{46}$, and R_4 and R_5 , together with atoms they attached to, form a ring;

R₇ is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl comprising an O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl comprising an O;

each of R₈ and R₉ is independently selected from the group consisting of H, deuterium, -CN, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, and C₁₋₃ alkoxy; or R₇ and R₈, and atoms attached thereto, form a ring;

or R₈ and R₉, together with atoms they attached to, form a ring;

R₄₄ is H, deuterium, halide, -CN, -OH, amino, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -C(=O)NH(C₁₋₆ alkyl), -C(=O)N(C₁₋₆ alkyl)₂, -S(C₁₋₆ alkyl), C₂₋₆ alkenyl, C₂₋₆ alkynyl, 4-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the groups consisting of O, N and S, aryl, and 5-6 membered heteroaryl, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, heterocycle, aryl and heteroaryl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH and C₁₋₃ alkoxy;

R₂₃ is selected from the group consisting of H, C₁₋₆ alkyl and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, and C₁₋₃ alkoxy;

each of R₁₉, R₂₀, R₂₁, R₂₂, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, and R₃₀ is independently selected from the group consisting of H, deuterium, -CN, -OH, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide,

deuterium, -OH, amino, -NH(C₁₋₆ alkyl), -N(C₁₋₆ alkyl)₂, -NHC(=O)(C₁₋₆ alkyl), -NHC(=O)O(C₁₋₆ alkyl), and C₁₋₃ alkoxy; or R₂₂ and R₂₃, together with atoms they attached to, form a ring; or R₁₉ and R₂₆, together with atoms they attached to, form a ring; or R₂₁ and R₂₆, together with atoms they attached to, form a ring;


each of R and R₂₄ is independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ heterocycloalkyl comprising N or O, -C(=O)(C₁₋₆ alkyl), -C(=O)O(C₁₋₆ alkyl), and -C(=O)NH(C₁₋₆ alkyl), wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₆ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, and C₃₋₆ heterocycloalkyl comprising N or O; or R and R₂₄, together with N atom they attached to, form a 5-7 membered heterocycle; or R and R₂₁, together with N atom they attached to, form a 5-7 membered heterocycle;

R' is selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, -S(=O)₂(C₁₋₆ alkyl), -C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O; or R' and R₂₁, together with N atom they attached to, form a 5-7 membered heterocycle;


and

each of R₄₅ and R₄₆ is independently selected from the group consisting of H, deuterium, halide, C₁₋₃ alkyl; or R₄₅ and R₄₆, together with the atoms they attached to, form a ring.

9. The compound of claim 8 according to Formula IIIa or IIIb:



IIIa



IIIb

wherein

each of E₁, E₂, and E₃ is independently selected from the group consisting of O and

CR₄₅R₄₆; and

each of R₄₅ and R₄₆ is independently selected from the group consisting of H, deuterium, halide, C₁₋₃ alkyl; or R₄₅ and R₄₆, together with the atoms they attached to, form a ring.

10. The compound of claim 9, wherein each of E₁, E₂, and E₃ is independently selected from the


group consisting of CH₂, O and ; and at least one of E₁, E₂, and E₃ is .

11. The compound of claim 8, wherein

A₃ is CR₄₄;

each of A₁ and A₂ is independently selected from the group consisting of N and CR₄₄,

wherein at least one of A₁ and A₂ is N;



W₂ is .


12. The compound as in any one of claims 1, 2, 3, and 4, wherein


each of R₁₉, R₂₀, R₂₁, R₂₂, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, and R₃₀ is independently selected from the group consisting of H, deuterium, –CN, –OH, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₃ alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, –OH, C₁₋₆ alkyl, and C₁₋₃ alkoxy;

each of R₂₃ and R₂₄ is independently selected from the group consisting of H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl, wherein each of C₁₋₆ alkyl and C₃₋₆ cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, –OH, amino, C₁₋₆ alkyl, and C₁₋₃ alkoxy; or R₂₂ and R₂₃, together with atoms they attached to, form a 5-7 membered heterocycle; and

each of R and R' is independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl comprising N or O, wherein each of C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₃₋₈ heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, –OH, –CN, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₃ alkoxy, –S(=O)₂(C₁₋₆ alkyl), –C(=O)(C₁₋₆ alkyl), and C₃₋₆ heterocycloalkyl comprising N or O.

13. The compound as in any one of claims 1, 2, 3, and 4, wherein the compound is selected from the group consisting of:





14. The compound as in any one of claims 1, 5, 6, and 7, wherein

R_{23} is selected from the group consisting of H, C_{1-6} alkyl, and C_{3-6} cycloalkyl, wherein each of C_{1-6} alkyl and C_{3-6} cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, amino, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl)₂, and C_{1-3} alkoxy;


each of R_{19} , R_{20} , R_{21} , R_{22} , R_{25} , R_{26} , R_{27} , R_{28} , R_{29} , and R_{30} is independently selected from the group consisting of H, deuterium, $-CN$, $-OH$, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3} alkoxy, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{1-3} alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, amino, $-NH(C_{1-6}$ alkyl), $-N(C_{1-6}$ alkyl)₂, $-NHC(=O)(C_{1-6}$ alkyl), $-NHC(=O)O(C_{1-6}$ alkyl), and C_{1-3} alkoxy; or R_{21} and R_{23} , together with atoms they attached to, form a ring;

each of R and R_{24} is independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} heterocycloalkyl comprising N or O, $-C(=O)(C_{1-6}$ alkyl), $-C(=O)O(C_{1-6}$ alkyl), and $-C(=O)NH(C_{1-6}$ alkyl), wherein each of C_{1-6} alkyl and C_{3-6}


cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, $-CN$, C_{3-6} cycloalkyl, C_{1-3} alkoxy, and C_{3-6} heterocycloalkyl comprising N or O; or R and R_{24} , together with atoms they attached to, form a 5-7 membered heterocycle;

R' is selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-8} heterocycloalkyl comprising N or O, wherein each of C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-8} heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, $-OH$, $-CN$, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-3} alkoxy; or R' and R_{21} , together with atoms they attached to, form a 5-7 membered heterocycle.


15. The compound as in any one of claims 1, 5, 6, and 7, wherein the compound is selected from the group consisting of:




D1




D2




D3




D4




D5




D6




D7




D8




D9




D10




D11




D12




D13




D14




D15




D16




D17




D18




D19




D20




D21




D22




D23




D24




D25







D51




D52




D53




D54




D55




D56



D57




D58





D59


16. The compound as in any one of claims 1, 8, 9, 10, and 11, wherein $-C(R_5R_6)W_2$ is selected from the group consisting of:





17. The compound as in any one of claims 1, 8, 9, 10, and 11, wherein the compound is selected from the group consisting of:





















18. The compound of any one of claims 1-11, wherein U is unsubstituted or substituted with is unsubstituted or substituted with 1-3 groups selected from the group consisting of deuterium, halide, -OH, C₁₋₃ alkyl, and C₁₋₃ alkoxy, and U is selected from the group consisting of:





19. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-11, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof, and a pharmaceutically acceptable carrier, diluent, adjuvant or excipient.

20. A combination composition comprising:

- (a) a compound of any one of claims 1-11, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof; and
- (b) one or more additional compounds selected from the group consisting of antitumor agents, anti-cancer agents, antibacterial agents, antiviral agents, central nervous system agents, and anti-diabetes agents.

21. A compound of any one of claims 1-11, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof, for treating diseases, mobilizing stem cells, and treating wounded or burned skin by antagonizing the CXCR4 pathway, wherein the diseases is selected from the group consisting of HIV infection, myocardial infarction, diseases associated with hematopoiesis, inflammation, allergic diseases, asthma, allergic pneumonia, interstitial lung disease, lupus erythematosus, ankylosing spondylitis, multiple sclerosis, systemic sclerosis, polymyositis, rheumatoid arthritis, myasthenia gravis, juvenile diabetes, glomerulonephritis, autoimmune thyroiditis, graft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, scleroderma, psoriasis, dermatitis, retinitis pigmentosa, proliferative vitreoretinopathy, Best's vitelliform macular degeneration, eczema, urticaria, vasculitis, eosinophilic fasciitis, wet and dry age-related macular degeneration (ARMD), diabetic retinopathy, retinopathy of prematurity (ROP), diabetic macular edema, uveitis, retinal vein occlusion, cystic macular edema, glaucoma, vein branch occlusion, breast cancer, lung cancer, bladder cancer, pancreatic cancer, liver cancer, head and neck squamous cell carcinoma, thyroid cancer, sarcoma, osteosarcoma, desmofibroma, melanoma, prostate cancer, colorectal cancer, ovarian cancer, cervical cancer, esophageal cancer, gastric cancer, myeloma, lymphoma, mantle cell lymphoma, cutaneous T cell lymphoma, chronic and non-progressive anemia, spontaneous or primary thrombocytosis, idiopathic myelofibrosis, pulmonary fibrosis, renal fibrosis, liver fibrosis, cirrhosis, diabetic retinopathy, macroglobulinemia, leukemia, acute leukemia, chronic leukemia, lymphoblastic leukemia, myeloid leukemia, myelodysplastic syndrome, myeloproliferative disorders, encephaloma, astrocytoma, medulloblastoma, schwannoma, primary neuroectodermal tumor, and pituitary adenoma.

**FIG. 1****FIG. 2**




FIG. 3




FIG. 4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/52503

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/444; C07D 401/14; A61P 11/00; A61P 35/00 (2019.01)

CPC - A61K 31/444; C07D 401/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History Document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2011/0245265 A1 (ZUK et al.) 06 October 2011 (06.10.2011) para [0168]-[0181], [0230],[0232]	1-2, 12, 19-21
A	WO 2017/011517 A1 (EMORY UNIVERSITY et al.) 19 January 2017 (19.01.2017) abstract; Fig 1A	1-2, 12, 19-21
A	US 2008/0051387 A1 (XU et al.) 28 February 2008 (28.02.2008) para [0037]; pg 48, Table 1, compound 75	1-2, 12, 19-21
A	US 2013/0172330 A1 (ALTIRIS THERAPEUTICS, INC.) 04 July 2013 (04.07.2013) para [055]-[0056], [0826]-[0828], [0952], pg 118, Table 5	1-2, 12, 19-21
A	PUBCHEM-CID: 9897616 Create Date: 25 October 2006 (25.10.2006) pages 1-15; pg 4, Fig	1-2, 12, 19-21

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

30 January 2019

Date of mailing of the international search report

25 FEB 2019

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/52503

Attachment to Box.No.III:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I+: Claims 1-21 directed to a compound of formula I as described in claim 1, further represented by formula Ia, Ib, Ic, II, IIa, IIb, III, IIIa, IIIb, and selected from the compounds listed in claims 13, 15 and 17; and to a pharmaceutical composition comprising the same.

The compound of formula (I) will be searched to the extent that the compound encompasses the first species of claim 1, wherein

Ar is a 5-membered unsubstituted heteroaryl comprising 1 N and 1 additional heteroatom selected from N;

W is the first moiety of claim 1 and Y is -CR₄=CR₃-, wherein the carbon bonded with R₃ is bonded with the carbon bonded with R₂; such that the compound has the structure of Formula Ia, wherein X is a bond; n is 0;

R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ are each H;

U is the first moiety specified in claim 1, wherein

Q is a bond; each of R₁₉, R₂₀, R₂₁, R₂₂, R₂₃, R₂₄ and R is H.

It is believed that claims 1-2, 12 and 19-21 read on this first named invention, and thus these claims will be searched without fee to the extent that they encompass the first species of claim 1, described above.

Applicant is invited to elect additional compound(s) wherein each additional compound elected will require one additional invention fee.

Applicants must specify the claims that encompass any additionally elected compound. Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the '+' group(s) will result in only the first claimed invention to be searched.

Additionally, an exemplary election wherein different actual variables are selected is suggested. An exemplary election would be a compound of claim 1, further represented by the first-listed compound of claim 17, wherein

W is the second moiety of claim 1 and Y of Formula I is -CR₄=CR₃-, wherein the carbon bonded with R₃ is bonded with the carbon bonded with R₂; R₄, together with the atoms it attached to forms a carbocyclic ring;

R₇ is C₁-alkyl; R₈, R₉ are each H;

Ar is a 6-membered heteroaryl, having one additional heteroatom selected from N, wherein the heteroaryl is unsubstituted; and U is the second moiety specified in claim 1, where Q is a bond; R₁₉, R₂₀, R₂₁, R₂₂, R₂₅, R₂₆, R₂₇ and R₂₈ are each hydrogen and R' is C₁-alkyl (i.e., claims 1, 8-9, 11, 16-21).

The group of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I+ includes the technical feature of a unique compound, which is not required by any other invention of Group I+.

Common technical features:

The inventions of Group I+ share the technical feature of a compound having the core structure of formula (I).

This shared technical feature, however, does not provide a contribution over the prior art, as being anticipated by US 2013/0172330 A1 to Altiris Therapeutics, Inc. (hereinafter 'Altiris Therapeutics') teaches a compound of Formula I, having CXCR₄ modulatory activity (para [0027]-[0028]), wherein Y is -CR₄=CR₃-, wherein the carbon bonded with R₃ is bonded with the carbon bonded with R₂;

W is -CR₈R₉-NR₇-CR₅R₆-, wherein the carbon bonded with R₅ and R₆ is connected to the ring carbon bonded with Y;

R₄ and R₅ together with the atoms it attached to forms a carbocyclic ring; R₇ is C₁-alkyl; R₈, R₉ are each H;

Ar is a 6-membered heteroaryl, having one additional heteroatom selected from N, wherein the heteroaryl is substituted with one R₃₁, where R₃₁ is -N(C₁-alkyl)₂; and U is the first moiety specified in claim 1, where Q is -CR₂₉R₃₀, wherein R₁₉, R₂₀, R₂₁, R₂₂, R₂₃, R₂₄, R₂₉ and R₃₀ and R are each hydrogen (para [0952], structure (IF), pg 118, Table 5, compound CI).

As said compound was known in the art at the time of the invention, this cannot be considered a special technical feature, that would otherwise unify the inventions of Groups I+.

The inventions of Group I+ also share the technical feature of a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier.

This shared technical feature, however, does not provide a contribution over the prior art, as being anticipated by Altiris Therapeutics, which teaches a compound of Formula I, as described above, and further teaches a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier (para [0055], [0758]) and wherein said composition is a combination composition further comprising one or more additional therapeutic agents (para [0056]), selected from an anti-cancer agent (para [0826]-[0828], chemotherapeutic agent).

As said composition was known in the art at the time of the invention, this cannot be considered special technical features, that would otherwise unify the inventions of Groups I+. The inventions of Group I+, thus lack unity under PCT Rule 13.

Note: Claim 1 includes the description 'R₄ together with the atoms it attached to forms a carbocyclic, aryl, heterocyclic, or heteroaryl ring;' which lacks clarity. For the purposes of the above analysis, this description has been interpreted to mean 'R₄ and R₅ together with the atoms they are attached to form a carbocyclic, aryl, heterocyclic, or heteroaryl ring', based on the structures of the specific compounds A1, A2, A3 listed in claim 17.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/52503

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
--Please see attached sheet--

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-2, 12, 19-21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.